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The interest in exosomes and other extracellular vesicles (EVs) has been steadily increasing for the past 
several years, as a growing body of evidence for their potential use as non-invasive biomarkers for 
disease such as cancer has emerged. Evidence indicates that these EVs may contain high quantities of 
tumour specific proteins and nucleic acids (including DNA), and their ubiquity in bodily fluids make 
them ideal candidates for novel liquid biopsy methods. 
Four different methods for EV isolation was used on conditioned cell culture media from the PANC-1 
cell line and their performance was compared to that of traditional differential centrifugation (UC) for 
exosome isolation. The methods tested were qEV Size Exclusion Chromatography (SEC, Izon Science), 
ExoEasy affinity chromatography (Qiagen), as well as the Total Exosome Isolation (TEI, Thermo Fisher) 
and ExoQuick (System Biosciences) polymer precipitation reactions. Isolated EVs were characterized 
according to size, concentration and relative vesicle fraction by Tuneable Resistive Pulse Sensing (TRPS) 
analysis. Their relative content of exosome marker proteins was measured by bead-assisted flow 
cytometry (BAFC) analysis and their dsDNA content was isolated and then measured by fluorometry. 
The three best methods according to exosome content, purity and DNA content were selected for 
further validation by isolating exosomes from human plasma. EV isolation by TEI, qEV and ExoEasy 
techniques were validated on plasma from healthy control persons and patients with pancreatic cancer 
by the same analyses as described above. In addition, the level of tumour DNA in the EV fractions were 
estimated by KRAS Peptide Nucleic Acid (PNA) Clamp PCR assay. 
It was shown that traditional EV isolation method of differential centrifugation is ineffective with 
regards to EV yield, specificity and purity from contaminants, when compared to newly available EV 
isolation methods. All tested techniques performed as well or better than UC in every aspect 
investigated. It was demonstrated that the qEV technique provides the purest, least contaminated 
exosome isolates, and the most highly concentrated tumour DNA of all the tested techniques, but at a 
low overall EV concentration. TEI yielded the by far greatest dsDNA concentrations from both CCM and 
plasma, but co-isolated many non-target biomolecules. ExoEasy was shown to isolate some exosome-
like vesicles and some dsDNA, but with a generally heterogeneous and non-specific EV population. 
Tumour DNA, identified by mutated KRAS alleles, were detected in EV isolate samples of ExoEasy, TEI 
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exoDNA = Exosomal DNA 
cfDNA = Cell-free DNA 
dsDNA = Double stranded DNA 
ctDNA =circulating tumor DNA 
EV = Extracellular Vesicle 
MV = Microvesicle 
MVB = Multivesicular Body 
IEV = Intraluminal Endosomal Vesicle 
ApoBDs = Apoptotic Bodies 
ROS = Reactive Oxygen species 
DDR = DNA Damage Response 
SEC = Size Exclusion Chromatography 
qEV7 = qEV (Izon Science) SEC-column eluate fraction #7 (first 500µL fraction after void volume) 
qEV8 = qEV (Izon Science) SEC-column eluate fraction #8 (second 500µL fraction after void volume) 
qEV9 = qEV (Izon Science) SEC-column eluate fraction #9 (third 500µL fraction after void volume) 
TEI = Total Exosome Isolation (EV precipitation reagent) 
UC = Ultracentrifugation 
BAFC = Bead-assisted flow cytometry 
RCF = relative centrifugal force 
PC = Pancreatic cancer 
TR = Technical replicate 
BR = Biological replicate 
AChE = Acetylcholinesterase 
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LO = Large Oncosome 
CCM = Conditioned cell culture media 
HDL = High density lipoproteins 
PEGS = Polyethylene Glycols 
TRPS = Tuneable Resitive Pulse Sensing 
NTA = Nanoparticle tracking analysis 
ELISA = Enzyme linked immunosorbent assay 
PBS = Phosphate buffered saline 
DMEM = Dulbecco’s modified eagle medium 






















1.1 Pancreatic cancer and liquid biopsies 
 
Pancreatic cancer (PC) is a lethal malignancy which is notoriously difficult to diagnose, and carries a 
very poor prognosis [1, 2]. Typical symptoms of PC are very similar to many other, less serious diseases, 
and due to the placement of the pancreas behind the peritoneum, no diagnostic examination has 
proven clinically practical [2]. Additionally, high tumour content of stromal tissue may lead to 
inconclusive results [1]. This is despite early detection being one of the most reliable factors for an 
improved diagnosis [2]. Because of the challenging nature of diagnosing pancreatic cancer, liquid 
biopsies have attracted much interest in recent years [1]. By collecting circulating tumour cells and 
circulating tumour DNA, it is hoped that non-invasive methods of diagnosis with high prognostic value 
can be developed based on ctDNA mutation detection [1, 3]. Low quantities of DNA, low mutation 
frequencies and background noise has however posed major roadblocks on the way to developing such 
liquid biopsy methods [3]. Ways of isolating sufficiently concentrated amounts of tumour DNA are 
therefore highly sought-after, and the subject of much research. 
In recent years, an increasing body of evidence has building for a close relation between certain 
extracellular vesicle (EV) subtypes, and cancer [4, 5]. One aspect of this relationship is their reported 
specific enrichment in tumour DNA [6]. This has marked EVs as a promising candidate biomolecule for 
use in liquid biopsies and rapid diagnosis of challenging diseases such as PC [5]  
 
1.2 Extracellular vesicles 
1.2.1 Overview 
The term EV encompasses a wide range of membrane bound bodies, all of which are currently the 
subjects of intense study [7, 8]. Broadly divided into the three main categories of apoptotic bodies 
(ApoBDs), microvesicles/ectosomes (MVs) and exosomes,  EVs can vary greatly in both biological origin 
and function [9, 10]. As their name suggests, all EVs share the common trait of being located outside 
the plasma membrane of their parent cell (hence extracellular), and have been detected in biofluids 
as diverse as blood [11] (circulating EVs), urine [12] and even saliva [13]. These EVs span a large range 
of sizes, from the very small exosomes (50-150nm) [6, 14] to microvesicles (MVs, 100-1000nm)[15] 
very large apoptotic bodies (ApoBDs, 1-5µm) [16]. In between these ranges are the fairly newly coined 
“oncosomes” (100-400nm), a group of EVs proposed to be specifically released by cancer cells and, like 
exosomes [17], to carry potentially transforming mutant macromolecules [18]. The lipid bilayer 
structure of the EV membrane typically consists of material once part of the cell plasma membrane 
(figure 1), which has undergone a varying amount of intermediary stages depending on the type of EV. 
Even so, their contents, associated proteins and membrane structures are reported to vary widely 
depending on factors such as environmental conditions and cellular source [9]. 
1.2.2 Discriminating between EV subpopulations 
In the literature, the terminology surrounding EVs is not in all cases strictly defined, and many terms 
are used differently by different authors [19]. One of the earliest popular definitions of exosomes was 
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based on what relative centrifugation force (RCF) at which they were found to sediment, and another 
as “secreted vesicles that may serve a physiologic function”[19]. Similar confusion surrounding 
definitions also exist for MVs [19]. Broad definitions make claims regarding having isolated a certain 
type of EV less contentious. However, considering the likeness in external physical properties of EVs 
coupled with the large variability in cargo even within defined groups of EVs [9], there are many 
proponents of their definition not by size and density, but rather by biogenesis [9]. This, as well as the 
specific borders of the size ranges in which each type of EV is found, is still a topic of debate. This is of 
particular relevance, as many methods for isolation of exosomes and specific MVs rely on their relative 
sizes and densities to a very large extent [20]. Additionally, also in part because of the rapid 
development within the in the field, accurately classifying isolated EVs within a specific category 
according to biogenesis can be a time-consuming and expensive endeavour, as no single biomarker to 
guarantee a specific biogenesis is generally agreed upon [21]. It is however possible to become 
increasingly confident in characterizing the EVs in a sample by identifying more than one marker such 
as different proteins known to be enriched in the MV in question. Examples of such marker proteins 
for exosomes include ALIX and the tetraspanins CD9, CD63, among others [22]. Other intraluminal 
markers such as RNAs enriched in specific motifs have additionally been proposed [23] 
 
 
Figure 1: The biogenesis, release and relative scale of the three main classes of Extracellular vesicles. The top left part of the 
image illustrates how an early endosome (EE) matures to a multi-vesicluar body (MVB) filled with intraluminal vesicles (ILV), 
which upon release are known as exosomes. To the bottom left it is illustrated how micorvesicles (MVs) may form by outward 
budding of the plasma membrane. In the top right corner apoptotic bodies are shown “blebbing” (Zeiosis) off a cell undergoing 
apoptosis. The diameter range of each type of nanoparticle is given by the scale at the bottom of the image, the key for which 
is found in black box. This Illustration is reproduced with some modifications under the creative commons licence, © 2015 





1.3 Extracellular vesicle subtypes 
 
EVs have been reported to carry out several different roles in eukaryotes. These functions include tasks 
as diverse as functioning as cellular recycling bins and stretch all the way to novel EV-mediated cell 
signalling pathways, in which they allow for the transfer of macromolecules such as lipids, sugars and 
nucleic acids [9]. Discoveries leading up to a connection between tumours and EV’s were being made 
as early as the 1980’s, with discovery of  “membrane fragments” rich in antigenic sites typical of certain 
tumour tissue membranes [24]. This connection has been bolstered as research has progressed, and 
EVs have in recent years been proposed to play important and direct roles in  aspects as fundamental 
as maintaining tumour cell homeostasis [25], and metastasis and angiogenesis [26] 
1.3.1 Apoptotic Bodies 
1.3.1.1 Apoptotic Body Biogenesis 
ApoBDs are large EVs which originate as buds om the plasma membrane of the apoptotic cell[27]. In 
general, as the apoptotic cell moves through the stages of programmed cell death it shrinks and 
chromatin condenses (pyknosis). This is followed by plasma membrane blebbing and the breakdown 
of the nucleus (karyorrhexis). Cell fragments eventually separate into apoptotic bodies as the formed 
“blebs” transition into the process of budding [27]. Notably, while ApoBDs are created as an apoptotic 
cell is breaking down, they are not formed randomly, but follow distinct steps regulated by molecular 
factors. This process is generally known as cell disassembly [28]. 
1.3.1.2 Apoptotic Body Function and relation to cancer 
ApoBDs are traditionally known for performing the function of a cell component recycling bin, 
providing safe containers for the macromolecule components of an apoptotic cell as they are readied 
for clearance by a phagocyte [27, 28]. Their contents are diverse, and can contain entire organelles 
such as the Endoplasmic reticulum or Golgi apparatus, or large collections of macromolecules such as 
condensed chromatin [28]. The packaging of various cellular contents in this manner is believed to be 
involved in regulating immune response and tissue repair [29]. ApoBDs have additionally been 
suggested as vehicles for the horizontal transfer of biomolecules and oncogenes [30], and to be 
important regulators in the onco-regenerative niche [31] 
1.3.2 Exosomes 
1.3.2.1 Exosome Biogenesis 
A very different type of EV which has garnered a large amount of interest in the last few decades since 
their discovery, are the Exosomes. Descriptions of vesicles increasingly matching that of the modern 
definition of exosomes were being made throughout the 1980’s, with an outline of exosomes and their 
biogenesis being well formulated as early as 1987. Exosomes were at this time identified as part of a 
pathway for the expulsion of certain proteins from maturing reticulocytes, as a part of their normal 
maturation process [32]. The proteins found, included among others acetylcholinesterase (AChE) 
enzyme. What was particularly interesting, was that when following the fate of these proteins, it was 
discovered that the process first involved endocytosis, forming an endosome, which in turn also were 
subject to inward budding. This resulted in a so called multivesicular body (MVB), 0.5-1µm in length. 
The MVB was in turn found to fuse with the plasma membrane, releasing its very small internally held 
vesicles into the cell exterior (figure 1). These small vesicles, or exosomes, were found to be the 
vehicles for the further transport of the reticulocyte proteins in question. When viewed under the 
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electron microscope, exosomes were observed to have a cup-like morphology. This was later revealed 
to be an artefact of the microscopy fixation process [19, 33]. 
1.3.2.2 Exosome Function and relation to cancer 
In addition to their function in the maturation process of reticulocytes, exosomes have been shown to 
carry a plethora of biologically interesting proteins, including Rab proteins (Ras-like small GTPase 
superfamily), ALIX, Major histocompatibility complexes I and II and many more [10] (figure 2). In the 
course of the 2000’s, further discoveries were made, demonstrating many exciting potential functions 
of exosomes in the body, with potential future medical applications [5, 34]. Among the most exciting 
recently reported findings is the potential role of exosomes in preventing the accumulation of 
chromosomal DNA in the cytosol of cells, as an important part of the cell’s DNA damage response [25]. 
This would be done by targeted collection and export of cytosolic DNA out through plasma membrane 
by exosomes [25]. The rapid removal of generated cytosolic DNA may in this case be a critical feature 
of tumour cells in order to avoid natural senescence-associated tumour suppression, and produce 
exosomes loaded with tumour DNA cargo [25]. Others report that as much as 93% of amplifiable cell 
free DNA (cfDNA) in blood plasma is located in exosomes, while also asserting a connection between 
exosomes and double stranded DNA (dsDNA) [35]. Further finds link genomic dsDNA featuring mutated 
KRAS and p53 genes to exosomes from pancreatic cancer (PC) cell lines and PC patient serum [6]. 
Finally, exosomes  may play an important role in tumour growth and angiogenesis [36]. Tumour-
derived exosomes have further been found to be involved in metastasis by inducing pre-metastatic 
niche formation in distant organs [4] and for all these reasons provide a promising candidate for future 
use in liquid biopsies and diagnosis of cancer [5]. 
 
 
Figure 2: Structure and composition of an exosome (not all components shown). The lipid bilayer membrane holds many 
proteins characteristic to exosomes such as the tetraspannins CD9 and CD63, whereas the internal cargo typically includes 
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nucleic acids such as various RNAs. This Illustration is reproduced under the creative commons licence, ©Chahar HS et.al. 2015 
[37] 
1.3.3 Oncosomes and large oncosomes 
1.3.3.1 Oncosome and Large oncosome Biogenesis 
Oncosomes are a relatively newly coined group of EVs (2008) [18], characterized in part by being 
released exclusively by tumour cells. In this way the 100-400nm oncosomes differentiate themselves 
from EVs also produced by non-transformed cells, such as exosomes and ApoBDs. 
1.3.3.2 Oncosome and large oncosome function and relation to cancer 
Oncosomes were upon first discovery described as carrying phosphatidylserine on their surface and 
mediating the release of mutant macromolecules and oncogenes from tumour cells [18]. A year later 
in 2009, a different type of EV was discovered and coined  “Large Oncosomes” (LOs) due to their 
massive diameter of 1000 – 10 000nm [38]. It should be noted that while the two share similar names 
and are both produced exclusively by tumour cells, oncosomes and LOs have different size, contents, 
origins, and criteria for formation, and so the terms should not be used interchangeably [18]. The study 
of LOs is very young, and much has yet to be determined specifically with regards to their contents.  
Currently accepted marker proteins for LOs however include HSPA5 and HSPD1, and they have been 
reported to contain nucleic acids such as miRNA [39] 
1.3.4 Microvesicles 
1.3.4.1 Microvesicle Biogenesis 
Also known as ectosomes, MVs are EVs 100-1000nm in diameter formed thorough outward budding 
or “shedding” of the plasma membrane. MVs were previously known only as pro-coagulant platelet 
dust [40] generated by human blood platelets [15].They are today known to be produced by virtually 
all eukaryotic cells [41]. Due to their biogenesis, MVs have plasma membrane similar in composition 
to that of the cell membrane, but have been reported to lack the asymmetric distribution of lipids, 
such as phosphatidyl-serine and ethanolamine, across the two plasma membrane leaflets [21] 
1.3.4.2 Microvesicle function and relation to cancer 
MVs have been found to be abundant in various biofluids [9] and have been suggested as important 
paracrine messengers [42]. Among their cargo there has been reports of biologically active proteins 
[43] and circulating miRNAs[44] and various other nucleic acids [41]. MVs have been reported to have 
pro-metastatic functions in malignancies such breast cancer [15] 
 
1.4 Common substrates for EV isolation 
 
Per definition, EVs are exuded from their parent cell and into the external environment [9]. For cells in 
a culture, this corresponds to the cell culture media, which after hosting cells and exchanging 
biomaterials with the culture often is called conditioned cell culture media (CCM). CCM was in a 2016 
worldwide survey determined to be the most commonly used material for EV isolation, with 83% of 
respondents using it as their only or primary material for EV isolation [25]. When isolating EVs from 
CCM, it is important not to introduce external exosomes by ways of additives to the medium, such as 
for instance regular foetal bovine serum (FBS) or other supplements [45]. Additionally, as discussed 
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previously, cell death will lead to the formation of ApoBDs. It is therefore important to avoid undue 
stress on the cells or culturing past full confluence. In the case of excessive cell death, there is no way 
to guarantee the quality of the later measured exosomes. Cell live count should therefore be measured 
prior to proceeding with exosome isolation from a given batch of CCM. It is also essential to avoid any 
and all disruption of cells, so the collection process must be gentle [46]. After collection, CCM should 
be clarified by removal of cellular debris, ApoBDs and shedded vesicles through careful centrifugation 
and/or filtration steps [25] 
When it comes to liquid biopsy samples, EVs can be found in most body fluids, including blood [5, 35]. 
Therefore, when selecting material for the study of EVs for use in liquid biopsy, a natural choice would 
be blood plasma, as blood is a routinely collected and easily accessible bodily fluid rich in circulating 
EVs [20]. The plasma fraction in particular is not subject to the factors released by leukocytes during 
coagulation as is serum, and can be rapidly isolated from whole blood and used for EV isolation [20]. 
Even so, careful clarification should be performed by introducing centrifugation and filtration steps 
prior to exosome isolation in order to avoid contamination by platelets [20]  
 
1.5 Technologies for EV isolation 
 
1.5.1 Traditional EV isolation- Ultracentrifugation 
Ultracentrifugation (UC) was determined to be the most common technique for EV isolation in the 
same 2016 worldwide survey mentioned above, with 81% of respondents reporting to use 
ultracentrifugation (including differential centrifugation) as their primary EV isolation technique. This 
was coupled with a reported 64% using an ultracentrifugation washing step for clean-up/purification.   
[47]. EV isolation by centrifugation relies on the density, size and shape of the EVs to deposited, where 
the most dense and/or biggest particles deposit out of solution first [33]. In differential centrifugation, 
successive centrifugations at steadily increasing RCFs are therefore performed in order to deposit and 
discard large particles which are not wanted in the final EV isolate [20]. The full process of going from 
heterogeneous suspension to EV isolate using only centrifugation steps and ending with 
ultracentrifugation, is known as differential centrifugation[20]. The typical differential centrifugation 
protocol in this manner involves discarding the formed pellet at each step and further centrifuging the 
supernatant (figure 3). Large EVs (MVs, oncosomes) are generally considered to isolate out at 10 000 
– 20 000x g, whereas small EVs (exosomes) require RCFs of 100 000 – 200 000x g [20]. Isolation of EVs 
thorough differential centrifugation does however not discriminate against EV subpopulations or other 
particles of similar size and/or density to the target [48]. Ultracentrifugation has further been found to 
cause EV aggregation [49] as well as to co-isolate a various non-vesicular materials not easily removed 
by normal washing of the pellet [50]. Common contamination co-isolates include proteins, protein 
aggregates, lipoproteins, cell organelles and viruses [20]. Reports of the total recovery of EVs by 
differential centrifugation varies widely, from 2%-80%[20], and a typical protocol may take from one 





Figure 3: An example of a typical differential centrifugation workflow for isolation of small EVs like exosomes from CCM. After 
multiple steps of clarification of the CCM follow several long ultracentrifugation steps in order to deposit and wash the very 
small EVs. Example times and speeds for this particular workflow follow that of Takahashi et.al. 2016 [25] 
 
An alternative UC-based technique for EV isolation to differential centrifugation, is density gradient 
centrifugation [20]. In this technique the relative density of each EV subpopulation is further 
emphasized, allowing for more specific isolation [33]. It works on the principle of placing a density 
gradient medium in a centrifugation tube, where the medium has a progressively increasing density 
moving from the top of the tube to the bottom (sorting EVs by size and mass) or from the bottom to 
the top (mass density only) [20]. By placing the sample material on the top of the density gradient 
medium, the different suspended EVs will sediment at different rates during UC [33]. This causes 
distinct zones of EVs in the density gradient medium from which a specific fraction can be recovered. 
This method is particularly useful for isolating very small yet low density EVs such as exosomes, but is 
typically even more labour intensive than even differential centrifugation [51] 
1.5.2 Size Exclusion Chromatography 
In size Exclusion Chromatography (SEC), a specialized porous material such as CL-2B Sepharose in a 
column is used as a stationary phase, and the material from which EVs are to be isolated constitutes a 
mobile phase to be passed through the column. Particles with a small hydrodynamic radius are able to 
interact with the pores of the stationary phase, and are therefore hindered as they travel through the 
column. As radius increases, particles interact less with pores of the stationary phase, and therefore 
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pass through the column more quickly [52]. In this manner, nanoparticles of a very specific diameter 
may be isolated by collecting only the fractions of the mobile phase in which they are contained, as it 
passes through the column [33]. SEC is considered a gentle method of EV isolation, as it typically relies 
on gravity-flow elution and involves no potentially aggregating, deforming or disrupting centrifugal 
forces [52]. This is generally considered ideal for the purposes of maintaining the integrity of the 
isolated EVs, and the technique is also considered to be particularly concise and reproducible [52]. 
While SEC effectively removes contaminating high density lipoproteins (HDL) and plasma proteins, 
isolates may contain very low density lipoproteins (30-80nm) and chylomicrons (100-600nm) in small 
amounts. Overall, SEC has been reported as capable of removing more than as 95% of all non-vesicular 
proteins from a sample [53]. Overall vesicle yields have however been reported as low [54], and 
attempts at concentrating steps post-SEC may result in lowering both vesicle recovery and sample 
purity depending on the methods used [53]. 
1.5.3 Polymer precipitation 
A third option for EV isolation, are polymer precipitation reactions. Before isolation by such 
technologies, the sample must first be clarified from cells and cellular debris [33]. By adding a reactant 
to the material from which EVs are to be isolated which reduces their solubility, EVs can be precipitated 
from solution and at relatively low centrifugation speeds [33]. Water molecules are tied up by the 
addition of high-solubility polymers such as polyethylene glycols (PEGS), forcing the less soluble EVs 
out of solution [51]. However, in principle any solute less soluble than the added polymer is 
precipitated. Depending on the specific methodology used, polymer precipitation has been shown to 
co-precipitate contaminants such as lipo-proteins and other non-vesicular material [52]. 
1.5.4 Affinity spin-column purification 
Not unlike SEC, Affinity chromatography works on the principle of differences in interaction strength 
between a mobile phase and its different solute biomolecules, and a stationary phase. In the stationary 
phase of affinity chromatography however, there are immobilized ligands [55] specially designed to 
bind to the target, for instance EV’s. The crude sample (heterogonous mixture of target EVs and non-
target biomolecules) is mixed with a buffer changing the pH or other factors necessary to allow for 
binding to occur between EVs and the immobilized ligand. When the sample is passed through the 
stationary phase, the EVs bind to the ligand-enriched membrane, and non-target biomolecules can be 
washed away. The EVs can then be eluted by the addition of a buffer which releases them from the 
immobilized ligands [55]. 
By making the stationary phase a permeable membrane and placing it in centrifuge-compatible 
column, a single pass of the sample thorough the column can achieve more than a 1000-fold increase 
in purity of for example a protein target [55]. This however, comes coupled with warnings of the affinity 
spin technology resulting in a more heterogeneous mix of isolated EVs with a wider size-range than 
what can be obtained through SEC, more contaminating proteins of various types including 






1.6 Characterization of EVs and nucleic acid cargo 
 
As described above, all EV isolation techniques have the potential to co-isolate proteins or other non-
target vesicles. In order to determine the yield and homogeneity of the isolate from any given 
technique, the resultant nanoparticles must therefore be characterized. Because no single biomarker 
can sufficiently characterize a nanoparticle as a given EV, several characteristics must be used 
simultaneously. Several technologies are available today which may allow one to narrow down what 
nanoparticles have been isolated  
 
1.6.1 Tuneable resistive pulse sensing (TRPS) 
The size of isolated nanoparticles as well as their concentration can be determined by TRPS analysis. 
The concentration of isolated nanoparticles within the size range of your target EVs is an important 
indicator for the success of the isolation. TRPS works on the principle of applying a voltage across a 
small pore (nanopore) filled with an electrolyte, and continuously measuring the electrical resistance. 
By placing a liquid sample containing suspended nanoparticles of a suitable size on top of the nanopore 
and applying a pressure, nanoparticles will start to migrate thorough the nanopore. As each 
nanoparticle travels through the pore, it increases the measured electrical resistance, resulting in a 
“dip” in the current, also known as a “blockade event”. The length and magnitude of the dip can be 
used to calculate the dimensions of the nanoparticle [56]. By applying different pressures and 
measuring the difference in rate of blockade events, the concentration of nanoparticles in the 
detection range can be calculated. As data is collected on the size of each individual nanoparticle which 
passes through the nanopore, a very detailed size distribution of nanoparticles can also be measured. 
The “tuneable” part of the TRPS name, comes from each nanopore being stretchable, allowing for the 
user to move the detection range of a given nanopore up or down to some extent. The nanopores are 
also user replaceable, so that pores of different diameters entirely can be used[56]. One of the very 
few commercially available solutions using this technology is the qNano Gold instrument, by Izon 
Science [57]. 
Additionally, a study has shown that exosomes and larger EVs can be lysed effectively at 0,075% (v/v) 
of the non-ionic detergent Triton X-100, and that the use of the detergent is compatible with TRPS 
analysis on the qNano Gold [58]. This can therefore be used to estimate the relative fraction of vesicles 
in the sample, by comparing identical samples with and without triton x-100  
1.6.2 Enzyme linked colorimetric assay 
Exosomes have been found to be enriched in the enzyme acetylcholinesterase [32]. Based on this 
principle, a commercial colorimetric assay named the ExoCet exosome quantitation assay has been 
developed by System Biosciences (SBI). The assay works on the change in OD405nm caused by the 
action of the exosomal AChE enzyme on a substrate in the assay. SBI provides a standard solution of 
AChE as well as instructions for a dilution series in the kit. This is used to create a standard curve for 
the assay which SBI claims to be accurately calibrated to correspond to a given number of exosomes 
using Nanoparticle Tracking Analysis (NTA) [59].  
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1.6.3 Bead-assisted flow cytometry analysis 
In order to classify isolated EVs as exosomes, ideally more than one protein known to be enriched in 
the EV should be identified in the sample. In a Bead-assisted flow cytometry (BAFC) analysis of EVs, EV 
isolate samples to be analysed are incubated with and bound to aldehyde/sulfate-latex beads. After 
binding, unbound sites on the beads can be blocked, the EV-linked beads washed from unbound 
contaminants. EV marker protein antibodies can then be added before the protein-coupled beads are 
stained with fluorescent dye [60]. By running the sample of dyed EV-linked beads through a flow 
cytometer, the presence of the proteins in question, as well as their relative concentrations can be 
determined. The technique is in many ways similar to Enzyme Linked Immunosorbent Assay (ELISA), 
but can be used effectively on as little as 1/5 of the required sample volume (20µl), and can easily assay 
for several proteins simultaneously. Due to the nature of each bead being able to bind several EVs 
however, the method cannot be used for absolute quantitation, but rather only for direct comparisons 
of samples in the same assay [61]. 
1.6.4 EV associated nucleic acid analysis 
When isolating EVs in the range of exosomes, dsDNA cargo can be expected [35]. Detection of internal 
dsDNA cargo in isolated EVs can therefore be seen as an indication that the isolated nanoparticles are 
indeed EVs, like for instance exosomes. In addition to this comes the potential detection of tumour 
DNA, in the case of isolations from cancer patient samples. Somatic mutations to the KRAS gene has 
been shown to be present in 80-90% of pancreatic cancers [62]. It is therefore reasonable to expect 
MVs such exosomes which are reported to carry tumour DNA, to have DNA testing positive for 
mutation in this gene in the case that they themselves have been isolated from the blood of a person 
with pancreatic cancer (PC). A very sensitive method for detection would be preferable however, in 















1.7 Aims of the thesis 
 
The aim of the thesis was to compare four new methods for EV isolation from CCM and plasma to the 
traditional gold standard of EV isolation: ultracentrifugation. EVs including exosomes show great 
promise in delivering high concentration tumour DNA suitable for use in novel liquid biopsies. The 
criteria for evaluation of each isolation technique was therefore weighted towards their ability to 
isolate EVs showing typical exosome characteristics and a content of dsDNA. We further aimed to 
evaluate the best three techniques in terms of the relative content of tumour DNA in the vesicle 
isolates from plasma samples from pancreatic cancer patients, with the perspective of potential future 



























2.1.1 Cell lines 
 PANC-1 (ECACC # 87092802): 
2.1.2 medium formulations: 
Growth medium (standard): 
 DMEM, high glucose (500mL) 
 10% FBS (50mL) 
 2mM Glutamine (5mL) 
 Pen/strep antibiotics (5mL) 
Growth medium (exosome free): 
 DMEM, high glucose (500mL) 
 10% Exosome Depleted FBS (50mL) 
 2mM Glutamine (5mL) 
 Pen/strep antibiotics (5mL) 
 
2.1.3 Prepared solutions 
Acetylcholinesterase (AChE,1mg/mL, 8.2mL) 
 Lyophilized AChE enzyme (8.2mg) 
 Tris-HCL, pH= 7.5 (20mM, 8.2mL)  
1x PBS (200mL) 
 1 PBS tablet 
 200mL Milli-Q water (Milli –Q® Integral 5 water purification system) 
1x PBS, 20% ethanol (v/v) 
 1PBS tablet 
 160mL Milli-Q water 
 40mL Ethanol (99.9%) 
qNano Gold Stock PBS 
 1 PBS tablet 
 200mL Milli-Q water 
 0.6mL wetting solution (Izon) 
qNano Gold Measurement Electrolyte 
 12ml qNano Gold stock PBS 




2.1.3 Kits used 
 
Table 1: Kits used during experimentation.  
Kit Manufacturer Catalogue number Use 
AllPrep DNA/RNA/miRNA 
Universal Kit 
Qiagen 80224 DNA isolation (CCM) 
QiAmp Circulating Nucleic 
Acid Kit 
Qiagen 55114 DNA isolation (Plasma) 
Qubit™ dsDNA HS Assay kit Thermo Fisher Q32851 dsDNA quantitation 
TRPS Reagent Kit Izon Science N/A qNano Gold reagents 
TRPS Training Kit Izon Science N/A qNano Gold training 
ExoEasy Maxi Kit Qiagen 76064 EV isolation 
ExoQuick-TC™ SBI EXOTC10A-1 EV isolation 
qEVoriginal Izon N/A EV isolation 
TEI (from plasma) Thermo Fisher 4484450 EV isolation 
TEI (from CCM) Thermo Fisher 4478359 EV isolation 





Table 2: Reagents used during experimentation 
Material Manufacturer Catalogue number Use 
DMEM, high glucose Sigma D5671 Cell culture 
DPBS Sigma D8537 Cell culture 
L-Glutamine 200mM Sigma G7513 Cell culture 
Pen/strep antibiotics Sigma P4333 Cell culture 
FBS Sigma F7524 Cell culture 
Exosome depleted FBS Thermo Fisher A2720803 Cell culture 
Trypsin-EDTA Sigma T4049 Cell culture 
Trypan Blue (0.4%) Thermo Fisher T10282 Cell culture 
RQ1 DNase Promega M610A EV external DNA 
RQ1 10x Rxn buffer Promega M198A EV external DNA 
RQ1 Stop Solution Promega M199A EV external DNA 
PBS tablets Sigma P4417-100TAB EV suspension 
Buffer XBP Qiagen 76204 EV isolation 










2.2.1 Cultivation of PANC-1 cell line and preparation of Conditioned Cell Culture Media (CCM) 
samples for exosome isolation 
 
2.2.1.1 Resuscitation and of the PANC-1 cell line 
An ampulla of PANC-1 cells was collected from storage (LN2) and thawed briefly in a water bath (37°C) 
until only a small amount of ice remained. Resuscitation was completed by transfer of the cells to 10ml 
pre-heated (37°C) normal Dulbecco’s Modified Eagle’s Medium- high glucose growth medium (DMEM) 
with glutamine (2mM), Sterile Filtered Foetal Bovine Serum (10%, Sigma Aldrich, “FBS”), 1x sterile 
filtered Penicillin-Streptomycin (Sigma, P4333) in a T75 Nunc™ EasYFlask™ (Thermo Fisher, No.156499) 
cell culture flask in a Laminar Airflow (LAF) cabinet while observing good sterile technique. The newly 
resuscitated PANC-1 cell culture was incubated at 37°C, 5% CO2 for two days before sub culturing. 
2.2.1.2 Maintenance and sub culturing of the PANC-1 cell line 
The PANC-1 cell line was maintained in high glucose DMEM growth medium with all additives 
(described above). Cell confluence was estimated qualitatively each day by light microscopy. At around 
70% confluence, cells were sub cultured by first discarding conditioned cell culture media (CCM) and 
washing the adherent cell monolayer three times using pre-heated (37°C) Ca2+/Mg2+-free Dulbecco’s 
Phosphate Buffered Saline (10ml, “DPBS”). Cells were incubated in Trypsin/EDTA (2ml, Sigma Aldrich) 
at 37°C for 3 minutes. Growth medium (3mL) was added in order to neutralize the Trypsin. Based on 
the visual estimation of the cell density, a fresh T75 Nunc™ EasYFlask™ (Thermo Fisher) containing pre-
heated (37°C, water bath) high-glucose DMEM (20mL) with all additives was inoculated with a volume 
of the cell suspension appropriate for achieving a seeded cell density of roughly 20 000- 30 
000cells/cm2 and incubated at 37°C, 5% CO2. All open work with open cell lines was carried out in the 
LAF cabinet while observing good sterile technique. Subcultures were incubated at 37°C, 5% CO2. 
2.2.1.3 Cell enumeration 
For sub culturing of cells used in exosome isolation experiments, cells were seeded to 15000 cells/cm2. 
After suspension of adherent cells using Trypsin/EDTA (described above) a small aliquot of the 
suspension (50µL) was transferred to a 1.5mL microcentrifuge tube. The remainder of the suspended 
cell culture was placed under incubation (37°C, 5% CO2) for the duration of the cell enumeration 
process. The cell suspension aliquot was mixed with Trypan Blue Stain (0.4%) for use with the 
Countess™ Automated Cell counter (50µL, Thermo Fischer Scientific) by pipetting, and 10µL of the 
mixture was transferred to the chamber on a Countess™ Cell Counting Chamber Slide (Thermo Fischer 
Scientific). The slide was incubated at room temperature (RT) for 10 seconds before it was loaded into 
the Countess® II Automated Cell Counter (Thermo Fisher Scientific). Cells were enumerated by the 
instrument and reported as number of live cells, dead cells and the percentage of dead cells relative 
to the total. The cell concentration in the suspension was calculated automatically by the instrument.  
 
2.2.1.4 Sub culturing for production of CCM as a raw material for exosome isolation 
Exosome-free DMEM was prepared by replacement of the normal FBS additive with Gibco™ Exosome-
Depleted FBS, One-Shot™ format (50mL, Cat. A2720803 Thermo Fisher).  
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PANC-1 cell culture was sub cultured simultaneously to two T75 flasks as previously described, but 
using exclusively exosome-free high glucose DMEM. Subcultures were incubated at 37°C 5% CO2 until 
70% confluence. Cells were washed and trypsinated as previously described and enumerated using the 
Countess® II automated cell counter (Thermo Fisher Scientific). An appropriate volume of cell 
suspension (equation 1) was transferred to fresh pre-heated (37°C) exosome-free high glucose DMEM 
(50mL, all additives), for a seeded density of 15 000 cells/cm2 in four fresh T175 Nunc™ EasYFlask™ 
(Thermo Fisher, No.159910). PANC-1 cultures were subsequently incubated at 37°C, 5% CO2 until 95-
100% confluence before harvesting the CCM into conical base tubes (50mL, Sarstedt No. 62.547.004). 
Cell monolayer was washed and trypsinated as previously described. An aliquot (0.5mL) of the cell 
suspension was used to enumerate cells and verify a live-cell fraction of ≥95% using the Countess® II 
automated cell counter. 
 






                                                                                          (1) 
 
2.2.1.5 Clarification of collected CCM for use in exosome isolation 
Collected CCM was clarified by serial centrifugation for 10 minutes at RT at 300x g, 1500x g and 3000x 
g using the Allegra x-30R centrifuge (Beckman Coulter) with a swinging bucket rotor (Beckman Coulter 
SX 4400). The supernatant was aspirated and transferred to a fresh 50mL tube between each 
centrifugation, and the old tube was discarded along with the debris pellet. Supernatant was filtered 
using a 0,8µm Millex® AA Filter Unit (MF-Millipore, SLAA033SB) into a sterile container and mixed by 
gentle agitation. Clarified CCM was immediately used in the various protocols for exosome isolation 
(described below). 
 
2.2.2 Preparation of plasma samples for exosome isolation from whole blood 
 
Samples of whole blood (2x 9mL) were drawn from 3 presumed healthy control group donors into BD 
Vacutainer® EDTA haematology tubes (Becton, Dickinson and Company) and plasma isolated by 
centrifugation at RT, 2000x g for 20 minutes using a Kubota 2800 table centrifuge with a swinging 
bucket rotor (Kubota RS240). Plasma (approx. 4mL/vacutainer) was carefully transferred to sterile 
microcentrifuge tubes (2mL) and clarified by centrifugation at 10 000x g for 20 minutes at RT using the 
Eppendorf MiniSpin® Plus table centrifuge with a fixed angle rotor (Eppendorf F-45-12-11). While 
avoiding to disturb the debris pellet, clarified supernatant plasma was aspirated and filtered using a 
0.8µm Millex® AA Filter Unit (MF-Millipore, SLAA033SB) and stored on ice for a maximum of 3 hours 
before use in exosome isolation. 
Samples of isolated plasma (3x 1.5mL) previously prepared from whole blood as described above from 
late-stage pancreatic cancer (PC) patients was collected from storage (-80°C) and thawed on ice. Tubes 
were inverted several times before clarification by centrifugation and filtration as described above. All 




2.2.3 Techniques for exosome isolation 
 
2.2.3.1 ExoEasy Maxi Kit (Qiagen), membrane affinity spin columns for CCM 
Fresh clarified CCM (16mL) and ExoEasy Maxi Kit (Qiagen) buffer XBP (16mL, Qiagen) was mixed in 
each of two 50mL sterile conical base tubes (Sarstedt) by inverting the tubes 5 times. The mix from 
each tube was passed through separate ExoEasy spin columns in aliquots of 16mL by centrifugation at 
500x g, 1 minutes at RT using the Allegra x-30R centrifuge (Beckman Coulter) with a swinging bucket 
rotor (Beckman Coulter SX 4400). Flow-through was collected and discarded between centrifugations. 
Residual liquids were cleared from spin columns by centrifugation at 4000x g for 1 minute at RT. Buffer 
XWP (Qiagen) was added to each spin-column and subsequently centrifuged at 4000x g for 5 minutes 
at RT. The flow through was collected and discarded before transfer of the spin column to a fresh 
collection tube (Qiagen). Elution buffer (500µL, Qiagen buffer XE) was added directly to the spin-
column membrane and incubated for 1 minute at RT before centrifugation at 500x g for 5 minutes at 
RT. The eluate was collected and re-applied to the column and incubation repeated. Final 
centrifugation of the eluate was performed at 5000x g for 5 minutes at room temperature, before 
transferring the exosome isolate (500µL) in aliquots to 5 x 1.5 mL Protein LoBind micro centrifuge tubes 
(Eppendorf) and stored at -80°C.  
2.2.3.2 ExoEasy Maxi Kit (Qiagen), membrane affinity spin columns for plasma 
Clarified plasma samples (1mL) mixed with 1mL buffer XBP in 2mL sterile micro centrifuge tubes and 
homogenized by inverting the tubes 5 times. Tubes were incubated for 15 minutes at RT in order to 
ensure equilibration to room temperature, before proceeding with the ExoEasy protocol as described 
above for CCM.  
2.2.3.3 ExoQuick (System Biosciences), precipitation reaction 
Fresh clarified CCM (16mL) was transferred to conical base tubes (50mL, Sarstedt) and ExoQuick-TC™ 
precipitation reagent (3.2mL, System Biosciences) added before mixing by inverting the tubes several 
times. The mixed solution was incubated in an upright position at 4°C for 12 hours before 
centrifugation at 1500x g for 30 minutes at 4°C using an Allegra x-30R centrifuge (Beckman Coulter) 
with a swinging bucket rotor (Beckman Coulter SX 4400). While carefully avoiding to disturb the pellet, 
the supernatant was aspirated and discarded before centrifuging the tubes at 1500x g for 5 minutes at 
4°C and carefully aspirating the remaining supernatant. The pellet was suspended in 500µL 1xPBS and 
transferred to 1.5 mL Protein LoBind micro centrifuge tubes (Eppendorf) in aliquots for storage at -
80°C. 
2.2.3.4 Total Exosome Isolation (Invitrogen), precipitation reaction for CCM 
Fresh clarified CCM (16mL) was transferred to 100mL rounded bottom centrifuge tubes (Kubota) and 
mixed with Total Exosome Isolation (from cell culture media) (8mL, Invitrogen “TEI”) by pipetting and 
briefly vortexing the tubes until homogeneous. The mixtures were incubated at 4°C overnight in an 
upright position. Precipitate was pelleted by centrifugation at 10 000x g for 1 hour at 4°C using the 
Model 7780 High Speed Refrigerated Centrifuge (Kubota) with a fixed angle rotor (AG 1008A 8x 100mL) 
and the supernatant carefully aspirated and discarded. EV-containing pellets were suspended in 500µL 
1xPBS by pipetting, and transferred to 1,5mL protein LoBind micro centrifuge tubes (Eppendorf) in 
aliquots for storage at -80°C.  
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2.2.3.5 Total Exosome Isolation (Invitrogen), precipitation reaction for plasma 
Clarified plasma samples (1mL) were individually diluted with 500µL filtered (0.2µm, Millex®-MP 
0,22µm filter unit, Merck Millipore Ltd) 1x PBS and thoroughly mixed by vortexing. Total Exosome 
Isolation Kit (from plasma) precipitation reagent (300µL, Invitrogen™) was added to each sample, and 
the mixture vortexed briefly. Samples were incubated at RT for 10 minutes before the precipitate was 
pelleted by centrifugation at 10 000x g for 5 minutes at room temperature using the Eppendorf 
MiniSpin® Plus table centrifuge with a fixed angle rotor (Eppendorf F-45-12-11). The supernatant was 
carefully aspirated and discarded and the pellet submerged in 500µL of filtered (0.2µm) 1xPBS, and 
incubated at RT for 1 hour until partially resuspended. The partial suspension was homogenized by 
vigorous pipetting, and vortexed until apparent complete suspension was achieved. All TEI precipitates 
from plasma suspensions were observed to have an opaque yellow or white appearance, depending 
on the donor sample. EV isolates were subsequently pipetted into aliquots in 1.5mL protein LoBind 
tubes (Eppendorf) for storage at -80°C. 
2.2.3.6 qEV original columns (IZON science), Size Exclusion Chromatography (SEC) for CCM 
Fresh clarified CCM (16mL) was concentrated using Amicon® Ultra-15 Centrifugal Filter Device (10K 
Nominal Molecular Weight (NMWL), Merck Millipore Ltd.) and centrifugation at 4000x g for 30 minutes 
at RT using the Allegra x-30R centrifuge (Beckman Coulter) with a swinging bucket rotor (Beckman 
Coulter SX 4400). CCM concentrate for was collected from the filter device and diluted to 500µL total 
volume with filtered (Millex®-MP 0.22µm filter unit, Merck Millipore Ltd.) 1x PBS and stored on ice for 
a maximum of 30 minutes before use with the qEV columns. 
One fresh qEVoriginal Size Exclusion Column (IZON science, “qEV”) for each biological replicate to be 
processed was equilibrated to room temperature and rinsed by passing 10mL filtered (0,22µm) 1xPBS 
through each column. The bottom luer-slip was replaced in order to prevent the column from running 
dry. Remaining buffer over the column top filter was pipetted off immediately before loading of CCM 
concentrate sample (500µL) into each column, and the bottom luer-slip removed. The first 3mL of flow-
through was collected and discarded (500µl fractions 1-6, equating to the column void volume) before 
the three subsequent eluate fractions of 500µL (fractions 7-9) was collected and each divided into 
aliquots in 1,5mL protein LoBind tubes (Eppendorf) for storage at -80°C. 
2.2.3.7 qEV original columns (Izon science) SEC for plasma 
Clarified plasma samples (1mL) were concentrated by centrifugation at 4000x g, 20 minutes at RT using 
the Allegra x-30R centrifuge (Beckman Coulter) with a swinging bucket rotor (Beckman Coulter SX 
4400) using separate Amicon® Ultra -4 Centrifugal Filter Units (10K NMWL, Merck Millipore Ltd.). 
Concentrate was collected by pipetting from the filter to a 1,5mL microcentrifuge tube, rinsing the 
Amicon Ultra-4 filter with 30µL filtered (0,22µm) 1x PBS and adding to the transferred concentrate. 
The total collected concentrate was then diluted to 500µL using additional filtered (0,22µm) 1x PBS, 
and stored on ice for a maximum of 1 hour while qEVoriginal columns (Izon Science) were being 
equilibrated for use. Concentrated clarified plasma samples were subsequently equilibrated to RT 
before EVs were isolated using fresh qEVoriginal columns (Izon Science) as described above for CCM. 
EV isolates were stored at -80°C as aliquots suitable for downstream application. 
2.2.3.8 EV isolation by differential centrifugation with ultracentrifugation (UC). 
Freshly clarified CCM (see chapter 2.1.5) was transferred to a 100mL round bottom centrifuge tube 
(Kubota) and centrifuged at 10 000x g for 30 minutes at 4°C using the Model 7780 High Speed 
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Refrigerated Centrifuge (Kubota) with a fixed angle rotor (AG 1008A 8x 100mL). The supernatant CCM 
was aspirated and transferred to a sterile 50mL tube and stored at -80°C until ready for use. 
Before ultracentrifugation, the frozen CCM sample was moved to a separate laboratory and stored on 
ice overnight in a cold-storage chamber (4°C). The sample was then fully thawed by holding the tube 
in hand, and inverting several times. CCM supernatant (16,5mL) was transferred to a thickwall 
polycarbonate 32mL ultracentrifuge tube (Beckman Coulter, No.355631).  A second ultracentrifuge 
tube was filled to the same level, within a margin of ±0.0015g using the tare function of a laboratory 
scale. The accuracy of the weight measurement was verified by repeating measurement of the first 
tube. A marker was used on the exterior of each tube for simplifying localization of pellet after 
centrifugation. 
The ultracentrifuge tubes containing the CCM (16,5mL) were then placed into a pre-chilled (4°C) rotor 
(Beckman Coulter No. 337922, Type 70 Ti) and centrifuged at 118 000x gavg (acceleration =2, 
Deceleration =4) for 2 hours at 4°C using the Optima™ XPN-100 ultracentrifuge (Beckman Coulter). The 
supernatant was aspirated and discarded before dissolving and washing the pellet in 16.5mL 1x PBS 
and repeating the ultracentrifugation as described above. The supernatant was again aspirated and 
discarded before resuspending pellet in 500µL 1x PBS. EV isolates were stored at -80°C as aliquots 
according to downstream application. 
 
2.3 Quantitation and characterization of isolated EVs 
 
2.3.1 qNano Gold (Izon Science) TRPS nanoparticle analysis 
A TRPS reagent kit (Izon Science) were used in order to prepare coating solution and measurement 
electrolyte for all measurements using the qNano Gold (Izon Science).  Measurements were conducted 
using 3 recordings at varying pressures of each sample as per recommendation by the manufacturer. 
Each recording was set to a 90 seconds of recording time. Each EV isolate sample was measured using 
both Nano Pore (NP) 100 and NP200, paired with appropriate calibration particles (CPC). CPC100 and 
CPC200 (Izon Science) were used with NP100 and NP200 respectively. CPC100 was diluted in 
measurement electrolyte (Izon Science) to a concentration of 1,0*1010 particles/mL and CPC200 to a 
concentration of 2,0*109 particles/mL prior to use in calibrations, according to the manufacturer’s 
recommendations. EV isolate samples were similarly diluted to an appropriate concentration for 
measurement using freshly made filtered (Millex®-MP 0,22µm filter unit, Merck Millipore Ltd.) 
measurement electrolyte. The appropriate dilution factor was determined experimentally for each 
individual sample using concentration estimates previously collected using the ExoCet EV Quantitation 
Assay (SBI) (chapter 2.4.2) and fine-tuned using the qNano Gold. Low concentration samples were 
diluted as little as 2x, whereas high concentration samples were diluted as much as 40x, in order to 
achieve a suitable balance between number of recorded particles and measurement stability. 
All NP100 were tuned to the size interval 50nm-200nm, and NP200 to the interval 85nm-340nm. 
Calibration using the appropriate CPC was performed twice for each set of measurements, prior to- 
and after recording samples. To reduce the risk of errors due to pore blockages and other changing 
conditions, no more than 4 measurements were attempted for any given session, excluding 
calibrations. Measurements on the qNano Gold were carried out using the measurement assistant 
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function of the Izon control suite (v. 3.3.2.2001) for Microsoft Windows. The qNano Gold instrument 
and fitted nanopores were prepared according to the instructions provided in the Izon Control suite 
measurement assistant protocol for use with reagent kit, immediately prior to all recording sessions. 
Parameters for measurements such as current, drift and noise (RMS) were monitored and kept within 
margins specified in the Izon training manual for the qNano Gold (Izon science). 
The qNano gold instrument reports concentration EV sample (nanoparticles/mL). These were 
normalized to correspond to particles/mL starting material used during EV isolation. The concentration 
value reported by the qNano Gold was multiplied by 0,5mL (the total volume of EV isolate sample) to 
estimate the total number nanoparticles in the full sample volume. qEV fractions were pooled at this 
point by addition of the total measured nanoparticles of fractions 7, 8 and 9. The calculated 
nanoparticle values were then divided by the volume of starting material used during EV isolation. The 
final calculated value corresponds to the estimated nanoparticle yield per mL of starting material. 
 
2.3.2 qNano Gold analysis of triton x-100 treated samples 
An equal aliquot of EV isolate sample stock was transferred to each of two 1,5mL microcentrifuge 
tubes. Both samples were diluted to a concentration previously verified as appropriate for the sample 
stock using fresh filtered (0,22µm) measurement electrolyte, and one of the samples modified by the 
addition of Triton x-100 (10%) to lyse vesicles, and subtraction of an equal volume of diluent, to a final 
Triton x-100 concentration of 0,1% (v/v). Both samples were vortexed briefly and allowed to incubate 
at RT for 20 minutes prior to measurement using the qNano Gold. 
2.3.3 Making Combined Size Distribution Histograms (CSDHs) 
The data collected by measuring the diameter and concentration of the same EV isolate samples using 
NP100 and NP200 were used to create histograms showing the overall size distribution of 
nanoparticles by their concentration (CSDHs) for each EV isolation techniques. Each CSDH was based 
on data obtained in the size interval 50-340nm. Particle diameter data from qNano Gold measurement 
pressures 1 and 2 were considered technical replicates, and both included in the datasets. Data from 
pressure 3 in some cases suffered from low overall particle counts, resulting in less statistical power 
and increased chance of non-representative average particle diameters. The third pressure 
measurement data were therefore not included in the making of CSDHs. Data of measured 
nanoparticles from the NP100 and NP200 with a bin size of 10nm was exported from the Izon software 
suite and processed using a specially made script in the R software environment [63]. Data on the 
concentrations of nanoparticles of 50-120nm in diameter were used from the NP100 datasets, and 
from 121 to 340+ nm in diameter from the corresponding NP200 datasets. In EV isolates from CCM, all 
samples were measured in two TRs using the qNano Gold.  Each CCM based CSDH is therefore based 
on a total of 4 NP100 and 4 NP200 datasets. Each plasma derived sample was measured in one TR. 
Each plasma based CSDH is therefore based on 2 NP100 and 2 NP200 datasets. 
2.3.4 ExoCet Exosome Quantitation Assay (SBI) 
EV isolate samples from the TEI isolation technique were collected from storage (-80°C) and incubated 
for 20m on ice. They were then vortexed briefly, and incubated at RT for 3 hours prior to the ExoCet 
assay. Frozen samples were thawed completely by holding in the hand. ExoCet buffer A, PBS-B and 
lysis buffer were collected from storage (4°C) and placed on the benchtop 2 hours prior to the assay in 
order to equilibrate to RT. EV isolate samples of qEV 7, qEV 8, qEV 9, and ExoEasy were incubated on 
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ice 20 minutes prior to ExoCet Exosome Quantitation Assay (System Biosciences, “SBI”). Samples were 
thawed completely by holding in the hand and homogenized by vortexing briefly.  A positive control 
sample of Acetylcholinesterase (1µg/mL, Sigma Aldrich, “AChE”) was prepared by three steps of serial 
tenfold dilution in Tris-HCl (20mM, pH= 7,5) stock solution (1mg/mL, Sigma Aldrich, “AChE”) with Tris-
HCl (20mM, pH= 7,5). Negative controls consisting of the elution buffers of the various EV isolation 
techniques (Qiagen buffer-XE for ExoEasy samples, 1xPBS for all other samples) were additionally 
prepared. These were additionally used as blanks during calculations for the various samples. 
ExoCet lysis buffer (60µl) was added to 1,5mL one 1.5mL microcentrifuge tube for each planned 
reaction. Each EV isolate sample (60µl) was then added and mixed by briefly vortexing the tubes before 
incubation at 37°C for 5 minutes (dry block) in order to lyse EVs. Debris was removed by centrifugation 
at RT 1500x g for 10 minutes using the Eppendorf Mini Spin Plus table centrifuge, and the supernatant 
of each sample (110µl) was carefully transferred to a fresh set of 1,5mL tubes. Samples were stored 
on ice until completion of assay preparation (< 15 minutes), and then equilibrated to RT before assay. 
Double ExoCet standard curves were prepared by serial dilution by twice performing the dilution series 
described below (table 3). 
Table 3: The dilution series for the ExoCet Exosome Quantitation Assay (SBI) standard curve. A total of 8 points of data was 
prepared for each curve, with the last being a blank (column 1 from the left). The number of exosomes corresponding to the 
levels of AChE enzyme in each dilution (as estimated by the manufacturer) is shown in column 2. Column 3 gives the dilution 
factor of each data point relative to the stock solution, and the last two columns shows the required volumes to mixed for 
each dilution in the series. 
Tube # of exosomes Dilution factor Standard soln. (Stock) PBS-B 
1 1.28*1010 1 128µL 0 
2 6.40*109 1:2 60µL (from tube 1) 60µL 
3 3.20*109 1:4 60µL (from tube 2) 60µL 
4 1.60*109 1:8 60µL (from tube 3) 60µL 
5 8.00*108 1:16 60µL (from tube 4) 60µL 
6 4.00*108 1:32 60µL (from tube 5) 60µL 
7 2.00*108 1:64 60µL (from tube 6) 60µL 
Blank 0 Blank 0 60µL 
 
ExoCet reaction buffer was prepared by mixing ExoCet buffer B (0.5µL/rxn) with ExoCet buffer A 
(50µL/rxn) and vortexing briefly.  The reaction buffer (50µL/rxn) was then immediately loaded into 
each well of the ExoCet-kit included 96-well microtiter plate. In order to minimize time mixed with 
reaction buffer prior to measurement, each sample (50µl) was loaded into a separate 96-well staging 
microtiter plate in accordance with the planned loading order (see appendix section 7.4). While 
carefully avoiding making bubbles, a Pipet-lite 20-200µL 8-channel multichannel pipette (Rainin) was 
used in order to quickly transfer all samples from the staging plate to the ExoCet microtiter plate pre-
loaded with reaction buffer in each well. The plate containing the sample-reaction mix was then 
transferred to a Model 680 XR Microplate reader (BioRad) set with plate shake option enabled for 
gentle mixing of reagents. The optical density (OD) at 405nm was measured at 5 minute intervals from 
0 minutes to 40 minutes. 
The EV isolate samples were observed to have some variance in their apparent opacity (judging by 
eye), and as such, a series of further specialized blanks were designed for the ExoCet in an effort to 
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account for any sample opacity caused by colloid particles in the various samples. Material from each 
individual EV isolate sample from control group donor 2 (for the control group assay) and PC patient 
donor number (PC patient group assay) was used to prepare an additional set of ExoCet assay samples 
(2 ExoCet technical replicates), as described previously. The wells of the 96-well microtiter plate 
designated for these samples, were loaded with ExoCet buffer A (50µL/rxn), but buffer B was not mixed 
in, rendering the reaction mix inert. Samples were loaded in accordance with the loading order, and 
measured alongside the other samples as described previously. 
An estimation of the combined OD405nm in each microtiter plate well stemming from ExoCet reaction 
mix, sample buffer and individual innate sample opacity (OD405nm unrelated to enzymatic action) was 
achieved by adding together the OD405nm of a given samples normal blank +specialized blank. The 
resultant value was subtracted from the given sample as a new specialized blanking value. It was 
against using the values of these blanks during calculation of final ExoCet assay results (see discussion). 
2.3.5 Characterization of EVs by bead-assisted flow cytometry analysis 
EV isolates from CCM were analysed for the presence and relative concentration of CD9 and CD63 
protein by BAFC in 2 TR. Each TR consisted of one sample fraction (50µL) of stained sample assay mix 
(sample) and one fraction (50µL) of unstained sample assay mix (negative control). 
A volume of 0.91µL aldehyde/sulfate latex Beads (4% w/v, 4µm diameter, Molecular Probes) was 
added to Tris-buffered saline (1mL, 0.9% w/v NaCl, 5mM Tris-HCl “TBS”) in a protein LoBind 
(Eppendorf) microcentrifuge tube, for an overall bead-count of 105 beads/tube. The number of beads 
was determined so as to be large enough to prevent over saturation of EVs on each bead, yet small 
enough to allow for detection of EVs in small sample volumes. EV isolate samples (50µL) was added 
and mixed by pipetting, before overnight incubation at 4°C with agitation in a hula shaker. Bead-
coupled EVs were then pelleted by centrifugation at 3000x g for 10m at RT (swinging bucket rotor). 
Unbound sites on beads were blocked by the addition of Glycine (1mL, 100mM in TBS) and incubation 
for 30 minutes at RT. Bead-coupled EVs were again pelleted by centrifugation at 3000x g for 10 minutes 
at RT, before washing with 1mL TBS. Pellets were Then resuspended in staining buffer (100µL, PBS, 
0.5% Bovine Serum Albumin, 2mM EDTA). BAFCR Blocking reagent (25µL, Miltenyi Biotech) was added 
to each sample, before staining with either: 
a. CD9 phycoerythrin (10µL, “PE”, Methylene Blue “MB”, Clone: SN4 C33A2, Miltenyi Biotech) or 
isotype control (2µL, IgG1 PE, Miltenyi Biotech) 
b. CD63 Allophycocyanin (“APC”, 10µL, MB, clone HBC6, Miltenyi Biotech) or isotype control (2µL, 
IgG1 APC, Miltenyi Biotech) 
Samples were then incubated for 20 minutes at RT, shielded from light. Samples were washed with 
staining buffer (1mL) and beads re-pelleted by centrifugation at 3000x g for 10m at RT. Pellet was then 
resuspended in staining buffer (500µl) before analysis on the CytoFLEX Flow Cytometer Platform 
(Beckman Coulter). For analyses, the CytExpert software (Beckman Coulter) was used. Gating of EV 
coupled beads was tuned so as to include only single beads, using the SSD/FSC parameters, and the 
CD9 and CD63 expression was calculated as the median fluorescence intensity (MFI) of 5000 single 
beads.  
The work for the BAFC analysis fort CD9 and CD63 protein was done by another member of the 




2.4 Isolation, quantitation and characterization of EV DNA 
 
2.4.1 Elimination of non-EV DNA by RQ1 DNase treatment of EV samples  
 
2.4.1.1 EV isolates from CCM 
EV isolate samples from CCM were collected from storage (-80°C) and thawed on ice. Each sample was 
homogenized by vortexing briefly, and 70µL transferred to fresh 1,5mL micro centrifuge tubes before 
the addition of 7.5µl RQ1 RNase-Free DNase 10x reaction buffer and 1µL RNase-Free DNase (Promega). 
Samples were mixed carefully by pipetting before incubation at 37°C for 30 minutes (water bath). The 
reaction was terminated by the addition of 7.5µL RQ1 DNase stop solution (Promega). Sample and stop 
solution was mixed by briefly vortexing the tube, which was then incubated at 65°C for 10 minutes 
(dryblock). 
2.4.1.2 EV isolate from plasma 
EV isolate aliquots (from plasma) were collected from storage (-80°C) and thawed on ice in the same 
manner as described above. No more than 15 samples were processed at a time. Each sample was 
homogenized by vortexing briefly, and 100µL transferred to fresh 1.5mL micro centrifuge tubes before 
the addition of 11µl RQ1 RNase-Free DNase 10x reaction buffer and 1µL RNase-Free DNase (Promega). 
Samples were mixed carefully by pipetting before incubation in water bath at 37°C for 30 minutes.  The 
reactions were terminated by the addition of 11µL RQ1 DNase stop solution (Promega), mixing by brief 
vortex and incubation at 65°C for 10 minutes (dryblock). DNase treatment was carried out immediately 
prior to DNA isolation, without delay. 
 
2.4.2 EV DNA isolation 
 
2.4.2.1 DNA isolation from EV isolate samples from CCM (Qiagen Allprep) 
DNase treated EV isolate samples from CCM (70µL, diluted to 86µL with RQ1 DNase reagents during 
treatment, (section 2.4.1.1) were diluted to a total volume of 700µL with lysis buffer (Qiagen Allprep 
buffer RLT plus) and EVs lysed and homogenized by vortexing for 1 minute. All sample tubes were spun 
down briefly and the lysate transferred to AllPrep DNA mini spin columns in 2mL collection tubes. The 
continued isolation of DNA was performed directly in accordance with protocol for AllPrep® 
DNA/RNA/miRNA Universal Handbook provided by manufacturer (Qiagen). The final elution of isolated 
DNA was performed using 2x 50µL of elution buffer EB (Qiagen) in two centrifugation steps of 9000x g 
for 1 minutes at RT, for a total elution volume of 100µL. DNA isolate (20µL) was in all cases immediately 
analysed for concentration of dsDNA using the Qubit dsDNA HS assay the same day. Remainder DNA-
isolate (80µL) was stored at -20°C. The process was repeated for an additional isolation of DNA from 
samples of non-DNAse treated EV isolates (100µl). 
2.4.2.2 DNA isolation from EV isolate samples from plasma (Qiagen QiAmp circulating nucleic acid kit) 
DNA was extracted from DNase treated samples (100µL EV isolate solution diluted to 123µL with RQ1 
DNase reagents during treatment) according to protocol provided by the manufacturer (Qiagen) for 
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QiaAmp Circulating Nucleic Acid Kit for isolating of free-circulating DNA and RNA from human plasma 
or serum (1mL or less starting volume). No carrier RNA was used. The final elution of isolated DNA was 
performed using 50µL of elution buffer AVE (Qiagen) and centrifugation at 16 000x g for 1 minute. 
2.4.3 Quantitation of dsDNA by Qubit® dsDNA HS assay 
Samples of isolated nucleic acids (see Allprep and QiaAmp above) were thawed on ice for dsDNA 
quantitation using the Qubit™ dsDNA HS assay kit (Thermo Fisher Scientific) and Qubit™ 2.0 
fluorometer (Invitrogen, Life technologies). 
Qubit Workings Solution (200µL,”WS”) was prepared for each reaction by mixing of Qubit reagent with 
Qubit™ dsDNA HS buffer (1:200). The Qubit™ 2.0 fluorometer uses two standard solutions in order to 
automatically generate a standard curve for measurements of concentrations. These were prepared 
by adding WS (190µL) to each of two Qubit™ Assay Tubes (Thermo Fisher Scientific) and adding a 
volume of 10µL of either Qubit™ dsDNA HS Standard solution 1 or 2. WS (180µL) was then added to 
one Qubit™ Assay for each sample to be measured, and sample (20µL) was added to each tube. All 
standard and sample reaction mixes were homogenized by vortexing for 3 seconds before spinning 
down briefly using a table centrifuge. The reaction mix was incubated for 2 minutes at RT before 
measuring the standard solutions on the Qubit™ 2.0 fluorometer (Invitrogen, Life technologies, dsDNA 
HS setting). Samples were subsequently analysed, and the dsDNA concentration of the DNA isolate 
samples determined using the Qubit™ 2.0 fluorometer calculator function. 
 
2.4.4 Identification of KRAS mutation by PNA clamp qPCR assay 
Isolated exoDNA (20µL, see Allprep, QiaAmp above) was amplified and screened for KRAS mutations 
by PNA Clamp quantitative real-time PCR (qPCR) Assay for KRAS mutation. Each sample was tested in 
two TRs, each consisting of PNA positive (+PNA) and PNA negative (-PNA) assay sample (each original 
DNA isolate divided into 4 sample aliquots in total). A negative control consisting of WT isolated plasma 
DNA (5µL) from a healthy individual was used along with a positive control (5µL, 10ng/µL) consisting 
of a 1:100 diluted mixed LS174T (heterozygous GGT > GAT codon 12 KRAS mutation ([c.35G > A]) in 
Caco-2 (KRAS WT) cell line DNA isolate. 
PNA (sequence 5’-CCTACGCCACCAGCTCC-3’) and PCR forward (5’-GCCTGCTGAAAATGACTGAATATAA-
3’ KRAS-PNA-FB, Oligodatabase ID 85) and reverse (5’-CGTCAAGGCACTCTTGCCTAC-3’ KRAS-PNA-RB, 
Oligodatabase ID 88) primers  were acquired and prepared as in Tjensvoll et.al. 2015 [64] 
Reagents and DNA samples were thawed on ice in separate LAF benches, and mastermix sufficient for 
all reactions in accordance with table 4 below. Before the addition of PNA, the mastermix was 
separated into two tubes, and PNA added to one (+PNA) and Milli-Q water to the other (-PNA, see 
table 4). Mastermix (20µL) was then added into wells on a 96-well PCR plate meant for 
samples/controls. The PCR plate with master mix was moved to the LAF bench with the DNA samples, 
and sample (5µL) was added to each well in accordance with the planned loading order. The PCR-plate 





Table 4: Reagents and volumes for the PNA Clamp PCR Assay for KRAS mutation. The order in which reagents were added 
follows the table from top to bottom. 
PNA-clamping  PCR  Phusion   20 l  mastermix 
        +PNA -PNA 
Number of rxn: 112     56 56 
            
Reagent Conc. Volume/rxn Mastermix   +PNA  -PNA 
Vann   12,987 1454,5     
5x Phusion HF buffer 1x 5 560     
25 mM dNTP 0,2 mM 0,2 22,4     
KRAS-FB primer 0,15 0,375 42     
KRAS-RB primer 0,15 0,375 42     
SYBR Gr. I 1:200   0,75 84     
2 U/µl Phusion pol. 0,02 U/µl 0,25 28     
Final   19,937 2232,9 1116,47 1116,47 
            
100 µM PNA 0.25 µM 0,063   3,500 0 
MQ-H2O       0 3,500 
Final   20,000   1120 1120 
 
The PCR program was then run using the following program: 
- 98°C, 30 seconds (activation of enzyme) 
- 45 cycles: 
o 98°C, 20 seconds (denaturing) 
o 76°C, 10 seconds (PNA annealing) 
o 60°C, 20 seconds (primer annealing) 
o 72°C, 72 seconds (elongation), with measurement of fluorescence 
 
The work for the PNA Clamp qPCR assay for KRAS mutation was done by another member of the 














An overview of the overall workflow for the experimentation in this study is shown below (figure 4). 
The main phases of EV isolation and characterization is shown for samples form CCM and plasma. 
More in-depth descriptions will be given under each individual section. 
 
 
Figure 4: Outline of the workflow for EV isolation and characterization with samples from CCM shown to the left, and samples 
from plasma shown to the right. In each case the general workflow goes from raw material to isolated EVs. These are then 




3.1.1 EV isolations using CCM as starting material 
For EV isolations using CCM as a starting material, PANC-1 CCM was produced (section 2.2.1.4) and 
clarified (section 2.2.1.5) and a volume of 16ml CCM was used for each technique in two TR (section 
2.2.3). The only exception to this was the UC technique, for which some additional steps were taken 
(section 2.2.3.8). EV isolation on CCM was carried out using differential centrifugation (UC), SEC (qEV), 
affinity chromatography (ExoEasy) and polymer precipitation (ExoQuick, TEI). After EV isolation using 
each technique, EVs were resuspended/eluted to a volume of 500µL. The suspended EVs were then 
stored in aliquots at -80°C until use in the various analyses (table 5).  
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Table 5: Sample aliquots prepared from EV isolate from CCM (2x 16mL). The 500µL of EV isolate from each of the two EV 
isolate technical replicates (column 1 from the left) was divided into aliquots according to intended downstream application 
(column 2). The volumes of each aliquot is shown in column 4. 
# TR Downstream application Abbreviation Aliquot volume (µL) 
2 qNano Gold qNan 180 
2 DNA analysis (+DNase) DNA+ 70 
2 DNA analysis (- DNase) DNA- 100 
2 BAFC BAFC 100 
2 Other N/A 50 
 
Two replicate samples of each EV isolation technique was later thawed and used for each of the 
planned analyses (sections 2.3, 2.4) by TRPS (Size, concentration, vesicle fraction), BAFC (exosome 
marker proteins), and Qubit dsDNA HS assay (dsDNA cargo, effect of DNase). The dsDNA for the Qubit 
dsDNA assay was isolated using the Allprep DNA/RNA/miRNA kit. 
The goals of these experiments were to establish good methodology and get a general overview of the 
efficacy of each individual technique, was well as identifying the three most promising EV isolation 
techniques. Only the three best techniques would be used for the next phase of experimentation using 
human plasma as starting material. 
3.1.2 EV isolations from human plasma samples 
 
After establishing the methodology and testing results from CCM were reviewed, the three EV isolation 
techniques showing the best performance in relation to our criteria were advanced to the next stage 
of testing, using human plasma as starting material for EV isolation. The techniques selected were 
ExoEasy, TEI and qEV (section 3.3). 
Here, plasma was collected from control and PC patient donors, clarified (section 2.2.2), and used for 
EV isolation using the ExoEasy, TEI and qEV techniques. Samples were then used for determination of 
dsDNA content (Qubit dsDNA HS assay), levels of tumour DNA (PNA clamp), exosome concentration 
(ExoCet), nanoparticle concentration, size distribution and vesicle fraction (TRPS). DNA for the Qubit 










3.2 Comparison of methods of EV isolation from cell culture medium 
 
For EV isolations using CCM as a starting material, 200mL of PANC-1 CCM (passage 35) was produced 
(section 2.2.1.4) and clarified (section 2.2.1.5) and used to carry out exosome isolation on 16mL of 
CCM using each exosome isolation technique (section 2.4) in two TR. The only exception to this was 
the UC technique (section 2.4.8). In this case, an aliquot of 40mL freshly clarified CCM was first used 
for the preparatory centrifugation stage (10 000xg, 30m). This step was unique to the UC technique, 
and the larger volume was to allow for some shrinkage. Out of the supernatant from this 
centrifugation, two aliquots of 16.5mL were used during ultracentrifugation. This volume had to be 
used due to a particularity of the ultracentrifuge tubes, which required a filling level of 16.5mL. This 
difference in starting volume between the UC technique and the other EV isolation techniques (16.5mL 
versus 16.0mL) was corrected for mathematically in all results. 
Exosome isolation on CCM was carried out using differential centrifugation (UC), SEC (qEV), affinity 
chromatography (ExoEasy) and polymer precipitation (ExoQuick, TEI), the results are shown in section 
3.2 below.  
After exosome isolation using each technique, exosomes were resuspended/eluted to a volume of 
500µL. In the case of ExoEasy (Qiagen), the eluent used was the proprietary buffer XE, which was part 
of the ExoEasy maxi kit. For all other EV isolations, 1xPBS was used. The suspended EVs were then 
stored in aliquots at -80°C until use in the various analyses (table 5).  
Two replicate samples of each EV isolation technique was then used for each of the planned analyses 
(sections 3.2.1 – 3.2.4). The nanoparticle concentration and size distribution was determined for each 
EV isolation technique using the qNano Gold TRPS analysis (section 3.2.1). Additionally, the relative 
vesicle fraction in for each sample was estimated by treatment with Triton x-100 (0.1% v/v) and TRPS 
concentration measurements (section 3.2.2).  The relative levels of the exosome marker proteins CD9 
and CD63 was measured using BAFC assay (section 3.2.3) and the relative concentrations of EV dsDNA 
cargo achieved through each EV isolation technique was measured using the Qubit dsDNA HS assay 
(section 3.2.4). Here the relative amount of dsDNA contained within EVs was also estimated by DNase 
treatment of the raw EV isolate sample prior to DNA isolation.  
A schematic illustration of the workflow from clarified starting material to the various analyses is 




Figure 5: General workflow for EV isolate samples using CCM as starting material. The paths between various stages (black 
boxes) in the process from raw material to EV analysis is indicated by the black arrows. Next to each arrow is additional 










3.2.1 Determination of particle concentration and size 
 
In order to assess the yield and types of EV primarily isolated by each individual technique, nanoparticle 
diameter and concentration was determined by TRPS analysis using the qNano Gold (section 2.3.1). 
The instrument could not distinguish vesicles from other nanoparticles. Samples of ExoEasy, TEI, 
ExoQuick, qEV7, qEV8, qEV9 and UC were measured in two TR. Each sample was measured at the 
manufacturer-recommended three pressures, in order to achieve high quality concentration 
measurements. The qNano Gold instrument reported nanoparticles/mL were normalized so as to 
correspond to nanoparticles/mL CCM used during EV isolation (16mL in the case of CCM samples, 
16.5mL for UC samples). 
Nanoparticle concentrations 
The average nanoparticle concentration and standard deviation in the range of each nanopore was 
calculated based on the two TRs measured of each sample. A figure illustrating the measured CCM 
derived EV isolate nanoparticle concentrations is shown below (figure 6). The full collected data can 
be found in the appendix (Section 7.5) 
 
 
Figure 6: TRPS measurements on samples of EV isolates using CCM as raw material. NP100 (particle diameter 50-200nm) 
measurements are shown on the left, and NP200 (particle diameter 85-340nm) on the right. Fractions of qEV were measured 
individually and have been pooled mathematically. 
The qNano Gold measurements on samples from CCM indicated an overall concentration of 
nanoparticles much higher in the 50-200nm range than in the 85-340nm range. Interestingly, the 
observed reduction in nanoparticles between seize was variable between EV isolation techniques, 
indicating variance in nanoparticle size distribution. While the ExoEasy EV isolate yielded by far the 
highest measured concentration in the NP100 range (1,13E+09 P/mL vs. 5,05E+08 P/mL respectively), 
TEI gave the highest concentration in the NP200 range (TEI at 3,11E+08 P/mL vs ExoEasy at 1,86 E08 
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concentration in the NP100 range (6,0E+08 P/mL) and very nearly coming second also in the NP200 
range (1,81E+08 P/mL). ExoQuick, while not far behind, had the third highest yield in both particle size-
ranges, with NP100 and NP200 concentrations of 4.19E+08 P/mL and 1,14E+08 P/mL respectively. The 
UC samples provided the lowest nanoparticle concentrations of all the techniques by far, in both 
NP100 and NP200 ranges. 
Nanoparticle average size distributions 
The qNano gold, in addition to collecting concentration data, collects size data on each individual 
particle which passes through the nanopore, and is within the detection limit size range of the pore. 
An average particle diameter can therefore be calculated, and correlated with sample concentration 
as done for EV isolate samples from CCM below (figure 7).  
 
Figure 7: Average nanoparticle diameter as a function of concentration, by EV isolation technique. Values shown are calculated 
across all qNano Gold NP100 (50-200nm) measured particles from CCM. In the chart, movement to the right signifies 
increasing concentration, whereas movement upwards means increasing average particle diameter. Error bars on the y-axis 
are based on the standard deviation associated with average particle diameter as reported by the qNano gold. The error bars 
on the x-axis are based on technical replicate measurements of the concentration of each sample.  
On average, in EV isolates from CCM, the particles isolated by the UC technique gave the largest overall 
particles, combined with the lowest particle concentration (figure 7). Progressively smaller 
nanoparticle average diameters were achieved for the qEV fractions 7, 8 and 9, with the latter having 
the smallest average diameter of all the EV isolates using CCM as raw material. The TEI and ExoEasy 
techniques gave very similar average particle diameters.  
Combined Size Distribution Histograms 
We combined the size information obtained from the NP100 and NP200 pores for each of the EV 











































Figure 8: Combined Size Distribution Histograms (CSDH) for samples of ExoEasy, TEI, qEV 8 and ExoQuick from CCM. Each bin 
spans 10nm in particle diameter. All CSDHs are modelled based on size distribution data collected using the qNano Gold, and 
are a combination of data from nanopores NP100 (50-120nm) and NP200 (121nm+). The y-axis has for all histograms been 
set to 8E+09 particles/mL, and the x-axis to 600nm, for ease of comparison between EV isolation techniques. 
The combined size histograms (CSDHs) of ExoEasy, TEI, qEV8 and ExoQuick (figure 8) revealed a roughly 
similar size distribution of nanoparticles in the 4 samples. The smallest nanoparticles were in all cases 
most frequent, with modes around 60nm, and then rapidly declining as nanoparticle diameter 
approached 200nm. This substantiated the already reported findings of the particle concentration 
differences between the NP100 (50-200nm) and NP200 (85-340nm) for qNano gold NP100 
measurements on samples from CCM (figure 6). There were however some differences visible in how 
concentration decreased, as particle diameter increased from 70-200nm. TEI and ExoQuick were very 
similar in this regard, both showing many particles in the 70-100nm range, and then showing a smooth 
gradual decline of concentrations, continuing throughout the entire measured interval. TEI however 
appeared to have the overall greatest concentration in the interval from 100-150nm, the interval in 
which exosomes would fall. qEV 8 appeared to have a somewhat more rapid decline in concentration, 
as diameters exceeded 110nm, than did the other techniques compared here. ExoEasy appeared to 
have a very large number of particles in a plateau from 90-120nm. Concentrations then rapidly 
dropped off, to nearly half of that observed in TEI in the 120-130nm interval. 
It should be noted, that the sensitivity cut-off for all measurements was at 50nm. It is therefore 
possible that concentrations even higher than what is shown in the diagrams, is present in the 
diameter range from 50nm and below. It should further be noted that the histogram data reflects 
particles/mL measured sample, and has as such not been normalized so as to reflect particles/mL 
starting material during EV isolation.  
The qEV fractions and the UC sample yielded much lower absolute concentrations, than did TEI, ExoQ 
and ExoEasy. As such, they can better be compared using a slightly smaller scale (figure 9). Out of the 
qEV fractions, qEV 8 had the greatest overall concentration by far, with a very large amount of particles 
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measured in the 60-120nm range. Concentrations then dropped off sharply, for higher particle 
diameters. qEV 7 conversely, showed a much more gradual decline in concentrations as particle 
diameter increased, with overall low particle concentrations. qEV 9 showed a particle distribution in 
the 60-100nm range reminiscent to that of qEV 8, but with a much less sharp cut-off at higher particle 
diameters. The ultracentrifugation CSDH indicated a very flat distribution, somewhat favouring 
particles in the 60-110nm range. Larger standalone versions of each CSDH shown in figures 8 and 9 can 
be found in the appendix (section 7.5.2) 
 
 
Figure 9: Combined Size Distribution histograms (CSDH) for samples of qEV 7, qEV 8, qEV 9 and UC from CCM. Each bin spans 
10nm in particle diameter. All CSDHs are modelled based on size distribution data collected using the qNano Gold, and are a 
combination of data from nanopores NP100 (50-120nm) and NP200 (121nm+). Note that the scale of the y-axis has been 
reduced relative to figure 8. The y-axis has for all histograms been set to 2E+09 particles/mL, and the x-axis to 600nm, for ease 
of comparison between EV isolation techniques  
Relative presence of large EVs (200nm+) 
In addition to nanoparticles in the general size-range for exosomes (50-150), also the relative 
concentrations of potential EVs of greater dimension, such as MVs and oncosomes, are of interest. In 
order to better assess the concentrations of these nanoparticles, the scales of the y-axis of each CSDH 






Figure 10: Combined Size Distribution Histograms (CSDH) for samples of ExoEasy, TEI, qEV 8 and ExoQuick from CCM. Each bin 
spans 10nm in particle diameter. All CSDHs are modelled based on size distribution data collected using the qNano Gold, and 
are a combination of data from nanopores NP100 (50-120nm) and NP200 (121nm+). Note that the scale of the y-axis has been 
reduced even further relative to figure 8, in order to better allow comparisons of size distributions of particles with diameter 
>200nm. The y-axis has for all histograms been set to 3E+08 particles/mL and the x-axis to 600nm. 
Focusing on these nanoparticles with diameters exceeding 200nm (figure 10), TEI showed the overall 
most diverse concentrations of particles, with a relatively large amount found in the 200-300nm range, 
as well as a trail of particles of even larger diameters.  ExoEasy conversely, had the largest amount of 
particles in the 200-300nm range, but very few particles exceeding 300nm in diameter. ExoQuick and 
qEV 8 showed very similar distributions in the 200-500nm range, with a gentle slope from 200nm and 
out. ExoQuick did, however, display the overall larger amount of particles in this range, when 




Figure 11: Combined Size Distribution Histograms (CSDH) for samples of ExoEasy, TEI, qEV 8 and ExoQuick from CCM. Each bin 
spans 10nm in particle diameter. All CSDHs are modelled based on size distribution data collected using the qNano Gold, and 
are a combination of data from nanopores NP100 (50-120nm) and NP200 (121nm+). Note that the scale of the y-axis has been 
reduced even further relative to figure 9, in order to better allow comparisons of size distributions of particles with diameter 
>200nm. The y-axis has for all histograms been set to 3E+08 particles/mL and the x-axis to 600nm 
Also when comparing particles above 200nm, qEV7 and qEV8 displayed very similar distributions 
(figure 11), with a gentle slope stretching until about 500nm. qEV9 appeared somewhat different, with 
a very sparse and discontinuous particle population above 200nm. The UC sample showed a sloping 
distribution similar to that described for qEV7, qEV8, ExoQuick and TEI previously, although with much 
lower overall concentrations. 
 
3.2.2 Estimation of vesicle fraction by sample treatment with Triton x-100 
 
In order to estimate the fraction of EVs in the measured nanoparticle population (as opposed to 
protein aggregates and other contaminants), a set of TRPS measurements of EV samples from ExoEasy, 
TEI, ExoQuick, qEV7, qEV8, qEV9 and UC was performed with and without treatment with Triton x-100 
(0.1% v/v). By adding a non-ionic detergent such as Triton x-100, membrane bound bodies such as EVs 
will dissolve, and only non-membranous nanoparticles will remain. The difference in measured 
nanoparticles before and after treatment should therefore equate to the number of vesicles in the 
sample. 
In this set of measurements, two equal aliquots of EV isolate sample from each of the EV isolation 
techniques were diluted in fresh filtered (0.2µm) measurement electrolyte to the concentrations 
previously determined to be ideal for measurement of the that particular sample (section 3.2.1). One 
of the samples was treated with Triton x-100 (0.1% v/v, section 2.3.2). For a full list of all measured 
concentrations in this experiment, see the appendix (section 7.5.1).  
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Based on the two measured nanoparticle concentrations, the change (Δ) following treatment with 
Triton x-100 (0,1% v/v), corresponding to the vesicle fraction, was calculated and is show below figure 
12). Additionally, the Δ in mean nanoparticle diameters was calculated (figure 13) 
 
Figure 12: The vesicle fraction of the NP200 nanoparticle measurements in EV isolate samples from CCM, estimated by 
treatment with Triton x-100 shown in vesicle concentration (blue bars, left y-axis). Calculated vesicle fraction (%) of each 
individual EV isolate sample is shown in the same diagram (orange line, right y-axis). The height of each bar relative to the left 
y-axis corresponds to the estimated concentration of vesicles or other membrane-bound bodies per mL of CCM, within the 
measurement interval (85-340nm). The height of each point indicates the relative percentage of nanoparticles in the sample 
determined to be vesicles. 
When considering only the total vesicle yield (figure 12), ExoEasy gave the highest estimated number 
of vesicles, at 1.04E+08 vesicles/mL CCM. While none of the qEV fractions alone came close to this 
number, their combined contribution came out to be 9.18E+07 vesicles/ml CCM, and thus placing qEV 
at second best in this respect. Third was TEI at 8.75E+07 vesicles/mL CCM, followed by ExoQuick and 
UC respectively, with UC yielding the fewest overall vesicles by a wide margin. 
Conversely, when considering the vesicle fraction (figure 12), The qEV7 EV isolation fraction was 
determined to be of the greatest purity, with 86.73% of all measured NP200 particles being vesicles 
and other membrane-bound bodies. TEI was conversely determined the least pure, at only 43,34% of 
particles estimated to be vesicles. ExoQuick appeared to yield the second purest vesicle fraction, at 
73.3% vesicles. qEV fractions 8 and 9 were estimated to similar purities, with 56.56 and 59.48% vesicles 
respectively. Ultracentrifugation gave a marginally better purity than TEI, at 45,09%. This however has 


















































Figure 13: The Triton x-100 (0.1% v/v) induced change in mean particle diameter (nm) in the 85-340nm range. Change is 
calculated as diameter after treatment with Triton x-100, subtracted from diameter before treatment. Movement to the left 
in the figure indicates a measured overall decrease in nanoparticle diameter resulting from the treatment, whereas movement 
to the right signifies an increase in particle diameter. 
 
The overall largest change in particle diameter was observed in the UC sample, with a large increase 
in mean particle diameter (figure 13). The UC EV isolate was also the one with the largest starting 
average particle diameter, indicating the dissolution of many small particles during the treatment. 
While qEV and ExoEasy experienced moderate increases in mean particle diameter, the TEI and 
ExoQuick samples displayed the opposite, with small to moderate reductions in nanoparticle 
diameters. A reduction would indicate that the particles dissolved by the treatment was of an on 
average larger diameter than the remaining ones. 
 
3.2.3 Characterization of CD9 and CD63 protein levels in EV isolates 
 
As a means of characterizing the isolated EVs, a bead-assisted flow cytometry (BAFC) assay was used 
to measure the levels of CD9 and CD63 proteins of each sample. These are proteins known to be 
enriched in exosomes, but are not unique to them (section 1.2.2.). For this assay, samples of ExoEasy, 
TEI, qEV7, qEV8, qEV9 and UC in two TR were adsorbed to latex beads (4µm diameter) and stained 
using a phycoerythrin (PE)-conjugated CD9 antibody or a allophycocyanin (APC)-conjugated antibody 
against CD63 (section 2.5.6). Results were quantitated based on relative interaction between EVs 
bound to latex beads and CD9 as well as CD63 antibodies. The interaction when stained resulted in a 
median fluorescence intensity (MFI) fold change, relative to a negative sample stained with isotype 
control. A greater fold change meant greater relative levels of the target protein in the sample.  
In the BAFC assay for the presence of CD9, all qEV-fractions scored particularly well, with qEV9 
displaying the largest measured MFI of any sample at 4,69 (figure 14). The second largest MFI was very 
closely contested between the ExoEasy sample and the qEV 8 fraction, with values of 3,06 and 2,97 
respectively. The third highest detected MFI for CD9-antibody interaction, was the last qEV-fraction, 











qEV7, at 2,19, handily exceeding the values measured for TEI, ExoQuick and UC (1.43, 1.33, 1.23 
respectively). 
 
Figure 14: CD9 BAFC measured relative MFI fold change between EV isolate samples from CCM. The y-axis shows the relative 
MFI fold-change for each individual EV isolate sample. 
Using the CD63 antibody and APC stain resulted in a much higher overall signal strength, yet with 
overall similar relationships between samples as detected using CD9 (figure 15). All qEV fractions gave 
clear MFI fold change values also in the case of CD63. In contrast to the CD9-based measurements 
however, ExoEasy provided the single highest MFI fold change in this case, at a value of 20,15. In 
second, third and fourth place came qEV 9 (18.95), qEV8 (10.76) and qEV7 (7.48) respectively. Notably, 
while TEI, ExoQuick and UC samples all gave very low MFI fold change results relative to the ExoEasy 
and qEV samples, the UC sample here in fact scored marginally higher than TEI and ExoQuick. 
 
 
Figure 15: CD63 BAFC measured relative MFI fold change between EV isolate samples from CCM. The y-axis shows the relative 









































3.2.4 Determination of isolated EV dsDNA content 
 
Samples of ExoEasy, TEI, qEV7, qEV8, qEV9 and UC EV isolates (100µL) in two TR were treated with 
RQ1 DNase (Promega) prior to DNA isolation using the Allprep kit (Qiagen), and compared with DNA 
isolated from untreated samples. In this manner, the dsDNA concentration measured in the samples 
treated with DNase would represent the DNA internal to EVs (and therefore protected from the action 
of the enzyme) and the untreated samples represented the total DNA. After correcting fort starting 
volumes, the difference between the samples corresponded to the DNA which was exterior to EVs, 
and therefore vulnerable to the DNase treatment. All data were normalized to reflect the dsDNA 
content per mL of CCM used during EV isolation. For a breakdown of the calculations used in order to 
calculate the dsDNA/mL starting material see the appendix (section 7.1) 
The data showed a clear trend of exome isolate treatment prior to DNA isolation resulting in a slight 
reduction in the measured dsDNA. The TEI EV isolation technique provided the highest measured levels 
of dsDNA with 45.36 ng/mL CCM. This constituted nearly double that of the second highest yielding 
technique, ExoEasy (Qiagen) with its 23.18 ng/mL CCM. When the yields of the qEV fractions were 
pooled, the total dsDNA/mL without DNase treatment was 12.43ng/mL, and the yield from the DNase 
treated samples 5,47ng/mL (figure 16) 
 
 
Figure 16: dsDNA /mL CCM by EV isolation technique, with and without DNase treatment. Non-DNase treated samples are 
shown in blue, whereas DNase treated samples are show in orange. qEV fractions have been pooled mathematically (see 
appendix, section 7.1). Error bars are based on the calculated standard deviation of the two technical replicates of each 
sample.  
ExoQuick (SBI) proved to be the technique most greatly impacted by the DNase treatment, with a 
reduction in measured dsDNA by more than 34% from 14,29ng/mL in the untreated samples, and a 
mere 4,88 ng/mL in the treated sample. As such, the ExoQuick technique could be said to the lowest 
dsDNA yield internal to its isolated EVs with the exception only of UC. With the very lowest yield in 
dsDNA was the UC technique, with a calculated dsDNA/ml of only 2,65ng for the non-DNase treated 
























3.2.5 Comparison between measured dsDNA and nanoparticle concentrations 
 
3.2.5.1 dsDNA per nanoparticle 
The measured dsDNA concentrations for DNase treated EV isolates from CCM (section 3.2.4) were 
divided by the corresponding TRPS measured nanoparticle concentrations for the same samples. This 
resulted in a “dsDNA/nanoparticle” value, indicating what technique on aggregate isolated the EVs 
richest in dsDNA. The calculated numbers were multiplied by 1.0E+08 for a more intuitive scale (figure 
17). 
 
Figure 17: Calculated dsDNA (ng) per 1.0E+08 TRPS measured nanoparticle (50-200nm diameter) in EV isolates from CCM. 
dsDNA data is collected from EV isolate samples treated with DNase prior to DNA isolation using the Allprep kit (Qiagen). 
The division of dsDNA per nanoparticle calculation (figure 17) illustrated how the TEI technique 
isolated the most dsDNA enriched EVs, relative to its total amount of isolated nanoparticles. In the qEV 
fractions, an upwards trend could be observed in the relative dsDNA content per nanoparticle as the 
qEV fraction number increases. Interestingly, the UC technique, despite a generally very low yield in 
bot isolated nanoparticles and dsDNA, in fact isolated more dsDNA/nanoparticle than did any other 
technique apart from TEI, 
 
3.2.5.2 Correlation between 50-200nm diameter nanoparticles and dsDNA concentrations 
Additionally, in an effort to estimate the correlation between increasing yields of nanoparticles and 


































Figure 18: Correlation between TRPS measured nanoparticles (50-200nm) and dsDNA yield. The outlier (blue point) at 
approximately 45ng/mL dsDNA (y-axis) represents the TEI sample (marked “TEI”). When the outlier is included (top trend line) 
the R2 of the trend (shown above the trend lines) becomes very low (0.2811). When the outlier is removed (bottom trend line) 
the R2 value increases dramatically to 0,9538 (shown below the trend lines).   
The plot for correlation between 50-200nm TRPS measured nanoparticle and dsDNA concentrations 
was at first observed to yield a fairly low R2-value, due to an outlier data point with a drastically higher 
dsDNA concentration than would be expected based on the precedence set by the other samples. The 
outlier was determined to correspond to the TEI sample. By removing the TEI data point as an outlier, 
the fit of the trend line increased significantly, to an R2- value of 0.9538. 
 
3.2.5.3 Correlation between 85340nm diameter nanoparticles and dsDNA concentrations 
In the same manner as done previously (figure 18), the 85-340nm diameter nanoparticle 
concentrations were plotted against the same dsDNA data as previously (section 3.2.5.2) in order to 
estimate the correlation (figure 19). 
 
Figure 19: Correlation between the measured number of qNano Gold NP200 nanoparticles (85-340nm), and dsDNA yield. The 






















































TRPS (85-340nm) measured nanoparticles/mL CCM
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Interestingly, by plotting not the 50-200nm diameter particles against DNA concentrations, but 
choosing instead the 85-340nm size interval, a very well fitting trend line was immediately obtained 
(figure 19). In this case, TEI fit in on the trend collectively set by all samples, whereas the UC sample 
turned out to fit the least well into the established trend. 
 
3.2.5.4 measured dsDNA concentration vs CD9 and CD63 content 
Finally, a plot was constructed superimposing the measured dsDNA concentrations of each EV isolate 
sample from CCM with their corresponding measured CD9 and CD63 content (figure 20). The goal was 
to look for any trends between the two separate factors. 
 
Figure 20: The BAFC measured MFI fold change (left y-axis) of CD9 (blue bars) and CD63 (orange bars) vs. the Qubit measured 
dsDNA (ng/mL CCM, right y-axis, grey line). Note that the line and bars use different absolute scales.  
 
The comparison revealed a tendency of dsDNA concentration to increase as exosome marker protein 
increased in the ExoEasy and qEV samples. Notably, this trend did not hold true for either of the 
precipitation reactions (ExoQuick and TEI) which both showed disproportionately high dsDNA 
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3.3 Comparison of EV isolation methods for plasma 
 
After the initial phase of experiments using CCM as a raw material was completed, a second phase of 
plasma based tests were begun. Based on the data collected on all the EV isolation techniques during 
the initial testing phase, The ExoEasy, TEI and qEV techniques were deemed to show the most overall 
promise with regards to ability to isolate large quantities of vesicles, high dsDNA yields and EVs 
featuring exosome marker proteins (see discussion). ExoEasy, TEI and qEV were therefore selected for 
further testing using human plasma as starting material, in the search for the technique best suited for 
isolated tumour DNA.  
Blood from 3 healthy control donors was used to isolate plasma (section 2.2.2) and each used to 
generate two EV isolation (2 TR) using each of the three EV isolation techniques. This constituted the 
control group, with a total of 3 BR each in two TR of each of the three isolation techniques. Similarly, 
plasma samples previously isolated from three PC patients were collected from storage (-80°C) and 
used for EV isolation. In the same manner as the control group, plasma from each PC patient donor 
was used to generate one EV isolation using each of the three selected EV isolation techniques. Due to 
the limited amount and valuable nature of the PC patient sample material however, no technical 
replicates were created in this case. This constituted the PC patient group, with a total of three BR for 
each EV isolation technique. As for samples using CCM as starting material, the plasma derived EV 
isolates were divided into aliquots before storage (-80°C) according to their planned downstream 
application. 
One sample from the control group and one from the PC patient group were used for determination 
of the nanoparticle concentration and size distribution of each EV isolation technique (section 2.3.1). 
Additionally, control group samples (3BR x 2TR) and PC-patient group samples (3BR) were used to 
measure the concentration of exosomes achieved through each EV isolation technique by ExoCet 
Exosome quantitation assay (section 2.3.4).  The same set of samples as were used for determination 
of the nanoparticle concentrations were additionally used for estimation of the relative fraction of 
vesicles in each sample through treatment with Triton x-100 (0.1% v/v) by TRPS (section 2.3.2). Control 
group samples (3BR x 2TR) and PC-patient group samples (3BR) were used determine the EV cargo 
dsDNA yield was using Qubit dsDNA assay (section 2.4.3). The remainder of DNA isolate from the PC 
patient group was used to determine the relative amount of KRAS mutated alleles in EVs isolated by 
each EV isolation technique (section 2.4.4). An overview of the general workflow of EV isolation from 





Figure 21: General workflow for EV isolate samples using plasma as starting material. 3 control group and 3 PC patient (3+3) 
donors contributed the plasma used for EV isolation. The paths between various stages (black boxes) in the process from 
starting material to EV analysis is indicated by the black arrows. Next to each arrow is additional information pertaining to 
the particular step in question. TR= Technical Replicate. BR = biological replicate. 
 
3.3.1 Determination of particle concentration and size 
 
Similarly, to what was done with EV isolates from CCM, Nanoparticle concentrations and diameters 
from EV isolate samples plasma were determined using the qNano Gold (IZON science). Measurement 
results were normalized to reflect nanoparticles/mL starting material during EV isolation (here, 1mL 
plasma), as described previously (section 3.2.1) 
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3.3.1.1 Nanoparticle concentrations 
EV isolate samples from plasma (1TR) of one PC-patient and one control group donor was selected for 
measurement with the qNano Gold. The samples to be measured from each of the two donors was 
ExoEasy, TEI, qEV7, qEV8 and qEV9. As before, sample was measured at the manufacturer 
recommended three pressures. Each sample was measured using both NP100 and NP200 nanopores. 
Data was normalized to correspond to nanoparticles/mL plasma (as previously described) can be seen 
shown below (figure 22). A summary of the full collected data can be found in the appendix (Section 
7.5) 
 
Figure 22: TEI and qEV (pooled) nanoparticles/mL plasma, measured using qNano Gold with nanopores NP100 (particle 
diameter 50-200nm) and NP200 (particle diameter 85-340nm). Control group measured concentrations can be seen to the left 
of the chart, and PC patient group measured concentrations to the right. ExoEasy concentrations are not included in the 
diagram in this case, due to low qNano Gold measurement quality of these samples. 
During measurements however, it was discovered that no measurements could be made using the 
qNano Gold on samples of ExoEasy from plasma in all but two instances where poor quality 
measurements were obtained (see discussion). Various dilutions of the two separate ExoEasy samples 
ranging from a factor of 1:2 to 1:60 were attempted, as well as measuring using nanopores NP100, 
NP200 and NP250. While the exact reason for this apparent incompatibility is not known, some 
speculation may be done (discussion section 4.1.3). The only EV isolation techniques from plasma 
available for comparisons by TRPS were therefore TEI and qEV. 
Interestingly measured nanoparticle concentrations were higher for the selected control group donor 
than for the PC patient samples. This was true for both NP100 and NP200 measurements of both TEI 
and qEV (figure 22). In the NP100 range for both donors, the TEI isolation technique proved to yield a 
much higher concentration of particles/mL, than did even the pooled qEV fractions. In this range (50-
200nm particle diameter) the pooled qEV fractions nanoparticle yield for the control donor constituted 
only 15,1% of the corresponding TEI nanoparticle concentration. In the case of the PC patient samples, 
qEV similarly constituted only 15,8% of the corresponding TEI concentration in the same range. This 





























3.3.1.2 Comparing EV isolates from plasma and CCM nanoparticle concentrations 
The TRPS measured nanoparticle concentrations for TEI and qEV in the 50-200 and 85-340nm ranges 
were compared in order to assess the relative difference in isolated nanoparticles between the two 
starting materials (figure 23) 
 
Figure 23: Comparison of TRPS measured nanoparticles/mL starting material (CCM/Plasma), from TEI and qEV EV isolation 
techniques. Blue bars represent TEI data, whereas orange bars represent qEV. Both NP100 and NP200 measured 
concentrations are shown. The y-axis is in logarithmic scale, due to the difference in concentration between CCM and plasma 
derived samples. 
The comparison revealed that the plasma derived EV isolated had yielded up to several orders of 
magnitude more overall nanoparticles in both measured size intervals. 
 
3.3.1.3 Nanoparticle size distributions 
As with the EV isolates from CCM, the average nanoparticle diameters of isolates from plasma were 
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Figure 24: The average nanoparticle diameter calculated across all qNano Gold NP100 (50-200nm) measured particles from 
plasma. In the chart, movement to the right signifies increasing concentration, whereas movement upwards means increasing 
average particle diameter. Error bars on the y-axis are based on the standard deviation in average particle diameter reported 
by the qNano gold.  
In the plasma derived EV samples, again a general trend of decreasing average particle diameter could 
be observed as qEV fraction number increased from qEV 7 to 9 (figure 24). This applied roughly for 
both PC patient and the plasma control samples, with the plasma control sample in general giving 
somewhat lesser averages than the PC patient donor isolates. The TEI technique gave averages on the 
low end of the overall distribution, but with much higher overall particle concentrations than the 
various qEV fractions.  
 
CSDHs were constructed also for the EV isolate samples from plasma, and are displayed below (figures 












































Figure 25: Combined Size Distribution Histograms (CSDH) for samples of TEI for the selected PC patient (to the left) and control 
(to the right) from plasma. Each bin spans 10nm in particle diameter. CSDHs are modelled based on size distribution data 
collected using the qNano Gold, and are a combination of data from nanopores NP100 (50-120nm) and NP200 (121nm+). The 
y-axis has for both histograms been set to 2.0E+11 particles/mL and the x-axis to 400nm 
Overall, the CDSHs for the plasma samples showed a very narrow distribution, with no appreciable 
amount of nanoparticles beyond 300nm in diameter (see figure 25). The previously observed tendency 
towards smaller nanoparticles was even more pronounced in the plasma samples, with particle 
concentration peaking dramatically around 60nm in diameter, and rapidly declining so that only a 
minute fraction remains past 200nm in diameter. This was true for all qEV fractions (example figure 
26) as well as for TEI. Additionally, the plasma samples peaked much higher in the y-axis than the 





Figure 26: Combined Size Distribution Histograms (CSDH) for samples of qEV9 for the selected PC patient (to the left) and 
control (to the right) from plasma. Each bin spans 10nm in particle diameter. CSDHs are modelled based on size distribution 
data collected using the qNano Gold, and are a combination of data from nanopores NP100 (50-120nm) and NP200 (121nm+). 
The y-axis has for both histograms been set to 1.2E+10 particles/mL and the x-axis to 400nm 
 
3.3.1.4 Comparative size distribution between CCM and Plasma derived EV isolates 
 
A comparison was made between the CSDHs of qEV9 and TEI EV isolates from plasma and CCM (figure 
27). The scale was set to be equal for all CSDHs, and set to have a low x-axis max value, so as to better 




Figure 27: qEV9 and TEI from CCM (to the left) and from plasma (to the right) CDSHs set to the same scale for comparisons of 
large (>200nm) nanoparticles. While there are fewer large particles relative to small ones in the EV isolate sample from 
plasma, the absolute concentration of large particles is in fact greater. It appears to be a change in the relative fraction of 
small particles to larger ones which affects the average distributions. 
The comparison showed that while overall the size distributions of EV isolate samples from plasma 
may appear sharp and highly focused, the plasma samples in fact have more overall nanoparticles of a 













3.3.2 Estimation of vesicle fraction from plasma by sample treatment with Triton x-100 
 
3.3.2.1 Vesicle fraction of plasma control group samples 
In order to estimate the relative vesicle yield from each EV isolation technique, the samples of from 
plasma were measured with and without treatment with 0.1% triton x-100 (v/v). Samples of ExoEasy, 
TEI, qEV7, qEV8 and qEV9 were each measured in one biological replicate from one PC patient donor 
and one Control group donor in the manner described above (section 2.3.2). For EV isolates from blood 
plasma, 0.1% v/v Triton x-100 samples were measured using both NP100 and NP200 nanopores. As 
previously mentioned, no TRPS measurements of acceptable quality could be made of the ExoEasy 
samples from plasma. The vesicle fraction could only be estimated for TEI samples and qEV fractions. 
For a full list of measurements, see the appendix section 7.5.1. 
For plasma derived EV isolates from the control group, the calculated change (Δ) in concentration 
following treatment with Triton x-100 (0,1% v/v), corresponding to the vesicle fraction, is illustrated in 




Figure 28: Vesicle concentrations in EV isolates from the plasma control group. Estimated by TRPS and sample treatment with 
Triton x-100. The height of each bar (left y-axis) corresponds to the estimated concentration of vesicles or other membrane-
bound bodies within the measurement intervals. The orange line corresponds to the relative vesicle fraction (right y-axis) of 
each sample. ExoEasy concentrations are not included in the diagram in this case, due to low qNano Gold measurement quality 
of these samples. 
 
In the case of the estimated overall vesicle purities for the same samples, a large drop was observed, 
compared to that of the corresponding samples from CCM. This was especially true in the NP100 range, 
where qEV proved to yield the overall greatest purity, with an average of 29.57% vesicles across all 
fractions (figure 28). In the same range, TEI, although only 19,51% vesicles by particles/mL plasma, still 
gave the overall highest total number of vesicles. This was with an overall concentration of 4,80E+10 
vesicles/mL as opposed to qEV with a pooled fraction yield of 1,1E+10 vesicles/mL plasma. 
Interestingly, the roles appeared to be reversed in the NP200 range, where qEV yielded the overall 












































Δ Conc. % vesicles
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purity in the NP200 range, with only 2,5% of measured nanoparticles estimated to be vesicles. It should 
again be noted that the overall vesicle yield appears to be largest by far in the NP100 size range 
 
 
Figure 29: The measured change in mean particle diameter (nm) in the NP100 (50-200nm) and NP200 (85-340) range as a 
result of treatment with Triton x-100 (0,1%) in EV isolate sample from plasma (control donor). Change is calculated as diameter 
after treatment with Triton x-100, subtracted from diameter before treatment. Movement to the left in the figure indicates a 
measured overall decrease in nanoparticle diameter resulting from the treatment, whereas movement to the right signifies 
an increase in particle diameter 
Following treatment with Triton x-100 (0.1% v/v) on the EV isolate samples from the plasma control 
group donor, the direction of the change contributed as measured by the two nanopores was opposite 
between the two techniques. For qEV, a large decrease in average nanoparticle diameter was 
registered using the NP100, indicating that in the 50-200nm range, larger more than small 
nanoparticles were dissolved by the treatment. Conversely, the opposite was true for the TEI 
technique, where the NP100 measured change was positive, indicating that more small nanoparticles 
than large were dissolved. Both TEI and qEV however displayed the greatest overall change in the 
direction of smaller nanoparticles after treatment. 
3.3.2.2 Vesicle fraction of plasma PC-patient group samples 
The vesicle fraction in the PC patient donor EV isolate sample was determined in the same way as 
described above. The resultant change (Δ) in concentration following treatment with Triton x-100 
(0,1% v/v) can be seen below (figure 30), and the corresponding change in mean and mode particle 
diameters in figure 31. For a full list of all measured concentrations, see appendix section 7.5.1 








Figure 30: Vesicle concentrations in EV isolates from the plasma PC-patient group. Estimated by TRPS and sample treatment 
with Triton x-100. The height of each bar (left y-axis) corresponds to the estimated concentration of vesicles or other 
membrane-bound bodies within the measurement intervals. The orange line corresponds to the relative vesicle fraction (right 
y-axis) of each sample. ExoEasy concentrations are not included in the diagram in this case, due to low qNano Gold 
measurement quality of these samples. 
With regards to overall vesicle yield, similar trends were observed in the PC patient plasma donor 
samples as were discovered in those of the control group donor. Much greater concentrations of 
vesicles were estimated in the NP100 range, than in the NP200 range. Also, in the NP100 range the 
overall yield of vesicles was much greater in the TEI sample than in the qEV samples. It should be noted 
however that the TEI estimated purity was much higher here, compared to the control donor, with 
63,51% vesicles in the NP100 range, and very nearly that at 59,07% vesicles in the NP200 range.  In this 
manner, the TEI sample vesicle purity came close to that of the purest qEV fraction, qEV 8, with its 
vesicle% of 61,76 in the NP100 range and 64,36 in the NP200 range. qEV fractions 7 and 9 gave in this 
case very low vesicle purities in the NP100 range (12,93% and 15,69%) but much higher purities in the 
NP200 range at 47.01% and 30.27% respectively. The EV isolate from PC-patient plasma vesicle fraction 











































Figure 31: The measured change in mean particle diameter (nm) in the NP100 (50-200nm) and NP200 (85-340) range as a 
result of treatment with Triton x-100 (0,1%) in EV isolate sample from plasma (PC-patient donor). Change is calculated as 
diameter after treatment with Triton x-100, subtracted from diameter before treatment. Movement to the left in the figure 
indicates a measured overall decrease in nanoparticle diameter resulting from the treatment, whereas movement to the right 
signifies an increase in particle diameter. 
Following treatment with triton x-100, a reduction in NP100 mean particle diameter could be observed 
in both qEV and TEI EV isolates from the PC-patient donor sample (figure 31). Additionally, they both 
displayed an almost equal increase in NP200 mean. This indicates that the dissolved nanoparticles for 
both techniques were small relative to the NP200 measured interval (85-340nm), yet large relative to 
the NP100 measured interval (50-200nm), indicating a size in between the two. 
 
3.3.3 Determination of exosome concentration by enzymatic colorimetric assay 
While TRPS allowed for measuring nanoparticle yields of each EV isolation method, it is cannot directly 
distinguish between for instance exosomes and other nanoparticles within the same size range. We 
also had challenges measuring the ExoEasy isolates from plasma by the TRPS method. The 
concentration of exosomes was therefore additionally measured using the ExoCet Exosome 
Quantitation assay (SBI). Here, samples (70µL) of ExoEasy, TEI, qEV 7, qEV8 and qEV9 from each of the 
three control group (2 TR) and PC group (1TR) donors were assayed based on their AChE enzyme 
contents; an enzyme known to be enriched in exosomes (section 1.3.2). 
The ExoCet assay was performed on each sample as previously described (section 2.3.4). The average 
OD405nm for each incubation time was calculated based on the two technical replicates of each 
ExoCet standard dilution (blank subtracted). The qEV fractions were pooled by adding together the 
blank-corrected qEV values according to TR (see appendix 7.4) and standard curves constructed. It was 
determined that the dataset for 20 minutes of incubation provided the optimal relationship between 
curve linearity and noise. An illustration of the ExoCet standard curve used for the control group 
samples can be seen below (figure 32). 








Figure 32: ExoCet standard curve for exosome isolate samples from plasma control group (to the left) and PC patient group 
(to the right). Each curve represents data collected after 20 minutes of incubation. The formula for each curve, along with its 
R2 value is shown below and to the right of each curve. The y-axis in both cases signifies the optical density at 405nm 
(OD405nm), and the x-axis gives the corresponding number of exosomes divided by 1.0E+07. 
Standard curves were subsequently used to calculate the number of exosomes present in each well, 
as instructed in the protocol provided by the manufacturer (SBI). Blanks were subtracted as described 
preciously (materials and methods). The average OD405nm and standard deviation for all technical 
and biological replicates (2BR x 2TR for control group samples, 2xTR only for PC patient group) for each 
sample was calculated, and the standard curve used to determine the corresponding number of 
exosomes. This value was in turn divided by the assay sample volume per well (0,025mL) in order to 
achieve the concentration (exosomes/mL) of the EV isolate sample. This value was multiplied with the 
total volume of each EV isolate sample (0,5mL) in order to get the ExoCet estimated exosomes/mL 
plasma (1mL plasma was used for each EV isolate sample).  
The TEI sample yielded the overall highest measured concentration of exosomes, with an average 
Control Group concentration of 1.03E+12 exosomes/mL and a PC-patient average concentration of 
8.17E+11. ExoEasy measured out to approximately half the concentrations of TEI for control- and PC 
patient groups, with 35.4% and 43.8% of the corresponding TEI yields respectively. On average, 
ExoEasy was estimated to 3.65E+11 exosomes/mL for the control group and 3.58E+11 for the PC 
patient group. The pooled qEV fraction measured the lowest yield, with only 2.00E+10 control group 






Figure 33: ExoCet measurements of EV samples from plasma. All samples are normalized to reflect exosomes per millilitre of 
plasma used during EV isolation. Measurements corresponding to the control group (C) are coloured blue, whereas those 
corresponding to the PC patient group (P) are coloured red. Error bars are constituted by the calculated exosome /mL standard 
deviation between technical replicates of each individual biological replicate. 
 
Use of the designed specialized blanks resulted in a reduction in estimated exosome concentration of 
only 15,63% for ExoEasy and 14,88% for ExoEasy. The qEV samples, already close to the assay LOD, 
was further weakened by more replicates being pushed into the negative section of the standard curve 
equation. It was determined that the specialized blank results did not offer any benefit over the regular 
blank (discussion section 4.4.5). 
 
3.3.4 Determination of DNA concentrations in EV isolates 
 
3.3.4.1 concentrations of dsDNA in EV isolate samples from plasma 
The overall EV dsDNA cargo was isolated from EVs obtained using ExoEasy, TEI, qEV7, qEV8 and qEV9 
on plasma as starting material. A set of EV isolate sample aliquots (100µL) from plasma in two TR from 
each of the control group blood donors were treated with DNase (see materials and methods) in order 
to eliminate any extravesicular DNA, and used for isolation of DNA (QiaAmp circulating nucleic acid kit, 
Qiagen). The same procedure was carried out for a set of EV isolate samples (1 TR) for each of the 
three PC patient donors. A volume of each resultant DNA isolate sample (100µL) was then used in the 
Qubit dsDNA assay, and dsDNA/mL CCM was calculated (appendix section 7.1.) The final dsDNA 
concentration value for each was achieved by taking the average of the three biological replicates of 
each group (Control group, PC-patient group).  
In order to avoid cumulative error from addition of uncertainties, qEV fractions were in this case not 
pooled. An estimation of the pooled qEV data can however be found in the appendix (section 7.2). A 
full list of all measured dsDNA by donor can be found in the appendix (section 7.2.2).  
63 
 
As with the CCM derived dsDNA concentration data, TEI proved to be the technique with the overall 
greatest concentration of dsDNA/mL starting material, with 2.38ng/mL plasma on average in the 
control group, and 4,21ng/mL in the PC patient group. The qEV fractions for both groups measured as 
achieving the second third and fourth greatest average dsDNA concentration, with concentrations of 
1.67 ng/mL, 1.73 ng/mL and 1.98 ng/mL average in the control group and 1.87 ng/mL, 1.34 ng/mL and 
1.40 ng/mL plasma in the PC patient group for qEV 7,8 and 9 respectively. The lowest dsDNA yield was 
in both groups estimated in the ExoEasy derived samples, with only 1.61ng/mL plasma average in the 
control group, and 1.16 in the PC patient group (figure 34).  
 
 
Figure 34: dsDNA /mL plasma from by EV isolation technique, control group average (blue bars) vs. PC patient group average 
(orange bars). Error bars based on the standard deviation on all actual and estimated dsDNA concentration. Assay corrected 
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3.3.4.2 correlation between measured dsDNA and corresponding ExoCet measured exosome 
concentrations in EV isolates from plasma 
A scatter plot was created assessing the correlation between ExoCet measured exosome 
concentrations in EV isolates from plasma and the corresponding dsDNA measurements from the same 
EV isolate samples (figure 35) 
 
Figure 35: Correlation between the ExoCet Exosome Quantitation Assay estimated exosome concentration (exos/mL plasma), 
and the corresponding dsDNA ng/mL plasma isolated from the same sample. The R2 value for the correlation is shown above 
trend line. 
The plot revealed a modest correlation between dsDNA and exosome concentrations, somewhat 
marred by the clumping of the qEV fraction in the bottom of the chart. The R2-value for the trend line 
was 0.69. 
 
3.3.5 Measuring relative tumour DNA concentration in EV isolates from plasma 
 
As discussed in the introduction of this thesis (section 1.2), the reports of EVs containing tumour DNA 
are becoming steadily more frequent. In order to ascertain the efficacy of each EV isolation technique, 
it was therefore interesting to measure to what extent DNA isolated from each EV isolation in fact 
included tumour DNA, as opposed to WT. PNAs are oligonucleotides where the sugar-phosphate 
backbone has been entirely replaced by protein, and so are not extendable by DNA polymerase [64]. 
In brief, a PNA oligomer perfectly homologous to wild type (WT) KRAS was added in with the sample 
DNA a PCR assay. PNA binds well to perfectly homologous sequences, forming a DNA-PNA duplex, but 
is very sensitive to mismatching bases and is significantly destabilized by even a single base mismatch 
[65]. This results in the suppression of WT alleles and the selective amplification of mutated alleles in 
a PNA containing PCR assay. By running parallel real-time PCR (qPCR) sample with and without added 
PNA, the presence and relative amount of KRAS mutated alleles in the sample can be calculated [64].  
EV isolate samples (25µL total volume) from the DNase treated EV isolates of each of the three PC-
patient donors were divided into two TRs with PNA (supressing WT alleles) and without PNA (total 
DNA), and assayed for KRAS mutated allele DNA. The melting temperature Tm of the various PCR 
products were used to verify that they were a target sequence, and non-target sequence ΔΔCt results 
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and at least one positive find in by each EV isolation technique. On average going by Cq values alone, 
the amount of tumour DNA detected in each EV isolation technique (absolute, not relative to WT) was 
the same, except for qEV7 in which the average was slightly lower. This reflects the fact that there is a 
very low total concentration of DNA molecules loaded into the assay, and it is therefore reasonable 
that the effects of stochastic selection of individual DNA molecules play a major role in determining 
the absolute Cq values. Because of this statistical weakness, it is likely better to rely on the 
concentration measurements from Qubit, where relatively more DNA was loaded into each reaction. 
For a full breakdown of Cq values and results from the PNA-clamp assay, see the appendix (section 
7.2.3)   
The calculated ΔΔCq values, which are relative to the concentrations of DNA internally within each 
sample, can however be used to give an idea of the relative purity of KRAS mutated alleles in each 
sample, when compared to WT (figure 36). 
 
 
Figure 36: Relative purity of KRAS mutated alleles detected in samples of each EV isolation technique. The ΔΔCq contribution 
of each KRAS positive sample has been stacked according to the technique in which it was measured. The overall height of 
each bar is representative of the quantity of KRAS mutated DNA fragments relative to WT detected in EV isolates from the 
corresponding technique. The individual contributions of samples from a given PC-patient to the total ΔΔCq of each EV 
isolation technique is given by the key at the bottom left of the figure, and the corresponding ΔΔCq values of each sample in 
the table to the right of the key. A “0” in the table signifies that no KRAS mutation was detected in the sample. 
 
In the PNA-clamp KRAS assay, again each individual qEV fraction performed as well or better than the 
TEI and ExoEasy techniques with regards to relative amount of tumour DNA in the sample. This was to 
some extent with the exception of the qEV7 fraction which apparent performance was somewhat 
lower than that of the others. In overall quantity of KRAS mutated alleles, the qEV technique as a whole 
thus proved to extract by far the greatest purity of KRAS mutated alleles. The ExoEasy and TEI 
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PC patient 3 10,49 8,47 8,35 12,48 12,47
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4.1 Brief overview  
 
4.1.0 Criteria for evaluation of techniques 
When comparing the EV isolation techniques, there are several aspects of each technique which has 
to be considered. The goal of an isolation technique is to select for target particles, while discarding 
non-target particles and contaminants. The amount of particles isolated and their sizes however give 
only a rough estimate of the efficacy of a given technique, as it cannot discriminate between 
biologically active EVs and co-isolated biomolecules. Lipoproteins and protein may be found in the 
target size-range, yet have none of the desired properties of EVs (section 1.2.2) By also treating TRPS 
samples with a detergent such as Triton x-100, an estimation can be made of the relative amount of 
vesicles found in each sample, which may give a better idea of the actual amount of EVs present [58]. 
While exosomes and other EVs are often selected for based primarily by size, their most clinically 
relevant definition is that of biogenesis, and is tested for by the detection of exosome marker proteins 
such as the tetraspanins CD9 and CD63 [10]. The next step in assessing sample quality is validation of 
the actual yield of EVs from each technique therefore relies on the detection of such proteins, as 
identifying them allows for increased confidence that EVs isolated by a given isolation technique in fact 
are likely to have the wanted properties as a potential biomarker for cancer. Third is the investigation 
of DNA cargo found in the EVs isolated in each technique, including measured dsDNA concentrations. 
In principle, greater DNA recovery by a given EV isolation technique would indicate greater potential 
prognostic value, as less of any DNA present in a sample would be lost. This however only holds true 
in the case that said DNA hold a relatively high fraction of tumour DNA, as the selective nature of EV 
cargo is one of their main features over for instance direct recovery of cell free DNA from plasma. 
Finally, all these aspects of each EV isolation technique has to be evaluated up against the effort 
involved in the EV isolation process itself. Due to these many drawbacks of traditional EV isolation 
through ultracentrifugation coupled with the limitations placed on the possible number of parallel 
samples by the design of UC-rotors, there is a general consensus that differential centrifugation is not 
likely to ever been part of a clinical analysis pipeline [66, 67]. The time and effort efficiency of a given 
EV isolation technique is therefore also an important criterion for evaluation. 
4.1.2 Brief summary of findings 
The main goal of the project was to evaluate the efficacy of the various EV isolation techniques on 
human liquid biopsy samples, with the goal of investigating the isolated EVs for potential future use in 
diagnostics. As high concentrations of EVs were desirable, it was elected to use plasma for this testing, 
as opposed to other bio fluids (see introduction). By including EV isolate samples from patient of late 
stage pancreatic cancer, the efficacy of a given technique with regards to isolating EVs with tumour 
DNA cargo could be estimated. It was however decided that before testing with valuable PC patient 
samples, the scope of the testing should be narrowed by the elimination of the two least promising EV 
isolation techniques. This was done using CCM from PANC-1 cells as a stepping stone, and allowed us 
to get a general idea of the efficacy of each isolation technique. 
In general, it was discovered that the ExoEasy, TEI and qEV techniques gave the highest overall 
nanoparticle and vesicle yields, in measurements using TRPS (figure 6). Additionally, while not a part 
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of the overall technique comparisons of this thesis, ExoCet Exosome quantitation assay tests were 
performed on a set of samples from CCM (appendix 7.4 figure 16) showing significant Acetylcholine 
esterase activity only in samples of TEI and ExoEasy. The same was observed with regards to 
concentration of dsDNA cargo, UC and ExoQuick again being outperformed by the three above 
mentioned techniques. In the end it was concluded that ExoQuick and UC did not compete well, and 
should therefore be eliminated before moving forward with the next phase of the project, in which 
plasma would be used as starting material for EV isolation. 
In samples from plasma qEV resulted in relatively low overall nanoparticle yields compared to the very 
high TEI concentrations (figure 22). This trend was observed also in the Exosome Quantitation assay, 
where also ExoEasy appeared to have an overall greater exosome recovery. In overall dsDNA content 
the TEI technique provided by far the greatest yields (figure 34), yet the PNA clamp assay for KRAS 
mutations indicated that qEV had a much higher fraction of tumour DNA (figure 36). ExoEasy 
meanwhile performed reliably yet unexceptionally, never giving the best results of the three, but also 
rarely performing the worst.  
4.1.3 TRPS and the general distribution of isolated nanoparticles 
For exosome quantitation, the target window for analysis was the generally accepted window of 50-
150nm in which exosomes are known to fall [22]. It was however also interesting to measure the 
particles of greater diameter than 150nm, as a way to further investigate in the overall distribution of 
concentrations by particle diameter of the various EV isolation techniques. 
The NP100 nanopore can be tuned to measure particles of a minimum diameter range of 50-200nm, 
thus effectively covering all defined potential exosome diameters. Initial testing however quickly 
revealed that the vast majority of nanoparticles from all EV isolation techniques was found at the low 
end of the spectrum, increasing in concentrations as particle diameters approach 50nm. This principle 
appeared to be valid for all the tested EV isolation techniques for both CCM and plasma. To underscore 
the significance of this difference, take for instance the measured NP100 and NP200 concentrations of 
EV isolates from CCM (results, figure 6). As was done in all cases, the NP200 was tuned to a sensitivity 
range of 85-340nm; the lowest diameter window possible for this nanopore. The NP100 was similarly 
tuned so as to be sensitive in its lowest possible range, between 50-200nm. The part of the sensitivity 
window of the NP100 nanopore not also covered by the NP200 thus consists of only the range of 
particles with diameters between 50-85nm. As illustrated in the figure, the measured NP100 ExoEasy 
concentration of samples from CCM was 1,13E+09 particles/mL. The corresponding NP200 
measurement average of the same samples was of only 1,86E+08 particles/mL, far less than the NP100 
measurement, the former constituting more than a six-fold increase in concentration over the latter. 
This is despite the overlap between pores in the 50-200nm measurement window being an entire 
76.67%. As such, more than 83,54% of all measured nanoparticles were in this example found in the 
small range of 35nm, found in the non-overlapping section between the two nanopores in the range 
from 50-85nm. This general trend was the observed in all qNano measurements, and can be seen 
reflected in a more qualitative fashion in the generated CSDHs (results, figures 8,9,25 and 26). Because 
of this observation, it was decided to include NP200 data also wherever general trends in diameters 
were to be discussed, as the powerful shift in overall nanoparticles towards the low-end is so significant 
that particles measured by the two different nanopores often are affected very differently by for 
instance treatment with a detergent such as Triton x-100 (results, figures 29 and 31). 
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Additionally, it should be noted that the NP100 is unable to detect particles smaller than 50nm in 
diameter, and as such a very large amount of particles may be found just below the 50nm threshold. 
As size decreases below 50nm in diameter however, the likelihood of course increases of any given 
particle being a protein aggregate or other non-vesicular biomolecule, which, presuming their co-
isolation with EV’s by the EV isolation techniques, helps in explaining why the overall nanoparticle 
concentration increases with decreasing particle diameter 
All EV isolation techniques were evaluated using the qNano Gold TRPS analysis on EV isolate samples 
from CCM. It was discovered under measurements however, that due to an apparent incompatibility 
with the qNano Gold instrument, no measurements of acceptable quality could be obtained of samples 
of ExoEasy from plasma. Various dilutions of ExoEasy EV isolate were attempted, as well as attempts 
of measuring using several nanopores of sizes. All attempts failed to provide measurements of 
acceptable quality. In general, at medium to low dilutions using NP100, the measurement current was 
observed to skyrocket as pressure was applied in the instrument (essential for calculating 
concentrations), and measurement stability was immediately lost. At very high dilutions, the current 
did not trace as expected, and no definitive nanoparticles could be detected. Similarly, using larger 
nanopores (up to and including NP250), the current trace behaved in an unstable manner, and no 
definitive nanoparticles could be detected at any dilution. None of the ExoEasy samples from CCM nor 
any of the other samples from plasma suffered from these issues, indicating that there in fact was 
some sort of compatibility issue with the plasma derived ExoEasy EV isolates and the qNano Gold 
instrument. There is reason to believe that the plasma derived samples in general contain several 
orders of magnitude more very small (<50nm) nanoparticles, than CCM derived samples. One 
hypothesis for the apparent incompatibility, could be that these nanoparticles just below the 
measurement interval of the NP100 nanopore is related to the skyrocketing measurement current, 
and loss of stability. However, this cannot be confirmed definitively. 
 
4.2 EV isolation techniques, practical execution 
 
4.2.1 Differential centrifugation with ultracentrifugation 
When performing EV isolations targeting potential future clinical applications, aspects such as hands-
on time and overall isolation time are critical for their viability. This is in fact one of the commonly 
stated grievances regarding ultracentrifugation for exosome and small EV isolation, as the process 
requires many steps taking several hours, and as such is not likely to ever become clinically viable [20] 
(figure 3). UC is however one of the most traditional and most widely tested methods of EV isolation, 
and therefore provides a good standard to evaluate the more modern competing techniques up 
against, with regards both to time and effort involved, and the quality of the resultant EV isolates [47]. 
Another hurdle with UC, are the radically variable reported yields, with an EV recovery reports 
spanning between 2-80% [20]. Furthermore, while no expensive consumable materials are generally 
required to perform an EV isolation thorough UC, the technique is fundamentally biased in the 
direction of depositing larger and heavier particles first, as these are the most affected by the high g-
forces excreted during centrifugation [33]. Additionally, EV aggregation has been reported as a 
consequence of the large forces involved in UC [49] and may be a major inconvenience when targeting 
the very smallest EVs, such as exosomes. With shorter UC centrifugation times and/or lower RCFs, only 
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the larger EVs will reliably deposit. Conversely, if using very long centrifugation times or high speeds, 
one risks aggregating or otherwise damaging any larger EVs, while simultaneously co-isolating common 
contaminating non-vesicular materials such as protein aggregates, lipoproteins, cell organelles and 
viruses [20]. 
4.2.2 The precipitation reactions TEI and ExoQuick 
In general, the precipitation reactions require very little hands-on time, and are very easily performed. 
They also scale very well with any volume of starting material, which may be both economical and 
more environment friendly depending on the circumstances. In brief, the method by which 
precipitation reagents function, is to reduce the solubility of the target molecule (EVs), typically by 
binding water molecules and forcing other solutes to precipitate [51]. This however leads to the issue 
of discriminating against suspended non-EV components. Where TEI simply claims to precipitate any 
and all vesicles in the solution [68], ExoQuick claims to be able to precipitate exosomes specifically 
using a proprietary polymer [69]. Polymer precipitation in general has been shown to co-precipitate 
contaminants such as lipo-proteins [52]. With regards to isolation time, both techniques require 
overnight incubation before pelleting EV’s when using CCM as starting material, and so the complete 
isolation from CCM cannot be performed in a day. With plasma this incubation time is reduced to a 
few minutes (or one hour in the case of ExoQuick), and the full EV isolation time from plasma is 
therefore between 20 and 70 minutes. The TEI technique requires a somewhat higher centrifugation 
speed for precipitation of the final product in the protocol for CCM than the corresponding protocol 
for ExoQuick, which when coupled with the large volumes typically associated with EV isolation from 
CCM may be inconvenient. Large, low concentration starting volumes is inconvenient for these 
technologies in general, as the resultant pellet after centrifugation (as observed in the case of CCM) is 
not visible to the naked eye, and must be resuspended directly in the large centrifugation tube into a 
very small volume of solvent in order to achieve a concentrated EV isolate solution. This makes 
ensuring complete pellet resuspension versus excessive vortexing or mixing an unfortunate 
compromise to be made. In the case of TEI for plasma, the opposite is true, where a large yellow pellet 
is formed which I difficult to fully resuspend. After contact with the manufacturer (Invitrogen), it was 
determined that the optimal solution is to allow the TEI samples to incubate at RT for up to 3 hours in 
order to allow the pellet material to dissolve. In the literature, while exosomes and other EV have been 
found to be very robust, it is still recommended to minimize their stored at room temperature (RT) 
[20], so this solution is likely not entirely ideal. 
4.2.3 ExoEasy affinity spin 
With the ExoEasy Maxi kit (Qiagen), large volumes (up to 16mL) of starting material is not an issue, as 
all is passed through an affinity membrane and the flow through discarded immediately. While there 
are overall more steps involved, the overall process is comparable to that of the precipitation reactions 
with regards to time and effort involved in the isolation. The columns and their components are 
however one-time use, and while less of the liquid components of the kit may be used when isolating 
from smaller volumes of starting material, there is of course no way to use fewer columns. It can 
therefore not be said that the kit scales well with various sample volumes with regards to cost and 
waste generated. 
4.2.4 qEV SEC 
In the case of the qEV SEC columns (Izon science) there several factors to consider. While the SEC 
technology promises potentially very high quality isolation of vesicles [20]. It requires much more 
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preparation prior to EV isolation than the precipitation reactions and ExoEasy. The loading volume of 
the qEV column is exactly 0.5mL which is important to consider. Depending on the wanted starting 
volume, a concentrating step may have to be included in any protocol relying on qEV for EV isolation. 
Additionally, the qEV columns are stored at 4°C, and have to be equilibrated to RT before use. They 
also have to be rinsed with several millilitres of filtered buffer prior to use, further adding to the overall 
time required in order to complete the EV isolation process. When isolating EVs, the void volume 
(buffer in the column below the leading wave of large EV’s) must be carefully measured as it passes 
thorough the column, and the collection tubes rapidly switched out when the EV containing fractions 
are reached. While the columns are reusable up to 5 times according to the manufacturer, any such 
column should probably not be used more than once in the case that the EV isolates were to be used 
in a clinical setting, in order to avoid cross contamination. Using the column rack sold by the 
manufacturer (Izon) it is however not simple to use several columns at once for parallel EV isolations. 
Over all, the time required to complete an EV isolation using the qEV columns is approximately 1-2 
hours. This time considerably less than the total time required for the precipitation reactions in the 
case of CCM, and far less than the UC technique. Isolation of EVs through qEV does however consist of 
many very different steps, and is very much a hands-on process throughout. The overall time required 
is also much greater than all techniques apart from UC, when isolating EVs from plasma. 
 
4.3 Characterization of EV isolates from CCM 
 
4.3.1 TRPS measured nanoparticle yields from CCM 
As described in the results (section 3.2.1), the qNano Gold measurements of nanoparticle 
concentrations in EV isolates from CCM reveals a large variance between the EV isolation techniques. 
Focusing on the 50-200nm range, ExoEasy appears to have isolated the most overall nanoparticles, 
nearly doubling that of the second highest yielding technique (qEV). This relationship between qEV and 
ExoEasy in particular with regards to raw quantity of particles is as expected, based on the findings of 
Stranska et.al. 2018 [54] The two precipitation reactions, ExoQuick and TEI performed similarly to one 
another not far behind qEV, while UC resulted in a concentration of only 2.9% that of ExoEasy (figure 
6). This particularly low recovery also coincides well with what is generally expected from the 
technique [20, 51]. 
4.3.2 Size distributions 
With regards to size distributions among EV isolate samples from CCM, some general trends are 
apparent in the average particle diameter data (figure 7). The largest mean particle diameter in the 
was found in the UC sample, which is reflected by its very flat particle size distribution seen in the CSDH 
(figure 9). The ultracentrifugation step would therefore appear to deposit few particles compared to 
the other techniques, and relatively favour the larger particles present. This is to be expected, 
considering how the sedimentation rate is dependent primarily on particle mass and density, and could 
also be indicative of EV clumping [20]. The next largest average particle diameters can be found in the 
qEV7 fraction, and also here the similar observations with regards to size can be made as already done 
for UC. This is reasonable, as qEV7 is the first collected vesicle fraction from the SEC column, and should 
therefore theoretically contain the largest particles. Smaller particles would be hindered by the 
internal structure of the SEC column, and deposited in a later fraction (qEV8, qEV9) [52]. 
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Simultaneously, qEV7 and UC turned out to be the lowest yielding samples from CCM, with regards to 
total particle concentration. This apparent correlation would seem to indicate that the majority of the 
particles not only in the EV isolates (section 4.1.3), but of the raw materials themselves are very small. 
If this is the case, techniques which to a lesser extent are able to deposit the smallest nanoparticles 
will exhibit both larger average particle diameters, and lower overall particle concentrations. 
Near the opposite end of the size spectrum, TEI and ExoEasy are situated with nearly identical average 
particle diameters (results, figure 7). This would fit well with both techniques isolating nearly all types 
of vesicles present in the sample, regardless of size. While the fundamental differences in the two 
technologies makes this an interesting results, it cannot be said to be entirely surprising based on 
reports on the ExoEasy column [51] or the general description of TEI by the manufacturer [68]. By to a 
large extent isolating very small particles (50-70nm) along with the larger ones, the overall particle 
concentration found in isolates from these techniques increases. Whether these nanoparticles are in 
fact exosomes, is however yet to be determined. ExoQuick meanwhile yielded an average particle 
diameter slightly greater than that of TEI, and slightly less than that of qEV8, perhaps indicating that it 
indeed isolates a different group of EVs than what is isolated by TEI. The very smallest average particle 
diameter is found in isolates of the qEV9 fraction: the last collected SEC fraction. This fits well with 
what would theoretically be expected from the SEC column, where the resistance should be the 
greatest for the smaller particles, which therefore takes longer to pass through. The qEV9 fraction 
should (also according to the manufacturer) be the one richest in proteins, out of the three collected 
qEV fractions.  
4.3.3 EV isolate vesicle fraction and average vesicle diameter 
When treating EV isolate samples with a detergent such as Triton x-100, it is expected that vesicles will 
have their membranes disrupted and lipids dispersed into the solution [58]. The overall concentration 
of nanoparticles in the sample will therefore fall. When measuring the same dilutions of samples with 
and without treatment with Triton x-100, the difference in nanoparticle concentration should 
theoretically correspond to the number of vesicles in that sample. Based on this reasoning, there are 
two main aspects of the samples which can be determined in this manner: the total vesicle 
concentration in the sample, corresponding to the change (Δ) in nanoparticles following treatment, 
and the relative fraction of vesicles, or “purity” of the sample. Additionally, by measuring the change 
in average particle diameter following treatment with detergent, something can be said of the size of 
the vesicles which were dissolved by the treatment. In the case that the average diameter is reduced 
after treatment, the dissolved particles would have to be on average larger, than the average of those 
remaining in solution. Conversely, if the average diameter is increased after treatment, the average 
diameter of the dissolved vesicles has to be smaller than the average of the remaining vesicles. In the 
EV isolates from CCM, only a somewhat rough idea of the vesicle fraction can be ascertained as only 
the 85-340nm range was measured (figure 12). This was due to a limited amount of sample material 
from CCM only allowing for one additional series of measurements with the qNano Gold. Based on 
these data however, the overall amount of vesicles in each sample followed a pattern similar to the 
previously discussed overall concentrations, immediately indicating at least some correlation between 
the isolated particles of each technique and EV’s. ExoEasy showed the overall greatest concentration 
of vesicles, followed by qEV and TEI. As advertised by the manufacturer, the qEV technique gave a 
particularly good sample purity (76% vesicles), and in this aspect performed much better than both 
ExoEasy and TEI, which were both closer to 50%. This increased apparent purity of qEV over ExoEasy 
is also what was reported by Stranska et.al. 2018 [54]. However, TEI was nearly 2% less pure than the 
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UC sample, which in turn was 12% less pure than ExoEasy. Therefore, in this experiment, the affinity 
spin technology of Qiagen’s ExoEasy appears to be superior to the TEI precipitation and UC. The 
ExoQuick precipitation technique, while producing the second to least vesicles overall after UC, in fact 
resulted in a relatively high purity, nearly matching that of qEV. 
Perhaps as interesting as the vesicle purity, is the change which occurs following triton x-100 treatment 
with regards to average particle diameter. In the case of UC, a very large increase in average diameter 
was observed (figure 13). This indicates that the vesicles disrupted by the detergent on average were 
smaller than the average diameter of the nanoparticles in the UC sample with no detergent added 
(149.67nm). Based on the methodology of the UC technique, it is expected that the particles will pellet 
in order from most to least dense. It is the differential centrifugation steps prior to the 
ultracentrifugation which are meant to remove large contaminants [20]. As such, any particles not 
pelleted at 10 000x g 30m at 4°C are expected to be contained in the ultracentrifugation pellet. 
Additionally, this could be further evidence that these larger bodies are adversely affected by the very 
large g-forces of the ultracentrifugation to a greater extent than the smaller and less dense vesicles 
which were apparently dissolved by the triton x-100 treatment. Under this hypothesis, the large 
undissolved bodies observed after treatment with detergent could be lipoproteins and various other 
debris which has clumped together, as mixed aggregates [20, 49]. 
The qEV and ExoEasy technique both experience moderate increases in nanoparticle diameter 
following the treatment, indicating a dissolved vesicle average diameter of less than 138.11nm and 
171.67 respectively. This places the dissolved vesicles of both techniques potentially within the defined 
size range for exosomes (50-150nm) and within the range of oncosomes (100-400nm) and MVs (50-
1000). Interestingly the two polymer precipitation techniques, ExoQuick and TEI techniques both 
displayed a reduction in average particle diameter. In the case of the ExoQuick sample, with an average 
diameter already as high as 161.33 before treatment, this indicates that the vesicles predominantly 
dissolved could not have been exosomes, but rather had to be larger vesicles such as oncosomes or 
MVs. TEI similarly, with a starting average diameter of 145nm prior to treatment with Triton x-100 
experienced the largest decrease of all the techniques in average particle diameter, also indicating that 
a sizable fraction of the dissolved nanoparticles is likely membrane bound bodies of a diameter larger 
than that of exosomes. 
4.3.4 Characterisation of isolated nanoparticles by bead-assisted flow cytometry analysis 
By virtue of the technology behind the BAFC, exact quantitation of proteins per vesicle is impossible. 
This is due to the fact that the amount of protein adsorbed to each individual bead is unknown (see 
materials and methods). However, samples in the same assay can still be compared relative to one 
another in terms of the total vesicle-associated amount of the studied protein in a semi quantitative 
manner. 
Our results showed that both CD9 (figure 14) and CD63 (figure 15) can be found in all tested EV isolate 
samples from CCM. However, the qEV technique in both cases contained by far the most of both 
proteins again hinting at a very good EV purity. In the case of CD9 in particular, the individual qEV 
fractions gave the by far the strongest signal, and in increasing order from qEV 7 to 9. As previously 
discussed under trends in nanoparticle size distributions, the qEV fractions displayed decreasing 
particle diameter as the fraction number increased. It therefore follows, based on the BAFC assay, that 
the smallest qEV isolated EVs (qEV9) in fact contain the most CD9 protein.  Notably, the ExoEasy and 
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TEI techniques by comparison gave the second and third smallest average particle diameter in the 
same measurement series, and additionally had 6.07 and 2.72 times greater particle concentration 
than the qEV9 fraction in the 50-200nm range (appendix section 7.5). Further emphasizing this trend, 
the qEV 8 fraction which was measured using TRPS to have a larger average particle diameter than 
both ExoQuick and ExoEasy, was in the BAFC measured to produce the third greatest signal, just 3% 
less than that of ExoEasy. This underscores that average nanoparticle size not necessarily is a reliable 
indicator of the type of particle present in a sample. While TEI and ExoEasy isolate many nanoparticles, 
the number of vesicles and exosomes, in particular, seems substantially lower. When considering 
overall concentration of vesicles (figure 12), the concentration of TEI and ExoEasy actually were very 
similar to that of qEV, with 113% as many in the case of ExoEasy and 95% as many in the case of TEI. 
The overall concentration of CD9 protein in the qEV sample per particle therefore appears to be very 
high compared to these two techniques. It is therefore tempting to assume that the qEV technique 
overall isolates a large fraction of EVs which at the very least have a different biogenesis to those 
isolated by the other techniques. The exact same pattern, apart from a relatively greater signal from 
the ExoEasy sample, can be observed in the BAFC for CD63 protein. 
When considering these and the above results, it should be kept in mind that the three qEV fractions 
all stem from the same initial volume of starting material, and as such each qEV fraction is 3 times as 
dilute as any other EV isolate sample. It would therefore appear the qEV SEC technique is extremely 
effective at isolating nanoparticles with the CD9 and CD63 proteins, and the results further indicate 
that there is a definitive difference in the sort of particles isolated by each technique. While on the 
surface ExoEasy may appear to have differentiated itself from TEI in the CD9 BAFC by producing 2.13 
greater MFI fold change (figure 14), it should be noted that the ExoEasy sample in this case was 
measured to be 2.23 times the TEI concentration. It is therefore plausible that there is not additional 
purity of CD9 containing nanoparticles in the ExoEasy sample, which cannot be explained by the 
greater concentration. In the CD63 BAFC on the other hand, this difference has increased to 10.22 
times greater signal in favour of ExoEasy, indicating that perhaps there is indeed some difference in 
the particles isolated between the two, at least with regards to CD63 specifically. The ExoQuick and UC 
samples in both cases performed only as well as could be expected, considering their overall low 
nanoparticle yields, indicating correspondingly low MFI fold changes. 
4.3.5 dsDNA in EV isolates from CCM 
In general, DNase treatment proved to have little effect on the final concentration of isolated dsDNA 
in the case of ExoEasy and TEI, reducing their overall dsDNA concentrations by only 13.89% and 2.26% 
respectively. This may indicate that the majority of the dsDNA contained in these samples is protected 
from the action of the DNase enzyme by being enveloped by a vesicle. ExoQuick and qEV conversely, 
lost 65.82 and 55,94% of their measured dsDNA during DNase treatment, indicating that more than 
half of their dsDNA contents are without the protection provided by vesicles, and as such are accessible 
to the DNase enzyme. The UC sample, while already having a very low dsDNA yield, was observed to 
suffer a further reduction by as much as 36.36% in dsDNA following DNase treatment. 
When considering only dsDNA remaining in each sample after DNase treatment, the technique yielding 
the decidedly greatest dsDNA ng/ml CCM, was TEI, with more than twice the dsDNA/mL of the second 
best yielding technique, ExoEasy. ExoEasy in turn produced a yield of 3.65 times the dsDNA/mL of the 
third highest yielding technique, qEV. Returning to the previously made points during discussion of the 
nanoparticle size distributions (section 4.3.2) and BAFC results (section 4.3.4), this would appear to 
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coincide well with the hypothesis that ExoEasy and TEI to a large extent isolate the same range of 
particles, but as discussed in the BAFC chapter; that ExoEasy also overlaps more with qEV than does 
TEI. The latter technique appears to isolate some distinct EV very rich in DNA and AChE-enzyme, yet 
relatively very poor in CD9 and CD63 indicating that it is perhaps not an exosome. A non-exosome DNA 
rich EV isolated primarily by TEI and to a lesser extent by ExoEasy, would also fit in well with the 
observation that ExoEasy and TEI DNA isolates both have high overall dsDNA yields which are 
unaffected by treatment of samples with DNase (figure 16). This EV may very well be an oncosome, as 
reported by Meehan et.al. [18]. It should be noted however, that the overall high concentrations of 
dsDNA in the two samples at least to some extent could be explained by their very high particle 
concentration, when compared to the other techniques.  
4.3.6 Purity of dsDNA-containing nanoparticles: dsDNA/particle 
On the topic of isolating the vesicles with the greatest dsDNA yield, a direct method of viewing the 
problem would perhaps be to take the dsDNA (after DNase treatment) concentration data and divide 
by the corresponding nanoparticle data, in order to get a “dsDNA/nanoparticle” value.  (figure 17) 
When interpreting this figure, it is first important to note that the nanoparticles in the EV isolates were 
not filtered so as to include only those of diameters 50-200nm prior to DNA isolation. As such, any 
isolated DNA may stem from particles both smaller than 50nm, or much larger. This comparison can 
however still be useful in estimating what particle size is likely to contain dsDNA. Additionally, it may 
be used to give an indication of the relative amount of contaminating particles in a sample i.e. the 
abundance of particles in the 50-200nm range which do not contribute any dsDNA. Based on the trends 
observed in the CSDHs (figures 10,11), it would seem very unlikely that large amounts of particles 
(relative to the total) of size greater than 200nm is present in any of the samples. 
When viewing the comparison (figure 17), what is immediately apparent is how it underscores the fact 
that while the ExoEasy technique isolated by far the most particles, the relative amount of DNA 
contained in these is very low compared to that of TEI. As previously discussed under size distributions 
(section 4.3.2), ExoEasy and TEI have very similar mean (and even mode) isolated nanoparticle 
diameters. It is therefore perhaps counter-intuitive that such a large disparity should be observed 
when comparing their relative yield of dsDNA from the same substrate. Returning to the CSDH of the 
two techniques however (figure 8), it may appear that the ExoEasy technique isolates nanoparticles in 
a slightly more concentrated fashion specifically in the 50-200nm diameter range. TEI conversely gives 
a much smoother and more rounded size-distribution profile, isolating relatively more particles in the 
above 200nm. As the exclusion of many smaller particles seems to lead to an increase in relative dsDNA 
concentration, this again leads back to the previously hypothesized non-exosome EV (section 4.3.5) 
which the TEI technique is superior to ExoEasy with regards to isolating, whereas the latter co-isolates 
very many smaller nanoparticles not necessarily associated with dsDNA. 
4.3.7 Correlations between isolated dsDNA and measured nanoparticles from CCM 
 
The speculation on purity of dsDNA containing isolates makes the direct comparison between 
measured nanoparticle concentration and dsDNA an interesting one. By plotting the TRPS measured 
50-200nm particle concentration in the various EV isolation technique against the dsDNA isolated from 
DNase treated aliquots of the same sample, an estimate of how strongly the trends correlate can be 
established (figure 18). As with the dsDNA yield per nanoparticle (figure 17), it was not possible to 
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separate out nanoparticles not within the range of the NP100 nanopores. As such, the dsDNA data for 
this comparison is based on any isolated EV present in the EV isolate, whereas the concentration values 
are based on nanoparticles in the 50-200nm range only. 
As is clearly demonstrated by comparison (figure 18), the correlation between dsDNA and measured 
nanoparticles/mL scores an R-value of only 0,28 in the 50-200nm range when all samples are included. 
There is however a very clear outlier around y=45. By removing this outlier, the R2 increases drastically 
to 0,95. This outlier corresponds to the measurements made of TEI. This emphasizes the previously 
discussed observations that based on the trend collectively set by all the other samples, the measured 
dsDNA concentration from TEI is disproportionally higher than what would be expected based solely 
on its measured particle concentration in the 50-200nm range alone. 
One potential explanation for this discrepancy would be that the TEI vesicle concentration somehow 
has been underestimated, and that the relative DNA-yield subsequently should be far lower. Based on 
the curves in figure 18, for the TEI sample to fall in on the curve, its concentration would have to be 
more than twice that of ExoEasy, the otherwise most highly concentrated sample. Previous data from 
the testing phase using ExoCet (not included in the main part of this thesis) however lends some 
additional credence to the ExoEasy exosome concentration in CCM is in fact being greater than the TEI 
concentration (appendix section 7.4 figure 16) 
By making the same plot as before but looking at the correlation between the NP200 measured 
nanoparticles and the isolated dsDNA, a much higher R2 score of 0.93 is achieved, even with all samples 
included (see figure 19). Notably, due to the previously discussed large overlap between the NP100 
and NP200 measurement intervals (section 4.1.3), plotting against the NP200 concentration data 
effectively equates to removing the “diluting” effects off nanoparticles between 50 and 85nm in 
diameter from the comparison. As also previously discussed, the CSDH for TEI (figure 8) would seem 
to indicate that the raw nanoparticle numbers contribution from particles of size greater than 200nm 
is relatively very small, yet cannot be ruled out as the source of the very high concentrations of 
measured dsDNA. The most notable outlier in this dataset (the data point closest to the graph origin) 
here (figure 19) corresponds to the UC sample, which displays a disproportionately high dsDNA 
concentration compared to the trend set by the other techniques. 
Based on these plots, there would appear to be a general correlation between the concentration of 
isolated nanoparticles, and concentration of dsDNA. Furthermore, based on how the TEI value fits 
much better into the correlation when comparing NP200 values than NP100, there is further reason 
to believe that the dsDNA yield from the TEI sample predominantly originates from particles larger 
than what is predominantly isolated by any of the other EV isolation techniques.  
Similar plots were attempted for triton x-100 determined vesicle concentrations vs. measured dsDNA, 
but no correlation with an R-value of greater than 0.42 could be found. This could have several 
explanations. One possibility would be that some of the samples have dsDNA content not contained 
within membrane bound bodies which can be disrupted using the described Triton x-100 treatment 
(section 2.3.2). This would however require said dsDNA to avoid digestion during the RQ-1 DNase 
treatment the EV isolates were subjected to prior to DNA isolation. It is therefore a much more likely 
scenario that the triton x-100 treatment was insufficient for entirely dissolving all vesicles in at least 
some of the samples, thus yielding inconsistent results. This somewhat weakens the credibility of the 
triton x-100 treated samples as a reliable estimate of the vesicle fraction, as it would likely result in 
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falsely low relative vesicle fraction estimates for samples containing overall very many vesicles, relative 
to samples containing very few. This, however, would go counter to the findings of Osteikoetxea et.al 
2015 [58], who concluded that a concentration of 0.1% (v/v) of Triton x-100 should be more than 
sufficient. A likely alternative is that the limited number of data points and random noise may have 
caused the relatively low R2-value. No matter the reason, it would still likely not invalidate conclusions 
drawn regarding vesicle sizes, as these do not depend on the complete dissolution of all vesicle to be 
accurate. 
 
4.3.8 Comparing dsDNA yield with BAFC measured CD9 and CD63 concentration 
 
Another interesting relationship to consider is that between an EV sample’s content of exosome 
marker proteins and the measured dsDNA yield. By comparing the two (figure20) it becomes clear that 
the dsDNA yield follows the same pattern for the qEV fractions as described previously, increasing in 
accordance with the fraction number and decreasing average particle diameter. Again it bears 
mentioning that for these comparisons the qEV fractions have not been pooled, and as such are three 
times as dilute as the other samples relative to the amount starting material (16mL CCM) which is the 
volume all three qEV fractions originate from. 
The ExoEasy sample, at 6.07 times the NP100 particle concentration of qEV9, gave 8.50 times the 
isolated dsDNA concentration. The ExoEasy sample did however also produce the largest CD63 signal, 
and the second largest CD9 signal, making conclusions on the relationship between BAFC signal 
intensity and dsDNA difficult to draw. It would however seem plausible that the ExoEasy technique 
may have co-isolated many of the same dsDNA rich nanoparticles typical of TEI, and simultaneously 
several EVs rich in CD9 and CD63. ExoEasy would in this manner fall in between the qEV and TEI 
techniques, with regards to the sort of overall nanoparticles isolated. The TEI sample, at only 2.72 times 
the qEV9 overall NP100 concentration, displayed 18.95 times the concentration of isolated dsDNA. 
Simultaneously, the qEV9 sample produced a 3.23 SD9 signal and 9.61 times the CD63 signal compared 
to TEI, perhaps indicating that there the particles containing the largest amount of dsDNA are not 




4.3.9 Summarizing overall performance of EV isolation techniques from CCM 
 
Taking all the above points into consideration, it is now possible to give a rough estimate of the 
performance of each individual technique. While no simple scoring system could take into account all 
the relevant factors discussed above, a simplified system may be used to give a rough estimate. One 
way of doing this is listing the most important criteria each technique is to be evaluated up against, 
and arranging the performance of each isolation technique from best to worst. By making the best 
performer by a certain criteria get the highest score of 5 and the worst performer the lowest score of 
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1, a higher total score across all criteria would mean a better performing technique. As per the defined 
criteria for comparison of EV isolation methods (section 4.1.0) these would be the total EV yield ([EV]), 
the EV purity (EV%), the amount of exosome marker protein (CD9/CD63), the dsDNA yield ([dsDNA]) 
and the effort required to complete the isolation. Considering that the final aim of the EV isolation is 
potential use as a biomarker for cancer, extra weight was given to the overall EV content and dsDNA 
yield. The summary is shown in table 6. 
 
Table 6: Each EV isolation technique from CCM scored against the defined criteria for ideal EV isolation. The overall yielded 
concentration of EVs ([EV]) has been weighted slightly, with a modifier of 1.5 on its original score to emphasize the importance 
of a high vesicle yield. The relative sample vesicle purity (EV%), relative amount of exosome marker proteins (CD9/CD63) and 
overall effort of the isolation process (Effort) has been weighted normally. The total dsDNA yield has been weighted with a 2x 
modifier, as the DNA content is perhaps the most interesting target EV-cargo molecule with regards to future clinical 
applications of EVs. Numbers in parenthesis are the original scores of the EV isolation technique, prior to applying the 
weighting modifier. 
 [EV] (x1.5) EV % CD9/CD63 [dsDNA] (x2) Effort Sum 
ExoEasy 7.5 (5) 3 4 8 (4) 5 27.5 
qEV 6 (4) 4 5 6 (3) 2 23 
TEI 4.5 (3) 1 1 10 (5) 3 19.5 
ExoQuick 3 (2) 5 2 4 (2) 4 18 





4.4 Findings in EV isolates from Plasma 
 
4.4.1 TRPS measured nanoparticle yields from plasma 
Due to the previously described complications with the qNano Gold and samples from plasma (section 
4.1.3), only TEI and qEV were left for direct comparisons with samples from CCM. For these samples 
however, TEI resulted in very high concentrations of nanoparticles with a yield 6.6 times higher than 
qEV (figure 22). It is notable how far out of proportion this is, when compared to the corresponding 
CCM results, where qEV in fact had a greater overall nanoparticle concentration than did TEI. 
Additionally, the measurements of TEI and qEV fractions revealed overall much higher nanoparticle 
concentrations in plasma samples, than was measured in the CCM-derived EV isolates. This can be 
illustrated by placing the qNano Gold data of the corresponding data samples from CCM and plasma 
in the same diagram (figure 23). It should be noted that a logarithmic scale has to be used, as the 
overall difference spans several orders of magnitude. This is despite the CCM-samples being based on 
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16 times as much starting material by volume as the plasma derived samples, with 16mL CCM being 
used compared to only 1mL plasma per technique.  
In addition to the generally higher concentrations of nanoparticles in the plasma samples, the plasma 
control group donor displayed a much higher nanoparticle yield per mL plasma, than did the selected 
PC patient. This is noteworthy at this point, as it constitutes the first of several indications of a 
potentially very large inherent variance in plasma nanoparticle content between individuals.  
4.4.2 Size distributions of samples from plasma 
With regards to the average nanoparticle diameter compared with concentration, similar trends to 
what was previously described for samples from CCM (section 4.3.2) can be observed also in the 
plasma samples (figure24). For both the control group donor and the PC patient derived EV isolates, 
the qEV fractions yield increasing numbers of total nanoparticles as the SEC fraction number increases. 
Additionally, the qEV7 fraction in both cases yield both the smallest overall number of nanoparticles, 
and simultaneously has the largest mean particle diameter. For the PC patient sample EV isolates, the 
particle diameters further follow the same pattern as described for CCM, with qEV8 having larger 
average particle diameter than TEI, which in turn has larger average particle diameter than qEV9. 
When comparing qNano particle measurements of CCM and Plasma there is further a striking 
difference in the overall spread of the data. As can be seen from the generated CSDH (figures 25, 26 
vs. 8, 9) the plasma data appear relatively much more tightly focused around 60nm than the CCM data. 
By again taking a look at figures showing the mean particle diameter spread for samples from CCM and 
Plasma (figures 7, 24) it becomes clear that this is reflected here. In general, the CCM derived EV 
isolates have the larger mean diameter. In numbers, the average diameter of all plasma values (TEI, 
qEV7, qEV8, qEV9) is 85.81nm (appendix section 7.5). The average of the same samples from CCM is 
91.44nm. This again coincides with the previously discussed observation that smaller particle 
diameters appear to correlate to higher particle concentrations (section 4.3.2). As has already been 
established, CCM samples have much lower overall particle concentrations than Plasma samples 
(figure 23). It is at this stage important to note however, that this does not equate to actually fewer 
large particles being present in the plasma samples than in the CCM samples, only that relatively more 
small particles are present thus affecting the average. In fact, in absolute numbers, the amount of 
nanoparticles with a diameter greater than 200nm appear to be much greater in the plasma derived 
samples (figure 27). 
4.4.3 EV isolate vesicle fraction and average vesicle diameter 
For the samples from plasma, both NP100 and NP200 data is available, allowing for comparisons of 
particles also in the interval of 50-85nm. By looking at the plasma derived EVs in the 85-340nm range 
and comparing to the samples from CCM, it becomes clear that also the overall amount of vesicles is 
much greater in the plasma samples than in the CCM samples, reflecting the overall increase in 
nanoparticles. In the case of the control group sample from plasma, qEV gave a higher overall vesicle 
yield than TEI, but this relationship appeared reversed in the PC-patient sample. More interesting was 
the changes observed in sample purity. In the NP200 interval, a very large drop in relative vesicle 
fraction for both techniques, with some exceptions (see table 7) 
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Table 7: Comparison of the measured vesicle purities of TEI and qEV EV isolates from PC-patient and control plasma, as 
illustrated in results figures 28 and 30. 
 Control donor sample PC patient donor sample 
 NP100 NP200 NP100 NP200 
TEI 19,51 2,50 63,51% 59,07% 
qEV 29,57 41,63 29,36% 36,37% 
 
As can be seen from table 15, a large reduction can be seen in both TEI measurements from the control 
donor sample, and all measurements from qEV, relative to samples from CCM. Strangely, and overall 
increase the vesicle fraction was observed specifically in TEI samples from the PC patient donor, 
holding true in both NP100 and NP200 intervals. In general, it can only be concluded that the what is 
isolated from various donors apparently may varies greatly between individual donors, especially when 
using the TEI technique. However, while the qEV technique proved the most consistent with regards 
to vesicle fraction quality, the TEI sample still provided the overall greatest number of vesicles in all 
but one instance. 
4.4.4 Average EV size distribution 
As previously done with the CCM samples, some general facts concerning the sizes of the plasma 
vesicles may be inferred by looking at the changes in nanoparticle diameters following treatment with 
detergent (figures 29, 31).  In the control donor sample’s NP200 range qEV showed an increase in 
particle diameter following treatment, while TEI showed a decrease. This indicated qEV vesicles smaller 
than 145.17nm (the average measured NP100 diameter with no Triton x-100) and TEI vesicles larger 
than 129.5nm. This places them both potentially within the range of exosomes [8]. Additionally, as 
NP100 data are available for these samples, even more can be said of these vesicle’s sizes. In the case 
of the qEV samples, a large decrease was observed in average nanoparticle diameter in the NP100 
range, implying that the dissolved vesicles were much larger than the average NP100 diameter 
measured without treatment of detergent of 84.33nm. It can therefore be said that the average vesicle 
size of the qEV sample in this case was between 84.33nm and 145.17nm, placing it very nicely within 
the set size range for exosomes. In the case of the TEI sample however, a moderate increase in 
nanoparticle diameter was observed in the NP100 range. This implies that the dissolved vesicles in the 
50-200nm range were on average smaller than the measured TEI average NP100 nanoparticle 
diameter with no Triton x-100, of 78.50nm. Considering that these vesicles would be below the 
detection limit of the NP200, this could indicate that in the case of the TEI sample, there is a large 
population of vesicles in the 50-78nm range, as well as a separate population of vesicles with an 
average diameter greater than 145nm. The reason this population of very small vesicles would have to 
be so large, is that the NP100 range extends to 200nm, and thus encompasses the mentioned large 
145nm average vesicles. The impact on average size by the removal of these larger particles needs to 
be negated by many small vesicles getting dissolved, in order to explain the observed results. 
Looking at the PC patient plasma sample a reduction in diameter following treatment with detergent 
was observed in the NP100 measurements from both qEV and TEI. In the NP200 range, the opposite 
was true, with an observed increase in average nanoparticle diameter following treatment. Following 
the same reasoning as previously, this would correspond to an estimated average qEV vesicle diameter 
of between 89.5nm and 149.33, positioning it perfectly for exosomes with respect to EV diameter. The 
corresponding TEI average diameter would be in between 86.50nm and 124.00nm, which is also within 
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the defined range. It should be noted that no conclusions can be drawn comparing the control and PC 
patient donors in these cases, other than that there appears to be some interpersonal variance 
affecting results, when working with EV isolates from plasma.  
 
4.4.5 Exosome quantitation using the ExoCet assay 
 
EV isolation technique performance in exosome isolation 
As has been discussed, comparing nanoparticles or even vesicles with size as the only metric is 
insufficient when trying to determine the technique best suited for isolating complex and biologically 
active biomolecules such as exosomes (section 4.1.0). As such, the ExoCet Exosome Quantitation Assay 
was used in order to further examine the relationship between the products of the various exosome 
isolation techniques. In this case, concentration measurements were based on the activity of the 
exosome-associated Acetylcholinesterase enzyme. 
In the ExoCet Exosome Quantitation Assay (SBI) on samples from plasma, TEI was estimated to be the 
decidedly highest yielding technique (figure 33), followed by ExoEasy with the second highest 
concentration barely registering above the LOD. While unfortunately no corresponding qNano Gold 
measurement could be made to verify this relation between the TEI and ExoEasy samples, the relative 
relationship between TEI and qEV can be confirmed for both control group and PC patient donor 
samples (figure 22). Notably, this is a very different relationship compared to what was observed in 
samples from CCM, where the relative concentration between ExoEasy and TEI samples was reversed. 
These results would appear to indicate that the ExoEasy technique performs poorly either with plasma 
as a substrate, or with the very small volumes used. 
A potential weakness with the enzyme-linked assay technology 
With regards to the estimated concentrations of exosomes in each sample by the ExoCet assay, TEI in 
the plasma control and PC patient group was estimated at 4,19 and 7,23 times the corresponding TRPS 
measurements of nanoparticles in the 50-200nm range. Similarly, qEV was estimated at 0,53 and 3,80 
times the corresponding NP100 values. When also taking into account the fact that the NP100 interval 
encompasses 50-200nm, and hence the entire possible range of diameters for exosomes, it would 
appear that the ExoCet assay may be overestimating the actual exosome concentration in the samples 
derived from qEV and TEI. 
Such an overestimation of the TEI sample concentration may be caused by inherent OD405nm in the 
TEI sample, unrelated to the enzymatic activity measured by the ExoCet assay. This was in part due to 
the appearance of the TEI EV isolates from plasma appearing somewhat opaque to the naked eye. In 
order to control for this, a series of specialized blanks were designed in order to account for sample 
opacity caused by potential colloid particles. When conducting ExoCet measurements, a significant 
increase in OD405 is associated with the addition of the strongly yellow coloured ExoCet buffer B. 
However, sample cannot be added to complete reaction mix without causing an enzymatic reaction. 
Simultaneously, the 1:1 dilution of the EV isolate sample in reaction mix is likely to affect any inherent 
non-enzymatic optical density contribution of the EV isolate sample. The OD405nm from the buffer a 
given sample is dissolved in when combined with the ExoCet lysis buffer (buffer A+B) therefore has to 
be measured separately in completed reaction mix and the, contribution of the sample diluted 1:1 in 
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ExoCet buffer A in a different microtiter plate well. With this in mind, the specialized blanks were 
designed to consist of two ExoCet TRs of the various EV isolates treated as normal samples during the 
assay preparation phase (see materials and methods), but loaded into wells on the microtiter plate 
with inert reaction buffer (no ExoCet buffer B added). By adding the measured OD405nm of this sample 
to that of the appropriate normal blank at a given time of incubation, a specialized blanking value 
which accounts for static opacity due to colloidal occlusion of the sample for that incubation time is 
obtained. This was done in an effort to improve accuracy by taking into account any opacity in the 
solution caused by colloid or other suspended particles in the various samples when subtracting blank 
OD405.  
Use of the specialized blanking values gave only minor reductions in the ExoCet assay estimated 
exosome concentrations (see results). The ExoEasy and TEI samples had very different apparent 
opacity (judging by eye) yet both experienced an approximate 15% reduction in estimated exosome 
concentration when using the specialized blanks. This does little to explain the sevenfold increase in 
estimated ExoCet exosome concentration relative to the qNano Gold estimated total 50-200nm 
nanoparticle concentration. There is therefore little reason to believe that the specialized blanks had 
their intended effect, when also considering that the relative relation between samples did not change 
in any meaningful way.  It would appear that the other measures taken to negate the effects of 
inherent sample opacity, such as increasing the centrifugation time of samples post-lysis (see materials 
and methods), in order to collect more debris, as well as the long RT incubation of the TEI samples 
prior to the assay, were sufficient for counteracting any ill-effects from internal opacity ad 405nm. 
Additionally, the long incubation time (20 minutes) selected so as to minimize the effects of noise 
further abates the issue. With this in mind, it was concluded that there was not sufficient evidence of 
gained benefits by use of specialized blanks, to justify deviating from the protocol provided by the 
manufacturer (SBI) by their inclusion in the sample blanking process. 
An alternative hypothesis would be that the already discussed large differences between even vesicles 
of similar size isolated by the different EV isolation techniques may play an important role in explaining 
this issue. The manufacturer of ExoCet, System Bio, also produces the ExoQuick EV isolation kits. The 
Exosome quantitation in the ExoCet assay is based on measured AChE-activity in samples of isolated 
exosomes, which have been quantified using NanoSight (NTA) analysis. NTA analysis, like the TRPS-
based qNano Gold, cannot easily discriminate between nanoparticles of the same diameter. According 
to the documentation provided by the manufacturer (SBI), the standard solutions used to produce the 
standard curve upon which the exosome quantitation is based, does not contain actual exosomes, but 
rather a predetermined concentration of AChE-enzyme. As such, the quantitation is highly dependent 
on the relative amount of AChE-enzyme per unit of nanoparticles isolated in the correct size range for 
exosomes (50-150nm) being consistent between isolations. Based on the differences in results 
between EV isolation techniques already discussed in this thesis, there may be reason to believe that 
the relative fractions of different types of nanoparticles isolated differs between exosome isolation 
techniques. In the case that the EV isolation technique used by SBI isolates a smaller relative fraction 
of AChE-containing nanoparticles in the correct size range, other techniques which isolate 
nanoparticles with more AChE-content will have their numbers overestimated. There is however not 
enough data to conclude strongly on the validity of this hypothesis. 
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4.4.6 dsDNA in samples from plasma 
With regards to the Qubit measured concentrations some issues were met with regards to low sample 
concentrations of dsDNA. Initially, the same Allprep (Qiagen) kit was attempted used for isolating DNA 
from plasma samples as were used for CCM samples. When in the testing phase no dsDNA could be 
measured using the Qubit dsDNA HS assay, it was decided that the issue may be related to the high 
DNA size cut-off of the AllPrep DNA Mini Spin columns of 15-30kb. It was therefore decided to switch 
to the QiaAmp Circulating nucleic acid kit (Qiagen) instead, for isolation of DNA from plasma, which 
performed better under testing. 
In general, only very low concentrations of dsDNA could be found in EV isolates from plasma. This 
turned out to pose some obstacles to overcome with regards to as representatively as possible 
portraying the estimated concentrations of dsDNA yielded by each technique. This came about as 
several of the samples measured in the Qubit dsDNA HS assay proved to have concentrations of dsDNA 
lower than the limit of detection (LOD) for the Qubit dsDNA HS assay for one or more of the biological 
replicates of each group. All values in the raw data (appendix section 7.2) were however hovering close 
to the LOD, providing reason to believe that the actual concentration in the non-measureable samples 
were >0ng/mL. Excluding these samples when calculating the average dsDNA concentration would 
therefore likely lead to an overestimation of the actual concentration, whereas setting them to 0ng/mL 
would equally likely result in an underestimation of the actual dsDNA concentration. It was therefore 
decided that when calculating the average of biological replicates, samples below the LOD should be 
set to LOD/2, thus minimizing the chance of radical misrepresentation of dsDNA concentrations. For a 
breakdown of the dsDNA concentration calculations, please refer to the appendix (Appendix 7.1, 
calculations). 
With this in mind, the results of the measurements of dsDNA from plasma derived EV isolates can be 
compared. Perhaps unsurprisingly considering the CCM results, TEI resulted in the greatest overall 
yield of dsDNA, when compared to ExoEasy and each individual qEV fraction. Interestingly, the ExoEasy 
technique in general gave very low concentrations from plasma, averaging just barely above the LOD 
in the control group, and in fact slightly below in the PC patient group. This is particularly interesting 
as it is less than each individual qEV fraction. The qEV isolation technique overall therefore in these 
experiments greatly exceed the efficacy of the ExoEasy technique with regards to isolating measurable 
quantities of dsDNA (figure 34). This relation between ExoEasy and TEI is also what was observed in 
the previously discussed ExoCet estimated exosome concentrations. This may be related to the fact 
that the ExoEasy spin column, in its effort to be simple and universally compatible, is dimensioned to 
support volumes of up to 16mL of starting material. The volume of starting material processed by the 
same type of column is therefore reduced 16-fold when moving from CCM samples to plasma samples. 
The qEV column conversely, is intended for use with small volumes (0,5mL loading volume), and 
subsequently requires a concentrating step prior to loading if large volumes of starting materials are 
to be processed. It may be the case that the efficacy of DNA isolation from very small volumes is even 
more adversely affected when using small volumes with the ExoEasy spin column technology, with its 
unchanging solid phase dimensions despite greatly changing volumes of starting material, than with 
the qEV SEC-columns. The TEI technique, relying on precipitation in solution without elusion through 




4.4.7 Correlations between isolated exosomes from plasma and measured nanoparticles 
In the case of ExoCet estimated exosomes from the plasma control group, the contribution in 
OD405nm of each individual qEV fraction was below the LOD determined by the standard curve 
equation for both qEV 7 and 8. As such there are too few data points in this series for any meaningful 
scatterplots looking for correlation to be made. An estimation could however be made based on the 
dataset from the PC-patient samples, showing at some apparent correlation (figure 35). 
Based on this estimation, it would appear that there is some correlation, albeit not a very strong one, 
with an R2 value of only 0,69 (figure 35).  It would appear that relative to the trend set by the qEV 
fractions (clustered in the bottom left) and that of TEI (top right), ExoEasy is relatively underperforming 
with regards to dsDNA content. The way the qEV fractions cluster indicate that qEV9 (topmost of the 
three) has a relatively higher dsDNA concentration than the norm, whereas qEV7 and 8 are in the 
middle. Interestingly, this perfectly reflects what was previously discussed in the dsDNA per 
nanoparticle plot for CCM (figure 18). 
 
4.4.8 PNA clamp assay for KRAS mutated alleles 
As progress has been made in EV research in the last decade, several observations of tumour DNA 
being carried by EVs has been reported (section 1.2) In order to measure the levels of such DNA in the 
EV isolates produced by the various techniques using plasma as starting material, a PNA clamp assay 
for KRAS mutation was performed.  
 
As previously mentioned, the KRAS gene has been shown to be present in 80-90% of pancreatic cancers 
[62]. One particularly interesting metric for evaluating the success of the EV isolation techniques, is 
therefore the PNA clamp assay for KRAS mutation. This is an important aspect, as it confirms the 
presence and relative purity of tumour mutated alleles in the DNA contained within each sample, and 
thus gives a very strong indication as to whether or not the EVs of each EV isolation technique contain 
nucleic acids usable for diagnostic purposes in the future. 
As with the BAFC analysis (figures 14, 15) the PNA clamp assay revealed very strong results for the qEV 
fractions, where qEV8 and 9 individually gave the greatest and second greatest total ΔΔCq across all 
PC-patient donors (figure 36). Also the qEV7 fraction, although contributing less, resulted in a KRAS 
detection, and with a respectable purity. As such, the overall qEV technique may be considered to 
isolate the EV’s with the greatest purity of relevant DNA. 
Both ExoEasy and TEI techniques however each collected DNA determined to be positive for KRAS 
mutation from two out of three PC-patient donors. This shows that both these techniques, although 
yielding less pure fractions of tumour DNA vs. WT, still isolate the correct EV’s to an extent 
measureable using PNA clamp assay. It must be noted however, that one of the main goals of using 
EV’s such as exosomes for DNA isolation, is their suggested ability to selectively enrich themselves with 
tumour DNA, as such purity is a very important factor to consider. 
One interesting observation at this point would be that qEV distinguishes itself particularly in exosome 
marker protein (section 4.3.4) and KRAS mutated alleles. This falls well in line with the numerous 




4.4.9 Summarizing overall performance of EV isolation techniques from plasma 
As the overall EV concentration and purity could not be reliable measured in the ExoEasy samples, 
these cannot be included in the final summary evaluation of the techniques. Instead, the relationship 
between the techniques as measured by the ExoCet Exosome Quantitation assay will be used. 
Furthermore, the results for CD9 and CD63 protein could not be successfully measured in samples from 
plasma, and requires more experimentation. The primary focus of the weighting will therefore in the 
plasma phase be on the ability of each technique to extract DNA from samples, and particularly tumour 
DNA.  In addition, the effort scores from the last phase will be included also this time. Like before, the 
general scoring will be that of rating the techniques from best (3 points) to worst performance (1 
point), and summing together the points of the EV isolation technique across all the evaluation criteria. 
Additionally, a modifier of x1.5 will be placed on the quantity of isolated dsDNA ([dsDNA]) and a 
modifier of x2.0 on the relative amount of detected KRAS mutated alleles (KRAS).  The summary is 
shown below (table 8) 
 
Table 8: Each EV isolation technique from plasma scored against the defined criteria for ideal EV isolation. The overall yielded 
concentration of dsDNA ([dsDNA]) has been weighted slightly, with a modifier of x1.5 on its original score to emphasize the 
importance of a high dsDNA yield. The relative sample estimated exosome concentration ([Exos]) and the overall effort of the 
isolation process (Effort) has been weighted normally. The total relative fraction of mutated KRAS alleles in the sample (KRAS) 
has been weighted with a 2x modifier. Numbers in parenthesis are the original scores of the EV isolation technique, prior to 
applying the weighting modifier. 
 [Exos] [dsDNA] (x1.5) KRAS (x2.0) Effort Sum 
TEI 3 4.5 (3) 2 (1) 2 11.5 
qEV 1 3 (2) 6 (3) 1 11 












5. CONCLUSIONS AND FUTURE PERSPECTIVE 
 
This study has shown that UC, the most traditional and widely used technique for EV isolation [70] is 
greatly outperformed by newly available cheaper, quicker and more effective methods of EV isolation. 
A distinct increase in EV yield, purity and quality was demonstrated for EV isolation by polymer 
precipitation, affinity chromatography and SEC over UC. Recovered dsDNA concentrations were also 
low, and findings indicate many large co-isolates which are not EVs. ExoQuick was found to isolate a 
relatively pure EV fraction, but to be unable to compete with the overall performance of TEI and 
ExoEasy with regards to factors such as overall vesicle yield, abundance of exosome marker proteins 
and dsDNA yield. 
qEV was shown to isolate the purest EVs of any technique, yielding nanoparticles in the ideal range for 
exosomes while also showing a significantly higher content of exosome marker proteins than any other 
tested technique. qEV additionally isolated by far the greatest fraction of KRAS mutated dsDNA alleles, 
falling in line with reports of a link between the two [8, 11]. qEV was shown to perform marginally 
better than ExoEasy with regard to overall dsDNA isolation. The total yield of dsDNA, however, in EV 
isolates from qEV were shown to be much lower than that of TEI in samples from both CCM and 
plasma. The TEI technique was shown to isolate a disproportionally large amount of dsDNA from both 
CCM and plasma when compared to any of the other techniques tested. TEI was also observed to co-
isolate a very large amount of non-vesicle macromolecules. Findings indicated that TEI may isolate 
large EVs such as oncosomes or MVs to a much greater extent than the other EV isolation techniques, 
and that the disproportionate dsDNA yield may originate from these larger EVs. While KRAS mutated 
alleles were identified in TEI samples, the relative fraction of these was less than that which was found 
in both qEV and ExoEasy. The TEI isolated EVs were found to be poor in exosome marker proteins. EVs 
isolated by the ExoEasy techniques were characterized by a very small average size and very high 
concentrations. The relative fraction of CD63 in EVs from ExoEasy was found to be greater than that of 
those from TEI, while CD9 was equal between the two. Findings indicated a heterogeneous 
nanoparticle population with a slightly better overall yield than qEV of dsDNA from CCM, but 
marginally less from plasma. The relative fraction of exosome marker proteins in EVs from ExoEasy 
was found to be greater than that of TEI, and the relative fraction of KRAS mutated alleles to be 
marginally better. It was found that overall, the performance of TEI and qEV was somewhat superior 
to that of ExoEasy, and overall the best when weighted against criteria deemed the most relevant for 
EV isolation with prospects of use as a biomarker for PC.  
In the short term, the findings in this study calls for future investigation of the specific properties of 
the EVs isolated by the qEV and TEI techniques in particular. Further testing needs to be done on EV 
isolates in order to more directly determine the types of vesicles present by further testing for different 
biomarkers, and preferably techniques such as electron microscopy. Further study is necessary in order 
to determine to what extent the lower measured concentration of EVs and dsDNA in qEV isolate is due 
to the exclusion of irrelevant material, and the dsDNA contents of the two techniques should be 
investigated in order to uncover any differences in fragment length and origin. While on one hand qEV 
appears to isolate very pure fractions of EVs and tumour DNA, overall low concentrations and EV yields 
make TEI a tempting option. Barring their low concentration, while the qEV isolates may appear to 
hold a much higher purity of relevant EVs and dsDNA, the process of SEC EV isolation is still significantly 
more laborious and time consuming than the process required for EV isolation by TEI. As such, it should 
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be studied if the TEI isolate quality is sufficiently high, as it would be preferable with a quicker process 
for any potential future clinical routine EV isolation. Finally, the extent to which SEC and polymer 
precipitation isolated dsDNA with the current methodology holds prognostic qualities which are 
different or superior to that of general cell-free DNA isolated directly from plasma, and if not; what 
changes can be made to increase their viability. 
The tumour DNA content taken into account, there can be little doubt that EVs and EV isolation will 
play a central role in future cancer diagnosis. As technologies within EV purification and next 
generation sequencing continue to progress, EVs are likely to provide a non-invasive window into the 
internal environment of organs and tissues which would otherwise require a large medical 
intervention. With further research, their circulating nature and general abundance may make 
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Calculation of dsDNA/mL starting material (Qubit dsDNA HS assay) 
 
For determination of dsDNA/ml CCM/plasma used during EV isolation, the calculation performed was 
structured as follows: 
1) 𝑄𝑢𝑏𝑖𝑡 𝑜𝑢𝑡𝑝𝑢𝑡 (
𝑛𝑔
𝑚𝐿
) ∗ 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑒𝑙𝑢𝑎𝑡𝑒 (𝑚𝐿) = 𝑡𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑖𝑠𝑜𝑙𝑎𝑡𝑒𝑑 (𝑛𝑔) =
"𝑎" 
Note: this volume = 100µL for all Allprep samples (= all CCM samples) and 50µL for all QiaAmp samples 
(= all plasma samples). 
2) “a” has to be scaled by a factor in order to reflect the DNA present in the volume of EV isolate 
which was not used for DNA isolation. This factor is obtained by dividing the full EV isolate 
volume by the volume used for DNA isolation: 
 




5 = 𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 
b. Allprep on 70µL EV isolate sample; full EV isolate volume = 500µL. 
500
70
≈ 7,143 = 𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 
 
𝑎 ∗ 𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟
= 𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑡𝑜𝑡𝑎𝑙 𝐷𝑁𝐴(𝑛𝑔)𝑖𝑠𝑜𝑙𝑎𝑡𝑒𝑑 𝑓𝑜𝑟𝑚 𝑡ℎ𝑒 𝑓𝑢𝑙𝑙 𝑒𝑥𝑜𝑠𝑜𝑚𝑒 𝑖𝑠𝑜𝑙𝑎𝑡𝑒 𝑠𝑡𝑜𝑐𝑘 𝑣𝑜𝑙𝑢𝑚𝑒 = "𝑏" 
 
3) Total volume of raw material (CCM or plasma) used during EV isolation for a given technique 
= “c” 





= 𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑡𝑜𝑡𝑎𝑙 𝑑𝑠𝐷𝑁𝐴(𝑛𝑔)𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑 𝑝𝑒𝑟 𝑚𝐿 𝑟𝑎𝑤 𝑚𝑎𝑡𝑒𝑟𝑎𝑙 
 
Note: in the case of plasma, the volume C =1mL, and as such steps 3 and 4 may be disregarded 
when calculating dsDNA/mL plasma. 
 
The qEV (Izon science) column protocol (Izon) dictates that the optimal EV concentration and purity is 
achieved by collecting the eluate in 3 separate fractions, each of 500µL. After discarding the column 
void volume of 3mL, this equates to qEV fractions 7, 8 and 9. While these qEV fractions were treated 
as separate samples during subsequent testing and measurements, they all originate from the same 
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volume of raw material. As such, these fractions were pooled together mathematically in order to 
better be able to compare the total dsDNA yields of the various EV isolation techniques: 
 
1. 𝑄𝑢𝑏𝑖𝑡 𝑜𝑢𝑡𝑝𝑢𝑡 (
𝑛𝑔
𝑚𝐿
) ∗ 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝐷𝑁𝐴 𝑒𝑙𝑢𝑎𝑡𝑒(𝑚𝐿) = 𝑡𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑖𝑠𝑜𝑙𝑎𝑡𝑒𝑑 (𝑛𝑔) = "𝑎" 
2. (𝑎𝑞𝐸𝑉7 + 𝑎𝑞𝐸𝑉8 + 𝑎𝑞𝐸𝑉9) = 𝑡𝑜𝑡𝑎𝑙 𝑑𝑠𝐷𝑁𝐴 (𝑛𝑔) 𝑖𝑠𝑜𝑙𝑎𝑡𝑒𝑑 𝑓𝑟𝑜𝑚 𝑎𝑙𝑙 𝑞𝐸𝑉 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑠 = "∑𝑎"  
 
∑a has to be scaled by a factor in order to reflect the DNA present in the EV isolate not used 
in the DNA isolation technique. This factor is obtained by dividing the full EV isolate volume 
by the volume used for DNA isolation: 
Ex: 
 
Allprep on 100µL EV isolate sample * 3 qEV fractions = 300µL 




= 5 = 𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 
 
3. ∑𝑎 ∗ 𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 =
𝑡𝑜𝑡𝑎𝑙 𝑑𝑠𝐷𝑁𝐴(𝑛𝑔) 𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙𝑙𝑦 𝑖𝑠𝑜𝑙𝑎𝑡𝑒𝑑 𝑓𝑟𝑜𝑚 𝑎𝑙𝑙 3 𝑓𝑢𝑙𝑙 𝑞𝐸𝑉 𝑒𝑥𝑜𝑠𝑜𝑚𝑒 𝑖𝑠𝑜𝑙𝑎𝑡𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑠 =
"𝑏" 




= 𝑇𝑜𝑡𝑎𝑙 𝑑𝑠𝐷𝑁𝐴(𝑛𝑔) 𝑖𝑠𝑜𝑙𝑎𝑡𝑒𝑑 𝑝𝑒𝑟 𝑚𝐿 𝑜𝑓 𝐶𝐶𝑀 𝑢𝑠𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑒𝑥𝑜𝑠𝑜𝑚𝑒 𝑖𝑠𝑜𝑙𝑎𝑡𝑖𝑜𝑛  
 
Note: in the case of EV isolates from plasma, the starting volume was 1mL. As such, steps 4 
and 5 may be disregarded when calculating total qEV dsDNA/mL plasma. 
 
Calculation of dsDNA from plasma, taking the Qubit LOD into consideration 
The Qubit LOD corresponding to dsDNA/mL plasma was calculated as follows: 
1. The LOD in the assay reaction mix = [dsDNA] ≥ 0,5ng/mL. For each assay, 20µL od DNA-isolate 









The minimum concentration of dsDNA required in the stock DNA isolate, in order to exceed 
the Qubit LOD 
 





∗ 0,05𝑚𝐿 = 0,25𝑛𝑔 = 




(100µL/500µl) =1/5 of the full EV isolate sample volume was used for DNA isolation 
4. 0,25𝑛𝑔 ∗ 5 = 1,25𝑛𝑔 = 
The mass of dsDNA required to be present in the full EV isolate stock, in order to exceed the 
Qubit LOD 
The full EV isolate volume stems in each case from only 1mL of plasma. 
5. 1,25 𝑛𝑔/1𝑚𝐿 = 
The concentration of dsDNA required per mL of plasma in order to exceed the Qubit LOD 
This method of minimizing estimation error however makes it all the more important to provide an 
accurate estimation of the uncertainty introduced by the method. In order to achieve the most 
accurate standard deviation when calculating across several parallel measurements, calculations were 
carried out as follows: 
1) Each Qubit measurement was split into two values, “Val1” and “Val2” 
a. For measurements falling below the LOD, Val1= 0 and Val2= 1,25. In this way, the 
average contribution of each below-LOD measurement would be 0,625ng/mL (= 
LOD/2). Additionally, as the number of included values increases, calculated STDAV 
will approach 0,625. This will allow error bars to reflect the uncertainty of ± ½*LOD. 
b. For measurements above the LOD, VAL1 = VAL2 = the measured concentration. Thus, 
the average contribution of each such value will be the actually measured 
concentration, and the local STDAV contribution = 0. 
2) The overall averages were then calculated using all data points (estimated and actual). This 
resulted in a large amount of data points for each dataset, bolstering the accuracy of the 
calculated STDAV. 
 
On calculating the number of exosomes from the ExoCet Exosome Quantitation Assay 
1. The OD405nm data from each well in the 96-well microtiter plate was correlated to its sample 
name according to the loading order 
2. Each value was corrected by its appropriate blanking value 
3. qEV fractions 7,8 and 9 were pooled by taking adding together the blanked OD405 of qEV 7, 8 
and 9 of the same biological replicate and with the same technical replicate # (ex: qEV7 control 
group donor #1 TR1 + qEV8 control group donor #1 TR 1 + qEV9 control group donor #1 TR1) 
4. Any negative values (those with an OD405nm lower than that of their respective blank) were 
removed. 
5. The blanked values for the various standard solutions were averaged, and a standard curve 
constructed. 
6. The formula of the standard curve was used in order to calculate the number of exosomes 
estimated to be present in each well. 
7. The calculated number of exosomes was divided by 0,025mL, in order to get the value for 
Exosomes/mL sample. For the pooled qEV values, this number was 0,075mL. 
 
This is because 50µL of sample (diluted 1:1 with ExoCet lysis buffer) was divided across two 
wells on the microtiter plate during loading. Each well was therefore loaded with the 
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equivalent of 0,025mL sample. As the qEV-pooled values are the OD405 values of 3 such wells 
(corrected for blank), the total loaded sample volume also has to be multiplied by 3.  
 
8. The value from (7) was multiplied by 0,5mL in order to get the value for total number of 
exosomes in the full EV isolate sample (the total elution volume of each EV isolation 
technique). For the pooled qEV values, this number was 1,5. 
 
This is because the total volume of EV isolate for each technique is 0,5mL. For the qEV sample, 
each fraction is 0,5mL. As such, when pooling the three, the total EV isolate volume is 1,5mL. 
9. The value from 8 was divided by the volume of starting material used, in order to get a value 
for exosomes isolated/mL starting material. Because 1mL of plasma was used for all isolations 

























7.2.1 dsDNA from EV isolates from CCM 
 
 
Summary: Qubit dsDNA from CCM isolated from EV isolates treated/untreated with DNase 
Table 11: Qubit dsDNA HS assay corrected concentrations of dsDNA from CCM derived EVs. The left of the table shows 
measured dsDNA (ng) from EV isolates with no DNase treatment prior to DNA isolation, whereas the right of the table shows 
those DNase treated prior to DNA isolation. To the right of each column of concentrations, is a column showing the associated 
standard deviation (STDAV) for each value, based on the two technical replicate samples. 
 No DNase treatment With DNase treatment 
Sample ID dsDNA ng/mL CCM STDAV dsDNA ng/mL CCM STDAV 
ExoEasy 23,18 3,41 19,96 3,36 
TEI 45,36 3,17 44,34 8,64 
ExoQuick 14,29 6,26 4,88 0,90 
UC 2,65 1,09 1,69 0,70 
qEV7 2,00 2,48 0,96 0,85 
qEV8 4,20 2,08 2,17 0,39 




Qubit dsDNA unprocessed data from CCM derived exoDNA isolate samples, no DNase treatment 
Table xx : Qubit dsDNA measurement data from 100µL non-DNase treated EV isolate samples from CCM. Each isolation 
techniques was measured in two technical replicated on the EV isolation from plasma level (ID 1 and 2), and each technical 
replicate was measured three times using the Qubit (“Meas.No.” 1,2 and 3). The concentration of dsDNA measured directly 
in the Qubit assay is displayed in the column “[dsDNA]assay, and the value corrected to reflect the actual concentration in 
the stock DNA isolate is show under “[dsDNA]” 





1 ExoEasy 1 1 84,30 843,00 
  2 81,40 814,00 
  3 80,00 800,00 
2 ExoEasy2 1 67,20 672,00 
  2 66,30 663,00 
  3 65,90 659,00 
3 qEV7 1 1 0,75 7,50 
  2 0,79 7,90 
  3 0,79 7,90 
4 qEV7 2 1 11,60 116,00 
  2 12,00 120,00 
  3 12,40 124,00 
5 qEV8 1 1 18,50 185,00 
  2 18,00 180,00 
  3 17,90 179,00 
6 qEV8 2 1 8,71 87,10 
  2 8,62 86,20 
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  3 8,84 88,40 
7 qEV9 1 1 19,40 194,00 
  2 19,20 192,00 
  3 19,40 194,00 
8 qEV9 2 1 21,50 215,00 
  2 21,10 211,00 
  3 19,10 191,00 
9 TEI 1 1 153,00 1530,00 
  2 152,00 1520,00 
  3 152,00 1520,00 
10 TEI 2 1 139,00 1390,00 
  2 138,00 1380,00 
  3 137,00 1370,00 
11 ExoQuick 1 1 60,00 600,00 
  2 59,70 597,00 
  3 60,00 600,00 
12 ExoQuick 2 1 31,50 315,00 
  2 31,50 315,00 
  3 31,70 317,00 
13 UC 1 1 6,42 64,20 
  2 6,20 62,00 
  3 6,03 60,30 
14 UC 2 1 11,70 117,00 
  2 11,20 112,00 




Figure xx: Qubit dsDNA HS assay measured dsDNA concentration per mL of CCM used, all TRs. DNA isolated from EV isolate 
material untreated with DNase. Error bare reflect the standard deviation between three sequential measurements of each 
prepared sample on the Qubit 2.0 fluorometer. 
 
Qubit dsDNA from CCM with EV DNase treatment, raw data 
Table xx: dsDNA measurement data (Qubit dsDNA HS assay) from 70µL of DNase treated EV isolate samples from CCM. Each 
isolation technique was measured in two technical replicates (ID 1 and 2), and each physical replicate measured three times 
on the Qubit 2.0 fluorometer (Meas. No. 1,2 and 3). The concentration of dsDNA measured directly in the Qubit assay is 
listed in the column labelled “[dsDNA]assay”, whereas the dsDNA concentration corrected to reflect that of the stock DNA 
isolate is shown in the column labelled “[dsDNA]”. 
Sample 





BR1 1 39,40 394,00 

















  3 38,20 382,00 
2 ExoEasyBR2 1 50,10 501,00 
  2 50,10 501,00 
  3 49,90 499,00 
3 TEI BR1 1 86,70 867,00 
  2 85,30 853,00 
  3 84,90 849,00 
4 TEI BR2 1 114,00 1140,00 
  2 113,00 1130,00 
  3 112,00 1120,00 
5 
ExoQuick 
BR1 1 10,10 101,00 
  2 9,25 92,50 
  3 9,20 92,00 
6 
ExoQuick 
BR2 1 12,50 125,00 
  2 12,40 124,00 
  3 12,20 122,00 
7 UC BR1 1 2,75 27,50 
  2 2,77 27,70 
  3 2,76 27,60 
8 UC BR2 1 5,16 51,60 
  2 5,05 50,50 
  3 4,92 49,20 
9 qEV7 BR1 1 0,79 7,90 
  2 0,79 7,90 
  3 0,79 7,90 
10 qEV7 BR2 1 3,54 35,40 
  2 3,44 34,40 
  3 3,50 35,00 
11 qEV8 BR1 1 5,52 55,20 
  2 5,47 54,70 
  3 5,48 54,80 
12 qEV8 BR2 1 4,33 43,30 
  2 4,22 42,20 
  3 4,17 41,70 
13 qEV9 BR1 1 8,20 82,00 
  2 8,11 81,10 
  3 7,68 76,80 
14 qEV9 BR2 1 2,61 26,10 
  2 2,50 25,00 


















Big Experiment 002, Qubit dsDNA concentration 
by biological replicate (with DNase)
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Table xx: Qubit measured concentrations of dsDNA from CCM derived EVs without DNase treatment 
(average of TR’s) 
Sample ID dsDNA/mL CCM STDAV 
ExoEasy 23,18 3,41 
TEI 45,36 3,17 
ExoQuick 14,29 6,26 
UC 2,65 1,09 
qEV 12,43 2,39 
 
 




CCM with DNase 
Table xx: Qubit measured concentrations of dsDNA from CCM derived EVs with DNase treatment 
(average of TR’s) 
Sample ID dsDNA/mL CCM STDAV 
ExoEasy 19,96 3,36 
TEI 44,34 8,64 
ExoQuick 4,88 0,90 
UC 1,69 0,70 























Figure xx: dsDNA /mL CCM by EV isolation technique with DNase treatment 
 
 
Table xx: Qubit measured concentrations of dsDNA from CCM derived EVs with and without DNase 
treatment, compared (average of TR’s). 
Sample ID 
dsDNA (ng) /mL 
CCM No DNase STDAV 
dsDNA (ng) /mL CCM 
With DNase STDAV2 
ExoEasy 23,18 3,41 19,96 3,36 
TEI 45,36 3,17 44,34 8,64 
ExoQuick 14,29 6,26 4,88 0,90 
UC 2,65 1,09 1,69 0,70 





























dsDNA per mL CCM, with DNase treatment
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7.2.2 dsDNA (Qubit) from plasma derived EV isolates 
 
Summary of corrected values for EV dsDNA/mL plasma can be seen below (table 13).  
Table 13: Qubit dsDNA HS assay corrected concentrations of dsDNA from plasma derived EV isolates. The left of the table 
shows measured dsDNA from control group samples, whereas the right of the table shows measured dsDNA from PC-patient 
samples.  To the right of each column of concentrations is a column showing the associated standard deviation (STDAV) for 
each concentration value, based on the three biological replicates for each EV isolation technique. Note that the limit of 
detection (LOD) of the assay is 1.25ng dsDNA/mL plasma (normalized).   
 Control group PC patient group 
Sample ID dsDNA /mL CCM STDAV dsDNA /mL CCM STDAV 
ExoEasy 1,61 1,51458518 1,16 0,94 
TEI 2,38 2,27157513 4,21 2,87 
qEV7 1,64 1,55188378 1,87 0,76 
qEV8 1,73 1,70423434 1,34 0,67 




(all data from DNase treated EV isolate) 















BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
2 SE003 
ExoEasy 
BR2 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
3 SE003 TEI BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
4 SE003 TEI BR2 1 0,63 6,3 
   2 0,64 6,4 
   3 0,66 6,6 
5 SE003 
qEV7 
BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
6 SE003 
qEV7 
BR2 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
7 SE003 
qEV8 
BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
8 SE003 
qEV8 
BR2 1 <0,50 N/A 
   2 <0,50 N/A 





BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
10 SE003 
qEV9 
BR2 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
 
SE004 (control group donor #2) 
sample # Sample Set Sample ID Meas. # Assay ng/mL dsDNA ng/mL 
1 SE004 ExoEasy BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
2 SE004 ExoEasy BR2 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
3 SE004 TEI BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
4 SE004 TEI BR2 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
5 SE004 qEV7 BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
6 SE004 qEV7 BR2 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
7 SE004 qEV8 BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
8 SE004 qEV8 BR2 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
9 SE004 qEV9 BR1 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
10 SE004 qEV9 BR2 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
 













1 SE005 ExoEasy 1 1,37 13,70 
   2 1,37 13,70 
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   3 1,33 13,30 
2 SE005 ExoEasy 1 1,76 17,60 
   2 1,38 13,80 
   3 1,35 13,50 
3 SE005 TEI 1 2,30 23,00 
   2 1,95 19,50 
   3 1,83 18,30 
4 SE005 TEI 1 2,66 26,60 
   2 2,15 21,50 
   3 2,60 20,60 
5 SE005 qEV7 1 1,45 14,50 
   2 1,41 14,10 
   3 1,39 13,90 
6 SE005 qEV7 1 1,56 15,60 
   2 1,54 15,40 
   3 1,48 14,80 
7 SE005 qEV8 1 1,26 13,60 
   2 1,32 13,20 
   3 1,36 13,60 
8 SE005 qEV8 1 1,79 17,90 
   2 1,84 18,40 
   3 1,80 18,00 
9 SE005 qEV9 1 1,91 19,10 
   2 1,93 19,30 
   3 1,82 18,20 
10 SE005 qEV9 1 1,96 19,60 
   2 1,85 18,50 
   3 1,77 17,70 
 













1 PC39B11 ExoEasy 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
2 PC39B11 TEI 1 0,95 9,5 
   2 0,95 9,5 
   3 0,94 9,4 
3 PC39B11 qEV7 1 1,18 11,8 
   2 1,16 11,6 
   3 1,14 11,4 
4 PC39B11 qEV8 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
5 PC39B11 qEV9 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
 
SE007 (PC patient donor #2) 
Sample 







1 PC47B7B ExoEasy 1 0,93 9,30 
   2 0,88 8,80 
   3 0,87 8,70 
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2 PC47B7B TEI 1 3,30 33,00 
   2 3,24 32,40 
   3 3,23 32,30 
3 PC47B7B qEV7 1 0,59 5,90 
   2 0,58 5,80 
   3 0,56 5,60 
4 PC47B7B qEV8 1 0,79 7,90 
   2 0,76 7,60 
   3 0,76 7,60 
5 PC47B7B qEV9 1 0,81 8,10 
   2 0,80 8,00 
   3 0,78 7,80 
 
SE008 (PC patient donor #3) 
Sample 







1 PC48B7 ExoEasy 1 <0,50 N/A 
   2 <0,50 N/A 
   3 <0,50 N/A 
2 PC48B7 TEI 1 0,83 8,30 
   2 0,85 8,50 
   3 0,85 8,50 
3 PC48B7 qEV7 1 0,51 5,10 
   2 0,50 5,00 
   3 0,50 5,00 
4 PC48B7 qEV8 1 0,60 6,00 
   2 0,60 6,00 
   3 0,57 5,70 
5 PC48B7 qEV9 1 0,65 6,50 
   2 0,64 6,40 




Table xx: Qubit measured concentrations of dsDNA from control group plasma derived EVs with EV 
DNase treatment 
ID dsDNA ng/mL STDAV LOD 
ExoEasy 1,61 1,51458518 1,25 
TEI 2,38 2,27157513 1,25 
qEV7 1,64 1,55188378 1,25 
qEV8 1,73 1,70423434 1,25 





Figure xx: dsDNA /mL plasma from control group by EV isolation technique, with EV DNase treatment 
Table xx: Qubit measured concentrations of dsDNA from control group plasma derived EVs with EV 
DNase treatment, qEV fractions pooled 
ID dsDNA ng STDAV LOD 
ExoEasy 1,61 1,51 1,25 
TEI 2,38 2,27 1,25 
qEV 5,35 1,76 1,25 
 
 
PC patient group: 
Table xx: Qubit measured concentrations of dsDNA from patient group plasma derived EVs with EV 
DNase treatment 
ID dsDNA ng/mL STDAV LOD 
ExoEasy 1,16 0,94 1,25 
TEI 4,21 2,87 1,25 
qEV7 1,87 0,76 1,25 
qEV8 1,34 0,67 1,25 













































Figure xx: dsDNA /mL plasma from PC patient group by EV isolation technique, with EV DNase 
treatment 
Table xx: Qubit measured concentrations of dsDNA from partient group plasma derived EVs with EV 
DNase treatment 
ID dsDNA ng STDAV LOD 
ExoEasy 1,16 0,94 1,25 
TEI 4,21 2,87 1,25 
qEV 4,61 0,73 1,25 
 
 
Figure xx: dsDNA /mL plasma from patient group by EV isolation technique, with EV DNase treatment 
 
Comparisons 
Table xx: Qubit measured concentrations of dsDNA from plasma derived EVs with EV DNase treatment, 
patient vs. control group 
ID Control group average STDAV PC patient average STDAV2 LOD 











































TEI 2,38 2,27 4,21 2,87 1,25 
qEV7 1,64 1,55 1,87 0,76 1,25 
qEV8 1,73 1,70 1,34 0,67 1,25 
qEV9 1,98 2,01 1,40 0,70 1,25 
 
Table xx: Qubit measured concentrations of dsDNA from plasma derived EVs with EV DNase treatment, 
patient vs. control group. qEV fractions pooled 
ID Control group average STDAV PC patient group average STDAV2 LOD 
ExoEasy 1,61 1,51 1,16 0,94 1,25 
TEI 2,38 2,27 4,21 2,87 1,25 
qEV 5,35 1,76 4,61 0,73 1,25 
 
 
Figure xx: dsDNA /mL plasma from by EV isolation technique, control group vs. patient group. With EV 








7.2.3 PNA clamping Assay for KRAS mutation data 
 
PC patient #1 
Table xx: PC patient #1 PNA assay for KRAS mutated alleles real-time PCR data. The sample ID column reflects the given ID 



















dsDNA average, PC patients and controll group donors, qEV 
fractions pooled
Control group average PC patient group average LOD
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The Cq value reflects the number of cycles required for each sample to reach the fluorescence threshold. Value(s) deemed to 
be of the wrong melting temperature (Tm), and therefore off-target sequences are marked in red. 
Well Sample ID Well Type Replicate Threshold (dR) Cq (dR) 
A1 PC39B11_ExoEasy+PNA Unknown 1 500 No Ct 
A2 PC39B11_ExoEasy+PNA Unknown 1 500 No Ct 
A3 PC39B11_ExoEasy-PNA Unknown 2 500 32,40 
A4 PC39B11_ExoEasy-PNA Unknown 2 500 32,25 
B1 PC39B11_TEI+PNA Unknown 3 500 No Ct 
B2 PC39B11_TEI+PNA Unknown 3 500 No Ct 
B3 PC39B11_TEI-PNA Unknown 4 500 32,51 
B4 PC39B11_TEI-PNA Unknown 4 500 32,32 
C1 PC39B11_qEV7+PNA Unknown 5 500 34,40 
C2 PC39B11_qEV7+PNA Unknown 5 500 No Ct 
C3 PC39B11_qEV7-PNA Unknown 6 500 35,67 
C4 PC39B11_qEV7-PNA Unknown 6 500 No Ct 
D1 PC39B11_qEV8+PNA Unknown 7 500 34,29 
D2 PC39B11_qEV8+PNA Unknown 7 500 No Ct 
D3 PC39B11_qEV8-PNA Unknown 8 500 No Ct 
D4 PC39B11_qEV8-PNA Unknown 8 500 35,16 
E1 PC39B11_qEV9+PNA Unknown 9 500 No Ct 
E2 PC39B11_qEV9+PNA Unknown 9 500 No Ct 
E3 PC39B11_qEV9-PNA Unknown 10 500 41,80 




Table xx: PC patient #1 calculated ΔCq and ΔΔCq values, based on the average of the two replicates for each of the PNA 
positive and negative samples detailed in table xx. Value(s) deemed to be of the wrong melting temperature (Tm), and 
therefore off-target sequences are marked in red.  
ID ΔCq ΔΔCq 
ExoEasy #DIV/0! #DIV/0! 
TEI #DIV/0! #DIV/0! 
qEV7 -1,27 12,54 
qEV8 -0,87 12,14 
qEV9 #DIV/0! #DIV/0! 
 
PC patient #2 
Table xx: : PC patient #2 PNA assay for KRAS mutated alleles real-time PCR data. The sample ID column reflects the given ID 
anonymized tag of the PC-patient donor. The threshold (dR) denotes the florescence threshold for the real-time PCR assay. 
The Cq value reflects the number of cycles required for each sample to reach the fluorescence threshold. Value(s) deemed to 
be of the wrong melting temperature (Tm), and therefore off-target sequences are marked in red. 
Well Sample ID Well Type Replicate Threshold (dR) Cq (dR) 
F1 PC47B7_ExoEasy+PNA Unknown 11 500 35,18 
F2 PC47B7_ExoEasy+PNA Unknown 11 500 36,67 
F3 PC47B7_ExoEasy-PNA Unknown 12 500 32,18 
F4 PC47B7_ExoEasy-PNA Unknown 12 500 33,42 
G1 PC47B7_TEI+PNA Unknown 13 500 35,64 
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G2 PC47B7_TEI+PNA Unknown 13 500 33,33 
G3 PC47B7_TEI-PNA Unknown 14 500 29,96 
G4 PC47B7_TEI-PNA Unknown 14 500 29,86 
H1 PC47B7_qEV7+PNA Unknown 15 500 No Ct 
H2 PC47B7_qEV7+PNA Unknown 15 500 No Ct 
H3 PC47B7_qEV7-PNA Unknown 16 500 No Ct 
H4 PC47B7_qEV7-PNA Unknown 16 500 No Ct 
A5 PC47B7_qEV8+PNA Unknown 17 500 No Ct 
A6 PC47B7_qEV8+PNA Unknown 17 500 38,30 
A7 PC47B7_qEV8-PNA Unknown 18 500 35,09 
A8 PC47B7_qEV8-PNA Unknown 18 500 33,95 
B5 PC47B7_qEV9+PNA Unknown 19 500 No Ct 
B6 PC47B7_qEV9+PNA Unknown 19 500 35,94 
B7 PC47B7_qEV9-PNA Unknown 20 500 36,31 
B8 PC47B7_qEV9-PNA Unknown 20 500 33,62 
 
Table xx: PC patient #2 calculated ΔCq and ΔΔCq values, based on the average of the two replicates for each of the PNA 
positive and negative samples detailed in table xx. Value(s) deemed to be of the wrong melting temperature (Tm), and 
therefore off-target sequences are marked in red. 
ID ΔCq ΔΔCq 
ExoEasy 3,13 8,15 
TEI 4,58 6,70 
qEV7 #DIV/0! #DIV/0! 
qEV8 3,78 7,49 
qEV9 0,97 10,30 
 
PC patient #3 
 
Table xx: PC patient #3 PNA assay for KRAS mutated alleles real-time PCR data. The sample ID column reflects the given ID 
anonymized tag of the PC-patient donor. The threshold (dR) denotes the florescence threshold for the real-time PCR assay. 
The Cq value reflects the number of cycles required for each sample to reach the fluorescence threshold. Value(s) deemed to 
be of the wrong melting temperature (Tm), and therefore off-target sequences are marked in red. 
Well Sample ID Well Type Replicate Threshold (dR) Cq (dR) 
C5 PC48B7_ExoEasy+PNA Unknown 21 500 35,77 
C6 PC48B7_ExoEasy+PNA Unknown 21 500 No Ct 
C7 PC48B7_ExoEasy-PNA Unknown 22 500 36,08 
C8 PC48B7_ExoEasy-PNA Unknown 22 500 33,89 
D5 PC48B7_TEI+PNA Unknown 23 500 35,38 
D6 PC48B7_TEI+PNA Unknown 23 500 No Ct 
D7 PC48B7_TEI-PNA Unknown 24 500 32,58 
D8 PC48B7_TEI-PNA Unknown 24 500 No Ct 
E5 PC48B7_qEV7+PNA Unknown 25 500 No Ct 
E6 PC48B7_qEV7+PNA Unknown 25 500 36,34 
E7 PC48B7_qEV7-PNA Unknown 26 500 34,01 
E8 PC48B7_qEV7-PNA Unknown 26 500 32,83 
F5 PC48B7_qEV8+PNA Unknown 27 500 35,47 
F6 PC48B7_qEV8+PNA Unknown 27 500 No Ct 
F7 PC48B7_qEV8-PNA Unknown 28 500 36,17 
F8 PC48B7_qEV8-PNA Unknown 28 500 37,18 
111 
 
G5 PC48B7_qEV9+PNA Unknown 29 500 34,07 
G6 PC48B7_qEV9+PNA Unknown 29 500 33,46 
G7 PC48B7_qEV9-PNA Unknown 30 500 34,94 
G8 PC48B7_qEV9-PNA Unknown 30 500 34,98 
 
 
Table xx: PC patient #3 calculated ΔCq and ΔΔCq values, based on the average of the two replicates for each of the PNA 
positive and negative samples detailed in table xx. Value(s) deemed to be of the wrong melting temperature (Tm), and 
therefore off-target sequences are marked in red. 
ID ΔCq ΔΔCq 
ExoEasy 0,79 10,49 
TEI 2,80 8,47 
qEV7 2,92 8,35 
qEV8 -1,21 12,48 









7.4.1. Exosome isolation from plasma, control group samples 
 
EV samples from blood plasma collected from 3 presumed healthy donors, constituting the EVs from 
plasma control group. 
 
Below is shown a summary of corrected ExoCet exosome quantitation result data for exosome isolates 
from plasma can be seen below (table 12) 
Table 12: ExoCet Exosome Quantitation Assay data for EV isolate samples from plasma. The rightmost column displays each 
sample ID in the format “control group ID/ PC patient group ID”.  Control group data is found to the left in the table, and PC 
patient group data to the right. All concentration data is normalized to reflect exosomes isolated/mL of plasma used. Standard 
deviations are based on 4 technical replicates of each sample for the control group, and 2 technical replicates for each sample 
for the PC patient group. 
 Control Group PC Patient Group 
Exosomes/mL Plasma STDAV Exosomes/mL plasma STDAV 
ExoEasy 3,65E+11 4,52E+10 3,58E+11 3,73E+10 
112 
 
TEI 1,03E+12 3,03E+11 8,17E+11 1,93E+11 






















































































































































































































































































































































































































































































































































































































































Control group sample loading order, Legend: 
 
TR= Technical replicate, 
BR= Biological replicate, 
SE= Big experiment # 
 
3EE 1-1: 3 = SE003, EE= ExoEasy sample, 1-1= TR (EV isolate level) 1 – TR (ExoCet level) 1 
3EE 1-2: 3 = SE003, EE = ExoEasy sample, 1-2= TR TR (EV isolate level) 1 – TR (ExoCet level) 2 
3EE 2-1: 3 = SE003, EE= ExoEasy sample, 2-1= TR (EV isolate level) 2 – TR (ExoCet level) 1 
3EE 2-2: 3 = SE003, EE = ExoEasy sample, 2-2= TR TR (EV isolate level) 2 – TR (ExoCet level) 2 
 
3TEI 1-1: 3 =SE003, TEI= Total Exosome Isolation sample, 1-1= TR (EV isolate level) 1 – TR (ExoCet level) 1 
… 
3q7 1-1: 3= SE003, q7= qEV7 sample, 1-1= TR (EV isolate level) 1 – TR (ExoCet level) 1 
… 
3q8 1-1: 3= SE003, q8= qEV8 sample, 1-1= TR (EV isolate level) 1 – TR (ExoCet level) 1 
… 
3q9 1-1: 3= SE003, q9= qEV9 sample, 1-1= TR (EV isolate level) 1 – TR (ExoCet level) 1 
 
4EE 1-1: 4 = SE004, EE= ExoEasy sample, 1-1= TR (EV isolate level) 1 – TR (ExoCet level) 1 
… 
S.NC: Specialized negative control for a given sample, constituted of 50µL of the sample loaded in a microtiter plate well containing (inert) 
reaction buffer A (no substrate-containing buffer B added) 
XE: ExoEasy (Qiagen) elution buffer XE (negative control, blank for ExoEasy samples) 
PBS: 1x PBS (negative control, blank for qEV and TEI samples) 
AChE: Acetylcholine esterase (from eel [details from bottle] 1mg/mL stock) diluted to a concentration of 1µg/mL (positive control) 
 
STD 1-1: ExoCet standard solution dilution 1 (no dilution), parallel 1 
STD 1-2: ExoCet standard solution dilution 1 (no dilution), parallel 2 






Table xx: OD 405nm, EV isolation samples from plasma control group, 10 minutes of incubation (RT) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0,713 0,448 0,467 0,979 0,453 0,641 0,405 0,421 1,666 0,052 1,594 0,54 
B 0,68 0,431 0,431 0,949 0,44 0,624 0,434 0,435 1,609 0,049 2,041 0,521 
C 0,668 0,445 0,452 1,017 0,451 0,647 0,439 0,45 0,052 0,051 1,039 0,491 
D 0,665 0,421 0,441 0,993 0,443 0,623 0,442 0,451 0,048 0,058 1,066 0,497 
E 1,259 0,442 0,626 0,438 0,446 0,907 0,443 0,449 0,128 N/A 0,756 0,475 
F 1,27 0,432 0,632 0,445 0,444 0,899 0,452 0,46 0,133 N/A 0,75 0,468 
G 1,267 0,45 0,641 0,434 0,455 0,801 0,451 0,448 0,043 N/A 0,605 0,451 
H 1,217 0,432 0,645 0,436 0,446 0,794 0,432 0,433 0,043 N/A 0,611 0,404 
 
Table xx: OD 405nm, EV isolation samples from plasma control group, 15 minutes of incubation (RT): 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0,783 0,447 0,457 1,101 0,453 0,698 0,403 0,421 2,053 0,052 1,97 0,565 
B 0,749 0,429 0,431 1,059 0,44 0,697 0,432 0,434 1,97 0,049 2,513 0,542 
C 0,732 0,444 0,452 1,169 0,45 0,707 0,435 0,448 0,05 0,052 1,245 0,504 
D 0,729 0,42 0,441 1,13 0,441 0,68 0,442 0,45 0,048 0,051 1,273 0,511 
E 1,465 0,44 0,674 0,436 0,447 1,038 0,438 0,446 0,129 N/A 0,863 0,482 
F 1,477 0,43 0,682 0,443 0,445 1,027 0,448 0,453 0,133 N/A 0,855 0,475 
G 1,475 0,448 0,694 0,433 0,455 0,894 0,448 0,444 0,044 N/A 0,655 0,45 
H 1,398 0,431 0,702 0,435 0,447 0,889 0,431 0,431 0,043 N/A 0,665 0,403 
 
 
Table xx: OD 405nm, EV isolation samples from plasma control group, 20 minutes of incubation (RT): 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0,853 0,446 0,467 1,227 0,453 0,759 0,403 0,421 2,403 0,056 2,326 0,598 
B 0,818 0,429 0,432 1,176 0,438 0,734 0,431 0,433 2,303 0,049 2,973 0,564 
C 0,793 0,443 0,455 1,324 0,449 0,767 0,433 0,45 0,049 0,052 1,447 0,513 
D 0,793 0,419 0,443 1,271 0,441 0,738 0,44 0,45 0,048 0,053 1,477 0,523 
E 1,662 0,44 0,727 0,435 0,447 1,171 0,437 0,445 0,128 N/A 0,969 0,489 
F 1,678 0,429 0,735 0,442 0,444 1,156 0,445 0,452 0,133 N/A 0,963 0,481 
G 1,664 0,447 0,749 0,432 0,455 0,988 0,446 0,442 0,043 N/A 0,707 0,449 
H 1,573 0,43 0,77 0,433 0,447 0,985 0,43 0,428 0,043 N/A 0,72 0,4 
 
7.4.2. EV isolation from plasma, PC patient group samples 
 
EV samples from blood plasma collected from 3 pancreatic cancer (PC) patient blood plasma samples, 
constituting the PC patient group. 
Loading order (96 well microtiterplate): 
116 
 























































































































































































































































































































































































































































































PC patient group sample loading order, Legend: 
 
TR= Technical replicate, 
BR= Biological replicate, 
SE= Big experiment # 
 
6EE 1: 6 = SE006, EE= ExoEasy sample, 1= TR (ExoCet level) 1 
6EE 2: 6 = SE006, EE = ExoEasy sample, 2= TR (ExoCet level) 2 
6TEI 1: 6 =SE006, TEI= Total EV Isolation sample, 1= TR (ExoCet level) 1 
… 
6q7 1: 6= SE006, q7= qEV7 sample, 1= TR (EV isolate level) 1 – TR (ExoCet level) 1 
… 
6q8 1: 6= SE006, q8= qEV8 sample, 1= TR (ExoCet level) 1 
… 
6q9 1: 6= SE006, q9= qEV9 sample, 1= TR (ExoCet level) 1 
 
7EE 1: 7 = SE007, EE= ExoEasy sample, 1= TR (ExoCet level) 1 
… 
S.NC: Specialized negative control for a given sample, constituted of 50µL of the sample loaded in a microtiter plate well containing (inert) 
reaction buffer A (no substrate-containing buffer B added) 
XE: ExoEasy (Qiagen) elution buffer XE (negative control, blank for ExoEasy samples) 
PBS: 1x PBS (negative control, blank for qEV and TEI samples) 
AChE: Acetylcholine esterase (from eel [details from bottle] 1mg/mL stock) diluted to a concentration of 1µg/mL (positive control) 
 
STD 1-1: ExoCet standard solution dilution 1 (no dilution), parallel 1 
STD 1-2: ExoCet standard solution dilution 1 (no dilution), parallel 2 








Table xx: OD 405nm, EV isolation samples from plasma PC patient group, 10 minutes of incubation (RT): 
 1 2 3 4 5 6 7 8 
A 0,597 0,439 0,457 0,43 0,42 0,049 1,456 0,502 
B 0,561 0,409 0,43 0,428 0,422 0,044 1,343 0,476 
C 0,676 0,548 0,452 0,431 1,148 0,054 0,945 0,428 
D 0,65 0,557 0,412 0,427 1,091 0,046 0,894 0,48 
E 0,424 0,792 0,572 0,434 0,048 0,045 0,683 0,472 
F 0,42 0,757 0,579 0,428 0,047 0,044 0,686 0,456 
G 0,427 0,415 0,83 0,418 0,087 N/A 0,584 0,437 
H 0,387 0,41 0,825 0,442 0,09 N/A 0,569 0,46 
 
Table xx: OD 405nm, EVisolation samples from plasma PC patient group, 15 minutes of incubation (RT): 
 1 2 3 4 5 6 7 8 
A 0,643 0,441 0,458 0,429 0,421 0,05 1,847 0,527 
B 0,605 0,408 0,431 0,427 0,421 0,044 1,679 0,489 
C 0,751 0,596 0,453 0,431 1,427 0,056 1,143 0,434 
D 0,737 0,605 0,416 0,427 1,337 0,046 1,076 0,482 
E 0,423 0,874 0,623 0,433 0,048 0,045 0,787 0,474 
F 0,42 0,84 0,632 0,428 0,048 0,044 0,779 0,457 
G 0,427 0,413 0,965 0,415 0,088 N/A 0,634 0,433 
H 0,386 0,407 0,964 0,438 0,091 N/A 0,616 0,454 
 
 
Table: OD 405nm, EV isolation samples from plasma PC patient group, 20 minutes of incubation (RT): 
 1 2 3 4 5 6 7 8 
A 0,69 0,442 0,485 0,429 0,42 0,051 2,214 0,552 
B 0,651 0,408 0,431 0,426 0,419 0,045 2,017 0,508 
C 0,828 0,642 0,454 0,432 1,693 0,056 1,337 0,446 
D 0,813 0,653 0,415 0,427 1,579 0,046 1,256 0,493 
E 0,423 0,956 0,627 0,434 0,048 0,046 0,889 0,479 
F 0,418 0,919 0,683 0,428 0,047 0,44 0,87 0,462 
G 0,426 0,411 1,098 0,412 0,088 N/A 0,686 0,43 
H 0,384 0,406 1,1 0,435 0,091 N/A 0,662 0,45 
 
ExoCet on samples from CCM 
While results using the ExoCet exosome quantitation assay (SBI) was considered generally too weak to 
be worth including in the main section of this thesis, some general observations could be made 
concerning the samples giving the strongest signal. In EV isolates from CCM, while most samples 
proved too weak to give a reliable signal over noise, ExoEasy and TEI were reliably giving an sufficiently 
strong signal to register. Additionally, the ExoEasy sample was observed to be stronger than that of 
the TEI sample.   
Note that the ExoCet data from CCM (figure 16) stems from a different (although identically prepared) 
batch of CCM (“SE001”), and can therefore not be considered directly comparable to the one discussed 
in the main portion of this thesis (“SE002”). 
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ExoCet SE001 (EV Isolates from CCM) Loading order: 
 1 2 3 4 5 6 7 
A PBS qEV7 1 qEV9 1 TEI 1 AChE 10-3 Std 4 Std 8 
B PBS qEV7 1 qEV9 1 TEI 1 AChE 10-3 Std 4 Std 8 
C XE qEV7 2 qEV9 2 TEI 2 Std 1 Std 5  
D XE qEV7 2 qEV9 2 TEI 2 Std 1 Std 5  
E ExoEasy 1 qEV8 1 ExoQuick 1 UC 1 N/A Std 2  
F ExoEasy 1 qEV8 1 ExoQuick 1 UC 1 Std 2 Std 6  
G ExoEasy 2 qEV8 2 ExoQuick 2 UC 2 Std 3 Std 7  
H ExoEasy 2 qEV8 2 ExoQuick 2 UC 2 Std 3 Std 7  
 
Table xx: ExoCet on EV isolates from CCM, raw data (samples) after 15 minutes of incubation. Note that the batch of CCM 
used for this experiment, while similarly prepared, is not the same as the one discussed in the main section of this paper and 
so is not directly comparable. 
Kolonne1 1 2 3 4 5 
A 0,406 0,396 0,399 0,488 1,992 
B 0,379 0,375 0,367 0,463 1,147 
C 0,413 0,392 0,374 0,451  
D 0,393 0,375 0,362 0,419  
E 0,616 0,38 0,387 0,36  
F 0,606 0,375 0,37 0,36  
G 0,596 0,376 0,381 0,486  
H 0,595 0,358 0,361 0,351  
 
Table xx: ExoCet on EV isolates from CCM, raw data for standard curve after 15 minutes of incubation. Note that the batch 
of CCM used for this experiment, while similarly prepared, is not the same as the one discussed in the main section of this 
paper and so is not directly comparable. 
Kolonne1 Kolonne2 Kolonne3 Kolonne4 Kolonne5 Kolonne6 Kolonne7 Kolonne8 
Standard: OD 405nm Subtract blank Standard: #Exos x10^7 Average STDAV 
Std 1 2,45 2,0865  Std 1 1280 2,051 0,05020458 
Std 1 2,379 2,0155  Std 2 640 1,145 0,05444722 
Std 2 1,547 1,1835  Std 3 320 0,5735 0,00989949 
Std 2 1,47 1,1065  Std 4 160 0,289 0,02757716 
Std 3 0,944 0,5805  Std 5 80 0,1405 0,01272792 
Std 3 0,93 0,5665  Std 6 40 0,0755 0,0311127 
Std 4 0,672 0,3085  Std 7 20 0,0265 N/A 
Std 4 0,633 0,2695  Std 8 0 0 0,00070711 
Std 5 0,513 0,1495      
Std 5 0,495 0,1315      
Std 6 0,461 0,0975  Well of STD 7  Double   Laoded.  
Std 6 0,417 0,0535  Ignore value Use only Parallell 1  
Std 7 0,39 0,0265      
Std 7 0,479 0,1155      
Std 8 0,364 0,0005      





Figure xx: ExoCet on EV isolates from CCM standard curve 
 
 
Figure 1: ExoCet Exosome Quantitation Assay (SBI) results from samples of EV isolates from CCM. The y-axis reflects the 
calculated number of exosomes/mL based on the optimal standard curve (15 minutes of incubation). Error-bars are based on 
the calculated standard deviation between 2 technical replicates (EV isolate level) in 2 technical replicates (ExoCet assay) for 
a total of 4 TR per sample. PBS and XE are negative controls. AChE 10^-3 is a Acetylcholine esterase positive control.  Only the 






































ExoCet Store Exp. 001, Concentration of Exosomes by isolation 
technique, biological and technichal replicates averaged.
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7.5 qNano Gold (Izon Science) 
 
EV isolates from CCM, processed qNano gold concentration and average particle diameter data. 
Table 4: qNano gold NP100 (top of table) and NP200 (bottom of table) measured concentrations of EVs isolate samples from 
CCM. P/mL CCM equates to the measured nanoparticles within the nanopore sensitivity range (50-200nm for NP100, 85-
340nm for NP200). All values have been normalized so as to represent the concentration of nanoparticles within the given 
size-range isolated from 1mL of the starting material (CCM) 
EV isolate from CCM, NP100 (50-200nm) 
ID P/mL CCM STDAV STDAV% P.Mean STDAV P.Mode STDAV 
ExoEasy 1,13E+09 2,56E+08 22,75 90,75 6,54 68,25 4,40 
ExoQuick 4,19E+08 2,38E+08 56,92 91,33 5,82 71,00 6,66 
qEV7 1,15E+08 8,78E+07 76,47 95,78 5,95 74,89 14,87 
qEV8 2,99E+08 6,72E+07 22,44 93,00 5,73 70,50 7,97 
qEV9 1,86E+08 3,80E+07 20,48 86,67 5,96 68,67 6,50 
TEI 5,05E+08 3,31E+07 6,57 90,33 5,32 68,83 5,78 
UC 3,28E+07 3,45E+07 105,15 98,17 17,09 97,67 4,04 
EV Isolate from CCM, NP200 (85-340nm) 
ExoEasy 1,86E+08 7,16E+07 38,56 162,83 19,51 128,33 22,07 
ExoQuick 1,14E+08 5,46E+07 47,69 151,56 10,25 111,67 7,14 
qEV7 6,38E+07 4,80E+07 75,15 140,78 7,17 108,22 7,31 
qEV8 4,32E+07 5,43E+06 12,57 143,78 9,99 111,44 7,88 
qEV9 7,44E+07 6,63E+06 8,91 134,83 12,29 107,67 7,03 
TEI 3,11E+08 1,03E+08 33,17 144,93 7,46 109,00 10,32 
UC 6,67E+06 1,74E06 26,10 139,80 9,82 124,00 18,30 
 
EV isolates from Plasma, processed qNano gold concentration and average particle diameter data. 
Table 5: qNano gold measured concentrations (NP100, NP200) of EV isolate samples from blood plasma. P/mL CCM equates 
to the measured nanoparticles within the nanopore sensitivity range, calculated back so as to represent the concentration of 
such nanoparticles in 1mL of the CCM starting material. The top section of the table is constituted of Control group data, and 
the bottom section of PC patient data. “P.Mean” refers to the nanoparticle mean diameter within the given sensitivity interval. 
“P.mode” refers to the mode particle diameter. *The qNano Gold measurement of the ExoEasy sample concentrations was in 
this case considered to be of insufficient quality, and is therefore disregarded in all comparisons. 
 NP100 (50-200nm) NP200 (85-340nm) 
Control group samples 
Sample ID P/mL plasma P. Mean STDAV P .Mode P/mL plasma P. Mean STDAV P .Mode 
ExoEasy 1,99E+10 * 72,00 19,00 61,00 N/A N/A N/A N/A 
TEI 2,46E+11 78,50 19,70 68,50 6,00E+10 129,50 39,75 105,00 
qEV7 3,84E+08 89,50 31,45 67,00 1,66E+08 147,00 57,80 129,00 
qEV8 8,75E+09 78,50 24,10 64,50 3,61E+09 149,00 47,60 119,50 
qEV9 2,81E+10 85,00 24,10 68,00 8,15E+09 139,50 41,85 114,00 
 PC patient group samples 
Sample ID P/mL plasma P.Mean STDAV P.Mode P/mL plasma P. Mean STDAV P .Mode 
ExoEasy N/A N/A N/A N/A N/A N/A N/A N/A 
TEI 1,13E+11 86,50 21,60 72,50 1,93E+10 124,00 31,20 108,50 
qEV7 2,17E+09 97,50 30,25 71,00 1,67E+08 157,50 60,00 118,50 
qEV8 5,40E+09 91,50 32,60 71,50 5,05E+08 142,50 50,65 110,50 




7.5.1 Triton x-100 (0,1% v/v) measured concentrations 
 
The CCM derived EV isolate samples, a separate set of measurements using the NP200 nanopore was 
performed in order to estimate the vesicle fraction. Twin dilutions were prepared, one featuring  0,1% 
v/v triton x-100, and the two were measured immediately following one another. The processed result 
data is show in tables 6 and 7 below. All values normalized to correspond to mL CCM used during EV 
isolation. 
Table 6: CCM sample measured changes following treatment with 0,1% Triton x-100. ΔConc. Signifies the change in 
concentration, equating to the estimated vesicles/mL plasma. The corresponding change in particle mean and mode diameter 
(nanometres) can be seen in the two subsequent columns, “ΔP.Mean.” And “ΔP.Mode” respectively. The final column tagged 
“%Vesicles”, shows the calculated percentage of nanoparticles in the sample estimaterd to be vesicles, based on the calculated 
ΔConc. 
Sample ID ΔConc. ΔP.Mean (nm) ΔP.Mode (nm) %Vesicles 
ExoEasy 1,04E+08 3,67 8,00 57,12 
ExoQuick 6,44E+07 -2,33 13,00 76,30 
TEI 8,75E+07 -7,67 -7,33 43,34 
qEV7 6,72E+07 7,33 28,33 86,73 
qEV8 2,21E+07 4,33 1,33 56,56 
qEV9 2,49E+06 2,00 -22,00 59,48 
UC 2,28E+06 27,33 29,33 45,09 
 
The unprocessed concentration data are shown below (tables xx, xx, xx, xx.). All values normalized to 
correspond to mL CCM used during EV isolation. 
Table 1: No triton x-100 treatment, CCM derived EV isolate samples measured using the NP200 nanopore.   
ID P/mL CCM P Mean P Mode STDAV mean STDAV mode 
ExoEasy 1,82E+08 171,67 109,33 1,53 6,81 
ExoQuick 8,44E+07 161,33 107,00 7,23 0,00 
TEI 2,02E+08 145,33 110,00 10,21 9,85 
qEV7 7,75E+07 144,00 107,00 12,29 6,08 
qEV8 3,91E+07 142,00 113,33 11,36 6,03 
qEV9 4,19E+06 128,33 115,67 3,21 6,03 
UC 5,06E+06 149,67 138,67 24,95 22,72 
  
Table 2: No triton x-100 treatment, CCM derived EV isolate samples measured using the NP200 nanopore, qEV fractions 
pooled. 
ID P/mL CCM P Mean P Mode STDAV mean STDAV mode 
ExoEasy 1,82E+08 171,67 109,33 1,53 6,81 
ExoQuick 8,44E+07 161,33 107,00 7,23 0,00 
TEI 2,02E+08 145,33 110,00 10,21 9,85 
UC 5,06E+06 149,67 138,67 24,95 22,72 





Table 3: With triton x-100 treatment, CCM derived EV isolate samples measured using the NP200 nanopore.   
ID P/mL CCM P Mean P Mode STDAV mean STDAV mode 
ExoEasy 7,81E+07 175,33 117,33 10,69 9,87 
ExoQuick 2,00E+07 159,00 120,00 15,62 19,29 
TEI 1,14E+08 137,67 102,67 7,09 6,66 
qEV7 1,03E+07 151,33 135,33 9,07 22,14 
qEV8 1,70E+07 146,33 114,67 14,64 0,58 
qEV9 1,70E+06 130,33 93,67 13,20 2,89 
UC 2,78E+06 177,00 168,00 N/A N/A 
 
Table 4: With triton x-100 treatment, CCM derived EVe isolate samples measured using the NP200 nanopore. qEV fractions 
pooled 
ID P/mL CCM P Mean P Mode STDAV mean STDAV mode 
ExoEasy 7,81E+07 175,33 117,33 10,69 9,87 
ExoQuick 2,00E+07 159,00 120,00 15,62 19,29 
TEI 1,14E+08 137,67 102,67 7,09 6,66 
UC 2,78E+06 177,00 168,00 N/A N/A 
qEV 2,89E+07 142,67 114,56 12,31 8,54 
 
For the plasma derived EV isolate samples, a separate set of measurements using the NP100 and 
NP200 nanopores were performed in order to estimate the vesicle fraction. Twin dilutions were 
prepared, one featuring 0,1% v/v triton x-100, and the two were measured immediately following one 
another. The processed result data is show in tables 16 and 17 below. All values normalized to 
correspond to mL CCM used during EV isolation. 
Table 16: Control donor plasma sample measured changes following treatment with 0,1% Triton x-100. ΔConc. Signifies the 
change in concentration, equating to the estimated vesicles/mL plasma. The corresponding change in particle mean and mode 
diameter (nanometres) can be seen in the two following columns, tagged “ΔP.Mean” and “ΔP.Mode” respectively. The final 
column named “%vesicles” gives the calculated percentage of nanoparticles estimated to be vesicles, based on the previously 
calculated ΔConc. *The qNano Gold measurement of the ExoEasy sample concentrations was in this case considered to be of 
insufficient quality, and is therefore disregarded in all comparisons. 
 NP100 NP200 









ExoEasy 1,75E+10* 10,5 9,50 88,04* N/A N/A N/A N/A 
TEI 4,80E+10 1,00 0,50 19,51 1,50E+09 -2,00 0,00 2,50 
qEV7 9,65E+07 -14,00 -2,00 25,16 7,50E+07 -18,00 -27,50 45,32 
qEV8 4,00E+08 0,00 4,00 4,57 1,79E+09 14,00 4,50 49,58 








Table 17: PC patient plasma sample measured changes following treatment with 0,1% Triton x-100. ΔConc. Signifies the 
change in concentration, equating to the estimated vesicles/mL plasma. The corresponding change in particle mean and mode 
diameter can be seen in the two following columns, tagged “ΔP.Mean” and “ΔP.Mode” respectively. The final column named 
“%vesicles” gives the calculated percentage of nanoparticles estimated to be vesicles, based on the previously calculated 
ΔConc. 
 NP100 NP200 
Sample ID ΔConc. ΔP.Mean ΔP.Mode %Vesicles ΔConc. ΔP.Mean ΔP.Mode %Vesicles 
ExoEasy N/A N/A N/A N/A N/A N/A N/A N/A 
TEI 7,15E+10 -3,00 2,50 63,51 1,14E+10 2,00 -8,00 59,07 
qEV7 2,80E+08 -6,50 5,50 12,93 7,85E+07 -7,50 -1,50 47,01 
qEV8 3,34E+09 -5,00 -3,00 61,76 3,25E+08 15,00 17,00 64,36 
qEV9 1,60E+09 3,50 6,00 15,69 7,90E+08 -0,50 5,00 30,27 
 
The unprocessed concentration data for triton x-100 experiments on samples from plasma are shown 
below (tables xx, xx, xx, xx.). All values normalized to correspond to mL CCM used during EV isolation. 
Table 16: qNano Gold measured nanoparticle concentrations from plasma derived EV isolate samples as with and without 
treatment with triton x-100. NP100 and NP200 nanopores. 
         
     
Control donor No triton x-100        
SE003 NP100 50-200nm        
All:     qEV fractions pooled:   
         
ID P/mL plasma P Mean P Mode      
ExoEasy 1,99E+10 72,00 61,00      
TEI 2,46E+11 78,50 68,50  ID P/mL plasma P Mean P Mode 
qEV7 3,84E+08 89,50 67,00  ExoEasy 1,99E+10 72,00 61,00 
qEV8 8,75E+09 78,50 64,50  TEI 2,46E+11 78,50 68,50 
qEV9 2,81E+10 85,00 68,00  qEV 3,72E+10 84,33 66,50 
         
         
         
     
Control donor with triton x-100        
SE003 NP100 50-200nm        
All:     qEV fractions pooled:   
         
ID P/mL plasma P Mean P Mode      
ExoEasy 2,38E+09 82,50 70,50      
TEI 1,98E+11 79,50 69,00  ID P/mL plasma P Mean P Mode 
qEV7 2,87E+08 75,50 65,00  ExoEasy 2,38E+09 82,50 70,50 
qEV8 8,35E+09 78,50 68,50  TEI 1,98E+11 79,50 69,00 
qEV9 1,76E+10 84,50 67,50  qEV 2,62E+10 79,50 67,00 
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Control donor No triton x-100        
SE003 NP200 80-340nm        
All:     qEV fractions pooled:   
         
ID P/mL plasma P Mean P Mode      
ExoEasy N/A N/A N/A      
TEI 6,00E+10 129,50 105,00  ID P/mL plasma P Mean P Mode 
qEV7 1,66E+08 147,00 129,00  ExoEasy N/A N/A N/A 
qEV8 3,61E+09 149,00 119,50  TEI 6,00E+10 129,50 105,00 
qEV9 8,15E+09 139,50 114,00  qEV 1,19E+10 145,17 120,83 
         
         
         
     
Control donor with triton x-100        
SE003 NP200 80-340nm        
All:     qEV fractions pooled:   
         
ID P/mL plasma P Mean P Mode      
ExoEasy N/A N/A N/A      
TEI 5,85E+10 127,50 105,00  ID P/mL plasma P Mean P Mode 
qEV7 9,05E+07 129,00 101,50  ExoEasy N/A N/A N/A 
qEV8 1,82E+09 163,00 124,00  TEI 5,85E+10 127,50 105,00 
qEV9 5,05E+09 144,50 114,00  qEV 6,96E+09 145,50 113,17 
         
         
         
PC patient SE006 NP100 (50-200nm), NO triton x-100      
         
         
All:     qEV fractions pooled:   
         
ID P/mL plasma P Mean P Mode      
ExoEasy N/A N/A N/A      
TEI 1,13E+11 86,50 72,50  ID P/mL plasma P Mean P Mode 
qEV7 2,17E+09 97,50 71,00  ExoEasy N/A N/A N/A 
qEV8 5,40E+09 91,50 71,50  TEI 1,13E+11 86,50 72,50 
qEV9 1,02E+10 79,50 66,50  qEV 1,78E+10 89,50 69,67 
         
         
         
PC patient SE006 NP100 (50-200nm), WITH triton x-100      
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All:     qEV fractions pooled:   
         
ID P/mL plasma P Mean P Mode      
ExoEasy N/A N/A N/A      
TEI 4,11E+10 83,50 75,00  ID P/mL plasma P Mean P Mode 
qEV7 1,89E+09 91,00 76,50  ExoEasy N/A N/A N/A 
qEV8 2,07E+09 86,50 68,50  TEI 4,11E+10 83,50 75,00 
qEV9 8,60E+09 83,00 72,50  qEV 1,26E+10 86,83 72,50 
         
         
         
PC patient SE006 NP200 (85-340nm), NO triton x-100      
         
         
All:     qEV fractions pooled:   
         
ID P/mL plasma P Mean P Mode      
ExoEasy N/A N/A N/A      
TEI 1,93E+10 124,00 108,50  ID P/mL plasma P Mean P Mode 
qEV7 1,67E+08 157,50 118,50  ExoEasy N/A N/A N/A 
qEV8 5,05E+08 142,50 110,50  TEI 1,93E+10 124,00 108,50 
qEV9 2,61E+09 148,00 115,50  qEV 3,28E+09 149,33 114,83 
         
         
         
PC patient SE006 NP200 (85-340nm), WITH triton x-100      
         
         
All:     qEV fractions pooled:   
         
ID P/mL plasma P Mean P Mode      
ExoEasy N/A N/A N/A      
TEI 7,90E+09 126,00 100,50  ID P/mL plasma P Mean P Mode 
qEV7 8,85E+07 150,00 117,00  ExoEasy N/A N/A N/A 
qEV8 1,80E+08 157,50 127,50  TEI 7,90E+09 126,00 100,50 






7.5.2. Combined Size Distribution Histograms (CSDH) from CCM 
 
Figure xx, ExoEasy from CCM CSDH 
 





Figure xx, qEV 7 from CCM CSDH 
 
 





Figure xx, qEV9 from CCM CSDH 
 





7.5.3. Combined Size Distribution Histograms (CSDH) from Plasma (No triton x-100) 
 
 
Figure xx, qEV7 from plasma (Control group donor) CSDH, No Triton x-100. 
 





Figure xx, qEV8 from plasma (Control group donor) CSDH, No Triton x-100. 
 
 





Figure xx, qEV9 from plasma (Control group donor) CSDH, No Triton x-100. 
 
 




Figure xx, TEI from plasma (Control group donor) CSDH, No Triton x-100. 
 
Figure xx, TEI from plasma (PC patient donor) CSDH, No Triton x-100. 
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7.5.4. Combined Size Distribution Histograms (CSDH) from Plasma (WITH triton x-100) 
 
 
Figure xx, qEV7 from plasma (Control group donor) CSDH, With Triton x-100. 
 
 






Figure xx, qEV8 from plasma (Control group donor) CSDH, With Triton x-100. 
 
 




Figure xx, qEV9 from plasma (Control group donor) CSDH, With Triton x-100. 
 
 





Figure xx, TEI from plasma (Control group donor) CSDH, With Triton x-100. 
 
 
Figure xx, TEI from plasma (PC patient donor) CSDH, With Triton x-100. 
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Table xx: measured MFI fold change as consequence of exosomal protein/ antibody interactions 
 Beads TEI ExoEasy ExoQuick qEV7 qEV8 qEV9 UC 
CD9 1,03 1,37 3,7 1,35 1,32 2,85 6,75 1,33 
CD63 1,93 1,76 22,8 2,43 1,62 8,83 31,61 3,24 
CD9 0,96 1,5 2,42 1,31 3,06 3,09 2,64 1,12 
CD63 0,65 2,18 17,51 2,17 13,34 12,68 6,3 1,74 
CD9 1 1,43 3,06 1,33 2,19 2,97 4,69 1,23 
CD63 1,29 1,97 20,15 2,3 7,48 10,76 18,95 2,49 
STDAV CD9 0,04 0,09 0,91 0,03 1,23 0,17 2,90 0,14 
STDAV CD63 0,90 0,30 3,73 0,19 8,29 2,72 17,90 1,07 
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